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Abstract	
Renal	cell	carcinoma	(RCC)	is	an	immunogenic	tumour	infiltrated	by	a	high	number	of	
leucocytes.	 However,	 this	 infiltrate	 is	 not	 able	 to	 induce	 an	 efficient	 anti-tumoural	
response.	 Recent	 studies	 have	 attempted	 to	 further	 identify	 the	 composition	 of	 the	
immune-infiltrate	 in	order	 to	gain	a	deeper	understanding	of	how	RCC	escapes	 from	
immune	 surveillance.	 Recently,	 a	 new	 dendritic	 cell	 (DC)	 subtype	 was	 discovered,	
co-expressing	DC	(CD209/DC-SIGN)	and	Mf	(CD14,	CD163)	markers.	As	this	subtype	was	
found	to	be	enriched	in	RCC	tissue	it	was	called	“enriched	in	renal	cell	carcinoma	DC”	
(ercDC).		
Functional	 tests	 investigating	 cytokine	 expressions	 and	 the	 migration	 ability	 of	 this	
subtype	revealed	 impaired	 functioning	of	ercDC	compared	to	conventional	DC	 (cDC).	
While	 being	 able	 to	 migrate	 towards	 fMLP,	 a	 chemoattractant	 for	 immature	 DC,	
maturated	ercDC	do	not	show	directed	migration	towards	CCL19,	which	is	involved	in	
the	recirculation	and	homing	of	maturated	DC.	Furthermore,	ercDC	secrete	higher	levels	
of	IL-10	and	TNF-a,	but	lower	levels	of	IL-12	upon	LPS	stimulation.	In	order	to	identify	
possible	 pathways	 responsible	 for	 differences	 between	 myeloid	 subtypes,	
transcriptomic	 profiling	 of	monocytes,	 cDC,	 ercDC	 and	Mf	was	 performed.	Amongst	
others,	regulation	was	found	especially	for	the	canonical	as	well	as	non-canonical	Wnt-
pathways.	 Following	 these	 findings,	we	 investigated	 the	 role	of	Wnt-signalling	 in	 the	
differentiation	and	functioning	of	myeloid	and	especially	dendritic	cells.	Striking	was	the	
high	expression	of	Wnt5a,	a	typical	non-canonical	Wnt-ligand,	in	cDC	in	comparison	to	
all	other	myeloid	subtypes.	Furthermore,	we	could	show	that	Wnt5a	is	highly	expressed	
in	 RCC	 and	 microarray	 analysis	 of	 RCC	 tissue	 samples	 revealed	 that	 Wnt-signalling,	
especially	non-canonical	Wnt-signalling,	changes	with	tumour	progression.		
Functional	 tests	 of	 DC	 showed,	 that	 the	 addition	 of	 Wnt5a	 during	 differentiation	
significantly	 increases	 IL-10	 and	 IL-12,	 but	 decreases	 TNF-a	 secretion.	 Surprisingly,	
Wnt5a	also	 inhibited	the	migratory	capacity	of	cDC,	resulting	 in	reduced	motility	and	
less	directed	migration	 towards	CCL19.	These	 results	 suggest	a	possible	 role	of	Wnt-
signalling	in	the	differentiation	and	functioning	of	myeloid	cells.	Through	its	autocrine,	
paracrine	and	juxtacrine	effect,	Wnt5a	present	in	the	tumour	milieu	may	influence	the	
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anti-tumoural	immune	response.	Gaining	further	insight	into	the	role	of	myeloid	cells	
and	Wnt-signalling	in	RCC	could	hence	reveal	new	possible	therapeutic	targets.		
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Zusammenfassung	
Das	Nierenzellkarzinom	(RCC,	renal	cell	carcinoma)	wird	als	 immunogener	Tumor	von	
einer	 Vielzahl	 an	 Immunzellen	 infiltriert.	 Trotz	 dieses	 Immunzellinfiltrats,	 kommt	 es	
jedoch	 nicht	 zu	 einer	 effektiven	 Kontrolle	 des	 Tumorwachstums	 durch	 das	
Immunsystem.	 Um	 die	 Mechanismen	 der	 Immunevasion	 des	 Nierenzellkarzinoms	
besser	 zu	 verstehen,	 ist	 das	 Ziel	 neuerer	 Studien,	 dieses	 Immuninfiltrat	 besser	 zu	
charakterisieren.	 Kürzlich	 wurde	 hierbei	 ein	 neuer	 myeloischer	 Zelltyp	 entdeckt,	
welcher	sowohl	dendritische	Zell	(DC)-	(CD209/DC-SIGN),	als	auch	Makrophagen	(Mf)-
Marker	(CD14,	CD163)	exprimiert.	Da	dieser	Zelltyp	im	RCC	im	Vergleich	zu	tumorfreien	
Nierenparenchym	 besonders	 angereichert	 ist,	 wurde	 er	 „enriched	 in	 renal	 cell	
carcinoma	DC“	(ercDC)	genannt.	
Bei	 unserer	 Untersuchung	 dieses	 Zelltyps	 zeigte	 sich	 interessanterweise,	 dass	
maturierte	 ercDC	 zwar	 zu	 fMLP,	 einem	 Chemoattractant	 unreifer	 DC,	 gerichtet	
migrieren,	allerdings	keine	gerichtete	Migration	zu	CCL19	aufweisen.	 Im	Vergleich	zu	
konventionellen	Dendritischen	Zellen	(cDC)	sezernierten	ercDC	nach	Stimulation	mit	LPS	
höhere	Mengen	IL-10	und	TNF-a,	aber	geringere	Mengen	IL-12.	Um	mögliche	relevante	
Unterschiede	in	den	Signalwegen	von	Monozyten,	cDC,	ercDC	und	Mf	zu	identifizieren,	
führten	wir	Transkriptomanalysen	an	Microarray-Daten	dieser	Zelltypen	durch.	Hierbei	
zeigte	 sich	unter	anderem	eine	differenzielle	Expression	 in	dem	„canonical“	und	den	
„non-canonical“	Wnt-Signalwegen.	 Auffallend	 war	 die,	 im	 Vergleich	 zu	 den	 anderen	
myeloischen	Zelltypen,	starke	Expression	von	Wnt5a,	einem	typischen	„non-canonical“	
Wnt-Liganden,	 in	 cDC.	 Darüber	 hinaus	 konnten	 wir	 immunhistochemisch	 eine	 hohe	
Wnt5a	 Expression	 im	 Gewebe	 des	 Nierenzellkarzinoms	 nachweisen.	 Auch	 in	 der	
Microarray-Analyse	von	Nierenzellkarzinomproben	zeigte	sich	eine	starke	differenzielle	
Expression	 der	 Wnt-Signalwege,	 mit	 evidenten	 Unterschieden	 abhängig	 vom	
Tumorstadium.		
Durch	 die	 Zugabe	 von	 Wnt5a	 während	 der	 Differenzierung	 von	 cDC	 konnte	 eine	
vermehrte	 Sekretion	 von	 IL-10	und	 IL-12,	 sowie	 eine	Reduktion	der	 TNF-a	 Sekretion	
erreicht	 werden.	 Interessanterweise	 führte	Wnt5a	 Zugabe	 auch	 zu	 einer	 geringeren	
Mobilität	und	Direktionalität	von	cDC	bei	der	Migration	zu	CCL19.	Zusammenfassend	
weisen	diese	Ergebnisse	auf	eine	Rolle	der	Wnt-Signalwege	in	der	Differenzierung	und	
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Funktionalität	 von	 myeloischen	 Zellen	 hin.	 Wnt5a	 im	 Tumormilieu	 kann	 so	 durch	
autokirne,	parakrine	und	juxtakrine	Mechanismen	die	Immunantwort	gegen	den	Tumor	
modulieren.	Ein	weitergehendes	Verständnis	über	die	Bedeutung	des	Wnt-Signalweges	
in	 den	 myeloischen	 Zellen	 des	 Nierenzellkarzinoms	 könnte	 so	 sogar	 mögliche	 neue	
Therapieansätze	aufdecken.		
	
	 	
1 Introduction	
1.1 Renal	cell	carcinoma		
Originating	from	the	renal	cortex,	Renal	Cell	Carcinoma	(RCC)	is	the	most	common	renal	
malignancy	accounting	for	90%	of	all	renal	neoplasms	with	an	incidence	of	over	3%	of	
all	 cancers	 in	 Europe	 [1].	 Despite	 ongoing	 research	 and	 a	 number	 of	 different	
therapeutic	approaches,	there	exists	no	satisfying	therapy	for	RCC.	While	nephrectomy	
is	the	most	effective	treatment	for	non-metastatic	RCC,	the	therapy	of	metastatic	RCC	
remains	difficult	with	poor	survival	rates.	Similar	to	certain	other	solid	cancers,	such	as	
melanoma,	 RCC	 is	 an	 immunogenic	 cancer	 showing	 infiltration	 by	 a	 multitude	 of	
immune	 cells	 [2].	 These	 include	 mainly	 CD3-	 Natural	 killer	 cells	 (NK)	 and	 CD3+	
lymphocytes	of	CD4	and	CD8	type	[3].		In	addition,	rare	cases	of	spontaneous	remission	
of	metastatic	lesions	have	been	observed,	and	there	is	evidence	that	IL-2	and	IFN-a	can	
induce	this	remission.	Contrarily	to	other	immunogenic	cancers,	for	example	colorectal	
cancer,	 RCC	 shows	 a	 negative	 correlation	 of	 lymphocyte	 infiltration	 with	 survival	
rate	[4].		
	
Because	of	this,	and	the	fact	that	RCC	is	highly	resistant	to	chemotherapy	and	radiation,	
the	application	of	immuno-	and	antiangiogenic	therapies	are	currently	of	high	interest	
in	 the	 treatment	 of	 RCC	 [5].	 While	 the	 treatment	 with	 IFN-a	 and	 IL-2	 have	 shown	
consistent	 results	 in	 remission	 of	 metastatic	 lesions,	 they	 have	 only	modest	 overall	
benefits	 for	 patients.	 Hence	 high	 dose	 IL-2	 remains	 the	 only	 supportable	 cytokine	
therapy	 for	 carefully	 selected	 patients	 [6].	 	 Antiangiogenic-therapy,	 such	 as	 vascular	
epithelial	growth	factor	(VEGF)-targeted	therapy	with	Sunitinib	and	Bevacizumab,	have	
improved	outcomes,	but	could	not	assure	a	sustained	remission	or	complete	response	
when	therapy	was	discontinued.	The	results	of	combining	cytokine	and	antiangiogenic	
therapy	suggest	enhanced	efficacy	and	an	additive,	albeit	not	a	synergistic	effect	of	this	
therapeutic	approach	[5].		
As	 RCC	 is	 able	 to	 avoid	 immune	 surveillance,	 and	 develops	 resistance	 to	
immunotherapies,	 it	 is	 important	 to	understand	 the	molecular	mechanisms	at	work.	
Some	 of	 the	 mechanisms	 involved	 in	 therapy	 resistance	 include	 the	 production	 of	
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specific	 cytokines,	 the	 presence	 of	 regulatory	 (CD4+CD25+)	 T-cells	 (T-regs),	myeloid-
derived	suppressor	cells	(MDSC),	and	increased	levels	of	VEGF	[6].		
	
To	address	these	phenomena,	a	number	of	novel	approaches,	such	as	vaccinations	and	
allogeneic	 bone	 marrow	 transplantation	 are	 currently	 under	 investigation.	 The	
programmed	cell	death	1	receptor	(PD-1)	and	its	ligand	PD-L1	have	been	suggested	to	
be	one	of	the	possible	pathways	responsible	for	RCC	resistance	to	immunotherapeutic	
and	antiangiogenic	therapies	[4].	A	blockade	of	the	immune	checkpoint	PD1,	reducing	
the	 tumour-mediated	 T-cell-inhibition	 and	 self-tolerance,	 seems	 a	 promising	
therapeutic	strategy.		
The	application	of	dendritic-cell	based	vaccinations	has	also	been	suggested	to	launch	
an	anti-tumour	immune	response	[7].	Although	this	approach	is	promising,	it	has	so	far	
only	shown	clinical	benefits	in	a	minority	of	patients.	This	rather	new	approach	takes	
into	account	that	while	RCC	is	commonly	infiltrated	by	a	number	of	immune	cells,	the	
tumour	milieu	can	 inhibit	their	effector	function.	While	the	anti-tumour	activity	of	T-
cells	in	RCC	has	been	widely	investigated,	only	little	is	known	about	the	potential	role	of	
myeloid	 cells.	 It	 has	 been	 shown	 that	 RCC	 is	 infiltrated	 with	 tumour-associated	
macrophages	 (TAM),	 NK	 cells	 [8]	 and	 dendritic	 cells	 (DC),	which	 exhibit	 impaired	 or	
differing	 functions	 compared	 to	 non-cancerous	 renal	 tissue.	 TAM,	 for	 example,	 are	
thought	 to	 contribute	 to	 immunosuppression	 and	 T-cell	 tolerance	 in	 RCC	 by	 their	
production	 of	 the	 	 immunosuppressive	 cytokine	 IL-10,	 proinflammatory	 chemokine	
CCL2	 and	 induction	 of	 factor	 forkhead	 box	 P3	 (FOXP3)	 and	 cytotoxic	 T-lymphocyte	
antigen	4	(CTLA-4)	[9].		
	
1.2 Immune	system		
The	immune	system	comprises	the	complex	interaction	of	different	cells	and	molecules	
for	effective	protection	against	disease.	Its	function	is	to	identify	and	eliminate	potential	
pathogens,	 such	 as	 viruses,	 bacteria	 and	 abnormal	 cells.	 It	 does	 this	 in	 part,	 by	
differentiating	between	self	and	foreign	antigens.	However,	disorders	of	the	 immune	
system,	such	as	deficiency	to	identify	pathogens	or	misidentification	of	healthy	cells	as	
pathogens,	can	result	in	the	development	of	infectious	diseases,	autoimmune	diseases	
and	also	cancer.		
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The	immune	response	is	subdivided	in	an	innate	and	an	adaptive	immune	response.	The	
innate	 immune	 system	 is	 an	 immediate,	 non-specific	 response	 to	 a	 pathogen.	 It	
comprises	a	humoral	as	well	as	a	cellular	response.	This	includes	a	physical	and	chemical	
barrier,	activation	of	the	complement	cascade,	cytokine	production	and	the	recruitment	
of	 immune	 cells	 to	 the	 site	 of	 infection.	 Leukocytes	 involved	 are	 NKs,	 mast	 cells,	
eosinophils,	basophils,	neutrophils,	macrophages	(MΦ)	and	DC.	These	cells	recognize	
the	 pathogen	 associated	 molecular	 patterns	 (PAMP)	 of	 a	 pathogen	 mainly	 through	
pathogen	recognition	receptors	(PRC),	which	activate	the	cell	and	result	in	cytokine	and	
chemokine	production.	While	the	innate	immune	response	allows	a	first	elimination	of	
the	pathogen,	it	is	not	able	to	develop	a	long	lasting	immunity.	Hence	the	activation	of	
an	adaptive	immune	response	is	an	important	continuation	of	immunity.		
	
The	 adaptive	 immune	 system	allows	 a	 specific	 and	 stronger	 response	 as	well	 as	 the	
development	 of	 an	 immunological	 memory.	 It	 is	 the	 interplay	 of	 two	 types	 of	
lymphocytes,	the	B-	and	the	T-cells,	which	originate	from	hematopoietic	stem	cells	in	
the	bone	marrow.	While	B-cell	 activation	 results	 in	a	humoral	 response	via	antibody	
production,	T-cells	initiate	a	cell-mediate	immune	reaction.	There	are	different	subsets	
of	T-cells,	including	T-helper	cells	(TH1,	TH2,	TH3,	TH9	and	TH17),	regulatory	T-cells	(TReg),	
cytotoxic	T-cells	and	T-follicular	cells	(TFH).	T-cells	are	activated	upon	the	recognition	of	
antigens	presented	on	major	histocompatibility	complexes	(MHC)	either	by	host	cells	or	
by	antigen	presenting	cells	(APC),	e.g.	DC.	It	is	the	T-cell	receptor	(TCR)	in	combination	
with	a	co-receptor,	either	CD4	or	CD8,	that	recognizes	the	Antigen-MHC	complex.	Hence	
T-cells	can	be	distinguished	by	their	co-receptor	in	either	CD4+	T-helper	cells,	or	CD8+	
cytotoxic	T-cells.	Similar,	to	B-cells,	CD8+	cytotoxic	T-cells	are	specific	for	the	recognition	
of	 one	 particular	 antigen	 presented	 by	 the	 host	 cell	 on	 the	 MHC	 I	 receptor.	 Upon	
binding,	the	cytotoxic	T-cell	is	activated	and	releases	perforin,	granzymes	and	granulysin	
in	 order	 to	 induce	 apoptosis	 of	 the	 host	 cell	 and	 thereby	 prevents	 for	 example	 the	
replication	of	a	virus	or	cancer	development.			
CD4+	T-helper	cells	generally	do	not	have	cytotoxic	activity,	but	regulate	and	potentiate	
the	immune	response	of	the	adaptive	as	well	as	the	innate	immune	system.	Activated	
upon	 binding	 to	 an	 Antigen-MHC	 II	 complex,	 they	 produce	 cytokines,	 which	 guide,	
influence	and	reinforce	the	activity	of	e.g.	MΦ	and	cytotoxic	T-cells.	Furthermore,	CD4+	
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T-cells	 can	 also	 develop	 into	 Treg-cells.	 These	 cells	 are	 critical	 in	 the	maintenance	 of	
immune	 cell	 homeostasis,	 the	 balance	 between	 immunity	 and	 self-tolerance,	 by	
preventing	overshooting	immune	reactions.	
	
1.3 Myeloid	cells	in	cancer:		
The	tumour	microenvironment	is	a	complex	system	of	epithelial	and	endothelial	cells,	
lymphatic	 and	 vascular	 vessels,	 cytokines	 and	 chemokines	 as	 well	 as	 myeloid	 and	
lymphatic	 cells	 [10].	 Within	 this	 milieu,	 the	 tumour	 develops,	 is	 influenced,	 and	
influences	 the	milieu	 itself.	Like	other	 tissues,	a	 tumour	 is	continuously	 infiltrated	by	
immune	cells,	which	affect	its	progression,	prognosis	and	differ	depending	on	the	type	
of	cancer	[11].	While	being	important	for	the	cancers’	characterisation,	these	immune	
infiltrates	are	also	an	interesting	approach	for	cancer	therapy.	Though	the	function	of	
immune	cells	is	the	protection	against	diseases	and	the	elimination	of	abnormal	cells,	
cancers	are	often	able	 to	prevent	 this	and	create	an	 immunosuppressive	milieu	with	
impaired	 immune	 cell	 functioning.	 Immune	 infiltrates	 associated	 with	 this	 include	
myeloid-derived	suppressor	cells	(MDSC),	TAM,	DC	and	T-cells.		
MDSC	are	immune	suppressive	immature	myeloid	cells,	which	are,	depending	on	their	
expression	 of	 plasma	 membrane	 markers	 and	 the	 content	 of	 immune	 suppressive	
molecules,	 subdivided	 into	monocytic	or	granulocytic	MDSC.	They	are	able	 to	 inhibit	
innate	 as	 well	 adaptive	 immune	 responses	 and	 promote	 angiogenesis	 within	 the	
tumour.	 By	 impeding	 cytotoxic	 T-cell	 activation	 and	 function	 and	on	 the	other	 hand	
promoting	Treg	cells,	they	contribute	to	an	immunosuppressive	tumour	milieu	[12].		
	
1.3.1 Macrophages	
Macrophages	are	key	regulators	of	the	adaptive	and	innate	immune	response	by	acting	
as	 APCs	 or	 by	 phagocytosis	 of	 infectious	 agents.	 Furthermore,	 they	 promote	wound	
healing	 and	have	a	homeostatic	 role,	 by	 for	 example	eliminating	 apoptotic	 cells	 and	
cellular	debris	[13].	The	original	idea	that	macrophages	develop	from	peripheral-blood	
mononuclear	cells,	which	migrate	into	the	tissue	in	steady	state	or	during	inflammation,	
has	been	revised	and	a	more	complex	spectrum	of	differentiation	is	now	thought	to	be	
a	more	appropriate	way	of	looking	at	these	cells	[14].	As	a	simplified	overview,	MΦ	have	
been	grouped	into	M1	and	in	M2.	Recent	research,	however,	suggest	that	these	only	
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represent	 extreme	 states	 of	macrophage	 differentiation	 and	 that	MΦ	 form	 rather	 a	
continuous	linear	scale	than	only	two	distinct	subtypes.	Their	differentiation	within	this	
scale	depends	on	the	tissue	milieu	and	soluble	factors,	such	as	granulocyte-macrophage	
colony-stimulating	factor	(GM-CSF)	and	macrophage	colony-stimulating	factor	(M-CSF)	
[15].			
The	combination	of	 IFN-g	and	TLR	signalling	 results	 in	 the	differentiation	of	M1,	also	
referred	 to	as	 classically	 activated	macrophages.	 This	 type	of	MΦ	 is	part	of	 the	 cell-
mediated	immunity	and	has	microbicidal	and	tumourdicidal	activity.	Distinctive	is	the	
secretion	 of	 high	 levels	 of	 pro-inflammatory	 cytokines,	 e.g.	 IL-1,	 -6,	 -12	 and	 -23,	
superoxide	 anions	 and	 oxygen	 as	 well	 nitrogen	 radicals	 [12]	 	 and	 the	 expression	 of	
MHCII.	Hence,	they	are	able	to	induce	a	Th1	and	Th17	response	[16].		
M2	alternatively	activated	macrophages	were	originally	thought	to	be	activated	upon	
IL-4	 and	 IL-13	 signalling.	 However,	 as	 the	 M2	 phenotype	 is	 represented	 by	 a	
heterogeneous	group	of	subtypes,		it	is	more	accurate	to	describe	their	differentiation	
as	 dominated	 by	 the	 STAT6-transcription	 factor,	 and	 incorporating	 signalling	 from	
different	mediators,	 such	 as	M-CSF,	 TGF-b,	 glucocorticoids,	 IL-1b,	 IL-4,	 IL-10	 and	 IL-
13	[17].	The	result	is	a	continuum	of	possible	phenotypes	and	functions,	depending	on	
the	combination	of	mediators.		At	least	four	different	subtypes,	M2a-,	M2b-,	M2c-	and	
M2d-MΦ,	have	been	suggested,	which	differ	in	expression	of	receptors	and	cytokine,	as	
well	as	chemokine	production.	The	general	phenotype	is	characterized	by	up-regulation	
of	 	 mannose	 and	 scavenger	 receptors,	 as	 well	 as	 Toll-like	 receptors	 (TLR)	 and	 high	
expression	of	IL-10,	TNF-a,	but	not	IL-12.	Their	functions	include	the	promotion	of	tissue	
remodelling,	e.g.	wound	healing,	angiogenesis,	parasite	encapsulation	and	regulation	of	
immune	response	by	recruiting	immune	cells	and	TH2-cell	promotion	[18].	M2d-	MΦ,	
have	only	 recently	 been	 associated	with	M2,	 and	 are	 also	 referred	 to	 as	 TAM.	 They	
promote	 tumour	 growth	 by	moderating	 angiogenesis,	 immune	 suppression	 and	 are	
linked	to	the	induction	of	metastasis.	They	also	produce	high	levels	of	IL-1b,	IL-10,	TGF-b	
and	MMP	and	low	levels	of	IL-12	[18].		
	
1.3.2 Dendritic	cells	
Similar	 to	MΦ	 and	 B-cells,	 Dendritic	 cells	 are	 professional	 APC	with	 the	 capacity	 to	
induce	a	primary	adaptive	immune	response	by	antigen-specific	activation	of	CD4+	and	
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CD8+	T-cells.	They	differentiate	from	bone-marrow	derived	progenitor	cells	that	migrate	
via	the	blood	into	lymphoid	and	non-lymphoid	organs.	Immature	DC	constantly	sample	
antigens	 from	 their	 surroundings,	 but	 only	 undergo	 maturation	 upon	 pathogenic	
antigen	uptake	and	stimulation.	The	complex	process	of	maturation	 includes	antigen	
presentation	 on	 MHC	 molecules	 on	 their	 surface,	 the	 down	 regulation	 of	 pro-
inflammatory	 chemokine	 receptors,	 and	 the	 expression	 of	 CCR7	 which	 facilities	
migration	towards	lymph	nodes,	cytokine	production	and	finally	T-cell	activation	[19].	
While	 acting	 as	 a	 link	between	 innate	 and	adaptive	 immune	 system,	DC	also	 induce	
tolerance	towards	self-antigens	and	maintain	tissue	homeostasis.	Simplified	there	are	
two	 broad	 subtypes	 of	 DC,	 plasmacytoid	 DC	 (pDC)	 and	myeloid	 or	 conventional	 DC	
(mDC/cDC).	 Phenotypically	 all	 DC	 express	 high	 levels	 of	 MHC	 II	 (HLA-DR),	 but	 no	
hematopoietic	 lineage	 markers	 CD3,	 14,	 15,	 19,	 20,	 and	 56	 [20].	 pDC	 are	
CD11c−CD123+	DC,	which	are	able	to	produce	high	amounts	INF-a	upon	virus	recognition	
via	TLR7	and	TLR9,	and	can	induce	TH1	and	TH2,	and	cross-present	antigens	to	CTL	[21].	
Furthermore,	they	express	BDCA2/CD303	(blood	dendritic	cell	antigen	2),	BDCA4/CD304	
und	IL-3R/CD123,	which	distinguishes	them	from	cDC	[22].		
While	 summarized	 into	 one	 subgroup,	 cDC	 present	 a	 heterogeneous	 spectrum	 of	
phenotypes	with	at	least	two	general	subtypes	CD1c+CD209+/-	DC	and	CD141+	DC.	They	
respond	 to	microbial	 and	 other	 pathogens,	 produce	 high	 amounts	 of	 IL-12	 and	 can	
induce	 TH1.	 CD1c+	 cDC	 represent	 the	 major	 population	 of	 cDC	 in	 blood,	 tissue	 and	
lymphoid	organs.	When	found	in	tissues,	CD1c+	cDC	appear	more	activated	as	compared	
to	their	blood	counterparts,	and	up	regulate	a	series	of	surface	markers	such	as	CD80,	
CD83,	CD86,	CD40	and	the	chemokine	receptor	CCR7	[20].	They	express	a	number	of	
lectins	and	toll-like	receptors	(TLR	1-8),	and	are	activators	of	naïve	CD4+	T-cells,	with	only	
moderate	 capacity	 to	 cross-present	 antigens	 and	 activate	 CD8+	T-cells.	 Furthermore,	
they	 produce	 a	 number	 of	 cytokines	 such	 as	 TNF-a,	 IL-8,	 IL-10	 and	 IL-12	 when	
stimulated	[20].	 CD141+	DC	are	 infrequent,	 as	 they	only	 represent	10%	of	 cDC.	 They	
express	less	CD11b	and	CD11c	than	do	CD1c+	cDC,	but	co-express	CADM1,	CLEC9A,	TLR3	
und	 XCR1	 [20].	 Additionally,	 they	 are	 more	 competent	 in	 phagocytosis	 of	 dead	 or	
necrotic	cells,	detection	of	viruses	with	TLR3	and	TLR8,	and	in	antigen	cross-presentation	
to	CD8+	T-cells.	They	also	secrete	TNF-a,	CXCL10	and	IFN-l,	but	produce	less	IL12p70.	
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1.3.3 Enriched	in	renal	cell	carcinoma	dendritic	cells	
In	order	 to	 launch	an	effective	anti-tumoural	 immune	 response,	 the	 recognition	and	
phagocytosis	 of	 tumour-specific	 antigens	 by	 DC,	 with	 consequent	 maturation	 and	
migration	towards	lymph	nodes	to	activate	T-cells,	is	required.	However,	various	studies	
have	shown	that	DC	found	in	RCC	tissue	samples	present	with	impaired	function	and	
reduced	ability	to	mature	and	activate	T-cells	[23].		While	the	percentage	of	DC,	cDC	as	
well	as	pDC,	in	peripheral	blood	of	RCC	patients	was	significantly	lower	than	of	healthy	
donors,	the	number	of	infiltrating	DC	in	RCC	tissue	was	found	to	be	higher	than	seen	in	
healthy	kidney	(unaffected	pole	of	kidneys	from	tumour	patients)	[24].	These	DC	in	RCC	
do	not	express	the	maturation	marker	DC-LAMP,	which	is	considered	to	be	a	prognostic	
marker	for	functioning	DC	[25].	These	RCC-DC	also	failed	to	up	regulate	CD80	and	CD86	
–	an	additional	 sign	of	 impaired	 functionality	 [23].	 Furthermore,	ex	 vivo	 cultured	DC	
obtained	 from	patients	with	RCC	exhibited	 a	 fully-matured	 surface	with	maturation-
associated	markers	CD54,	CD80,	CD40,	CD86,	CD83	and	CCR7,	and	were	able	to	induce	
RCC-specific,	 IFN-g	 producing	 T	 cells	 in	 vitro	 [24].	 This	 suggests	 that	 the	 impaired	
functioning	of	DC	in	RCC	might	be	due	to	the	surrounding	tumour	milieu,	e.g.	IL-6,	IL-10,	
VEGF	or	PGE2.		
In	another	study	by	A.	Figel	et.	al.,	 triple	positive	CD209+CD14+CD163+	DC,	which	are	
considered	 to	 represent	 interstitial	 immature	 DC,	 where	 found	 to	 be	 predominant	
within	the	RCC	and	hence	named	“enriched	in	RCC	dendritic	cells”	(ercDC)	[26].	These	
CD209+	DC	unusually	co-express	the	MΦ	markers	CD14	and	CD163,	which	results	in	a	
difficult	 demarcation	 between	 DC	 and	 MΦ.	 Functionally,	 ercDC	 show	 weak	
allostimulation	and	TH1	polarisation,	due	to	the	absence	of	specific	cytokine	production.	
Unlike	 TAM	 and	 MDSC,	 however,	 they	 do	 not	 compromise	 T-effector	 lymphocyte	
function,	as	 they	show	no	down-regulation	of	CD3e	or	CD3z,	 FOXP3	 induction,	T-cell	
apoptosis,	 inhibition	 of	 cognate	 CTL	 cytotoxicity	 or	 CTL	 cytokine	 secretion.	 They	 are	
shown	 to	 secrete	 high	 levels	 of	 MMP-9	 and	 CTL/tumour-cell	 co-cultures	 result	 in	
increased	 levels	of	TNF-a,	 and	a	 reduction	 in	CXCL10/IP-10	and	CCL5/RANTES	 levels.	
Both	TNF-a	and	MMP-9	are	known	to	be	tumour	supportive	cytokines,	which	result	in	
more	aggressive	tumour	growth	and	angiogenesis	[27].	The	chemokines	CXCL10/IP-10	
and	 CCL5/RANTES,	 however,	 are	 important	 in	 TH1-polarized	 effector	 cell	
recruitment	[28].	Furthermore,	attempts	to	in	vitro	differentiate	ercDC	from	monocytes,	
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showed	that	addition	of	CXCL8/IL-8,	IL-6	and	VEGF,	which	are	highly	expressed	within	
the	RCC,	is	sufficient	to	induce	this	RCC	DC	subtype	[29].	These	findings	suggest	that	the	
tumour	milieu	is	able	to	attenuate	DC	function	and	thereby	enables	one	mechanism	for	
RCC	to	escape	from	immune	surveillance.		
		
1.4 Wnt	signalling	
The	Wnt-signalling	pathway	has	been	the	focus	of	an	increasing	number	of	studies.	This	
pathway	plays	 important	 roles	 in	a	 variety	of	 cellular	processes,	 e.g.	 embryogenesis,	
cancer	development,	tissue	repair,	and	neural	as	well	as	immunological	processes	[30].	
Depending	on	tissue	milieu,	cell	type,	and	receptor	profile,	the	19	lipid-modified	Wnt-
ligands	 can	 activate	 a	 complex	 system	 of	 (Wnt-)	 signalling	 cascades,	 historically	
subdivided	into	“canonical-“and	a	subset	of	“non-canonical”	signalling	pathways.	There	
at	 least	15	different	Wnt-receptors	and	co-receptors,	 including	the	Frizzled-receptors	
(Fzd)	 [31],	 low-density	 lipoprotein	 receptor-related	 protein	 5	 and	 6	 (LRP	 5/6)	 [32],	
receptor-like	tyrosine	kinase	(RYK)	[33],	protein	tyrosine	kinase	7	(PTK7)	[34],	receptor	
Tyr	kinase-like	orphan	receptor	(ROR)	[35],	VANGL	planar	cell	polarity	protein	(VANGL)	
[36]	and	many	more.		
While	the	Frizzled-receptors	are	the	largest	group	of	Wnt-receptors,	it	is	not	yet	known	
whether	 they	 can	 function	 without	 a	 co-receptor.	 In	 addition,	 it	 is	 also	 difficult	 to	
distinguish	between	“receptors”	and	“co-receptors”,	as	some	receptors	can	act	in	both	
ways	 [37].	 The	 Frizzled-proteins	 are	 a	 group	 of	 10	 different	 seven-transmembrane	
domain	receptors	which	can	act	as	G-protein-coupled	receptors,	depending	on	cell	type,	
receptor	 setting	 and	 the	downstream	cascade	 [38].	 	 They	 are	 involved	 in	b-Catenin-
dependent	and	independent	signalling,	and	bind	Wnt-ligands	via	a	cysteine-rich	domain	
(CRD),	 which	 is	 also	 found	 in	 other	 receptors,	 such	 as	 the	 muscle-specific	 receptor	
tyrosine	kinase	(MUSK),	neuronal	specific	kinase	(NUSK2),	ROR1	and	ROR2	[39].	Similar	
to	 the	Fzd-receptors,	 it	 cannot	be	said	with	certainty	 that	 the	other	 receptors,	often	
wrongly	referred	to	as	“co-receptors”,	solely	activate	b-Catenin	independent	pathways.	
ROR1/2	for	example	are	single-pass	transmembrane	receptors	Tyr	kinases,	which	can	
bind	Wnt5a	and	mainly	activate	the	PCP-pathway	and	the	Ca2+-pathway	[37].	However,	
under	certain	 tissue	settings	ROR	can	also	 transduce	b-Catenin	dependent	signalling.	
The	same	can	be	said	about	the	divergent	receptor	tyrosine	kinase	RYK	and	PTK7	[40].		
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A	 complex	 system	 of	 intra-	 and	 extracellular	 processes,	 e.g.	 inhibitors	 and	
phosphorylation,	 decides	 which	 pathway	 is	 activated	 by	 a	 specific	 Wnt-ligand.	
Consequently,	it	can	be	difficult	to	predict	whether	a	specific	Wnt-ligand	is	a	“canonical”	
or	 a	 “non-canonical”	 ligand.	 Furthermore,	 the	 ligand-receptor	 (Wnt-Fzd)	 functional	
specificity	 is	 not	 well	 understood.	 A	 recent	 study	 showed	 that	 while	 Wnt3a	 has	
intermediate	to	strong	binding	to	most	Fzd-receptors,	other	Wnt-ligands	including	Wnt	
4,	5a,	5b	appear	more	selective	in	regard	to	their	Fzd-receptor	binding	[41].		The	current	
paradigm	 suggests	 that	 Wnt1,	 Wnt3a	 and	 Wnt8	 preferentially	 activate	 b-Catenin	
dependent	Wnt-signalling,	while	Wnt4,	Wnt5a	and	Wnt11	are	more	associated	with	b-
Catenin	independent	Wnt-cascades.		
	
1.4.1 Canonical	Wnt-pathway	
Upon	Wnt-b-Catenin	or	“canonical-pathway”	activation,	b-Catenin	accumulates	in	the	
cytoplasm,	 translocates	 into	 the	 nucleus,	 and	 binds	 to	 TCF/LEF-transcription	 factors	
resulting	in	the	modulation	of	target	genes.	At	the	beginning	of	this	signalling	cascade,	
a	Wnt-ligand	binds	to	a	Fzd-Receptor	and	the	(single-pass	transmembrane)	co-receptor	
LRP5/6	forming	an	oligomeric	complex,	called	signalosome	[42],	which	in	turn	initiates	
calveolin-mediated	 receptor	 endocytosis.	 The	 scaffolding	 protein	 dishevelled	 (Dvl)	 is	
then	 recruited	 to	 the	 cellular	membrane	 and	 co-recruits	 glycogen	 synthase	 kinase	 3	
(GSK3)	 and	 casein	 kinase	 1	 (CKIa),	which	 phosphorylate	 LRP5/6	 and	 thereby	 further	
recruit	AXIN	and	adenomatosis	polyposis	coli	(APC).	Hereby	the	b-Catenin-destruction	
complex	 (APC/Axin/GSK3b)	 is	 disrupted	 and	 inhibited,	 b-Catenin	 is	 not	 further	
phosphorylated,	and	recognised	by	the	Ubiquitin-Ligase,	and	thus	escapes	proteasomal	
degradation.	In	the	absence	of	Wnt-signalling,	Axin,	together	with	other	components	of	
the	 destruction	 complex	 GSK3,	 CKI	 and	 APC,	 orchestrates	 the	 sequential	
phosphorylation	 of	 b-Catenin.	 The	 phosphorylation	 enables	 b-transducin-repeat-
containing	protein	(b-Trcp),	an	E3	ubiquitin	ligase	subunit,	to	ubiquitylate	b-Catenin	and	
thereby	mark	it	for	proteasomal	degradation	[43,	44].		
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Fig.	1:	The	Wnt	–	b-Catenin	dependent	signalling.	The	graph	summarises	main	interactions	within	the	canonical	Wnt-	
signalling	pathway.	Boxes	indicate	gene	products,	arrows	either	activation	or	inhibition	and	“P”	phosphorylation	of	
the	enzyme.	
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1.4.2 Non-canonical	Wnt-pathway	
Apart	 from	 b-Catenin	 dependent	 signalling,	 there	 are	 also	 a	 number	 of	 b-Catenin	
independent	pathways,	 referred	 to	as	 “non-canonical”,	which	 include	 the	Planar	 cell	
Polarity	 pathway	 (PCP),	 Wnt-Ca2+	 pathway	 and	 other	 tissue	 specific	 Wnt	 activated	
signalling	cascades.	These	pathways	become	activated	when	Wnt-ligands	bind	to	Fzd-
receptors,	RYK,	ROR,	PTK7,	MUSK,	VANGL	and	others	or	a	combination	of	Fzd	with	the	
other	receptors	acting	as	co-receptors.		
	
The	planar	 cell	polarity	pathway	plays	a	 role	 in	epithelial	orientation,	as	 seen	during	
embryogenesis	 and	 in	 the	 structural	 orientation	 of	 multicellular	 tissues.	 It	 is	 also	
associated	with	human	diseases,	such	as	neural	tube	defect,	cystic	renal	diseases	[45]	
and	 cancer	 development.	 The	 planar	 cell	 polarity	 pathway	 regulates	 cytoskeletal	
rearrangements	as	well	 as	 the	 transcription	of	 target	genes.	When	a	Wnt-ligand,	 for	
example	Wnt5a	or	Wnt11,	binds	to	a	Fzd-receptor,	RYK	or	ROR1/2,	VANGL	and	Dvl	are	
recruited	 to	 the	 plasma	 membrane	 and	 dishevelled-associated	 activator	 of	
morphogenesis	1	(Daam1)	is	activated.	In	order	to	induce	cell	polarity,	so-called	“core	
PCP”	proteins	are	asymmetrically	organised	in	an	apical-basal	manner	within	a	cell	or	
between	cellular	 formations	upon	Wnt	stimulation	[46].	While	Dvl	 is	recruited	to	the	
apical	side	towards	the	activated	Fzd-receptor,	VANGL	is	recruited	to	the	basal	side	of	
the	cell	[47]	by	physical	interaction	with	receptor	for	activated	C	kinase	1	(Rack1)	[48].	
Furthermore,	 it	 has	 been	 shown	 that	 a	 Wnt5a-ligand	 gradient	 is	 transduced	 into	 a	
VANGL2	phosphorylation	by	forming	a	ROR2-VANGL2	receptor	complex,	which	seems	
to	be	of	importance	for	the	PCP-signalling	pathway	[49].	Downstream	of	Dvl	ras	homolog	
family	member	A	(RHOA),	Rho-associated	coiled-coil	containing	protein	kinase	(ROCK),	
ras-related	C3	botulinum	toxin	substrate	1	(RACI),	c-JUN	N-terminal	kinase	(JNK)	and	cell	
division	 control	 protein42	homolog	 (CDC42)	 can	be	 activated	 and	 affect	 cytoskeletal	
rearrangement,	as	well	as	transcription	of	target	genes	[50,	51].			
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Fig.	2:	The	Wnt	–	Planar	cell	polarity	pathway.	The	graph	summarises	main	interactions	within	the	non-canonical	
Wnt-	PCP	pathway.	Boxes	indicate	gene	products,	arrows	either	activation	or	inhibition	and	“P”	phosphorylation	of	
the	enzyme.			
Wnt5a	 stimulation	 can	 also	 induce	 an	 intracellular	 increase	 in	 Ca2+,	 Inositol-1,4,5-
triphosphate	(IP3)	and	Diacylglycerol	(DAG)	by	activating	Phospholipase	C	through	Wnt-
Fzd	and	ROR	receptor	 interaction.	 IP3	then	diffuses	through	the	cytosol	and	releases	
Ca2+	from	the	endoplasmic	reticulum	[52].	The	increase	in	Ca2+	and	DAG	activate	Calcium	
sensitive	 calmodulin-dependent	 protein	 kinase	 II	 (CAMKII),	 proteinkinase	 C	 (PKC)	 or	
calcineurin.	Downstream	of	CAMKII,	PKC	and	calcineurin	various	effector	proteins	are	
activated	 by	 dephosphorylation,	 such	 as	 nuclear	 factor	 kappa-B	 (NFkB),	 cAMP	
responsive	element	binding	protein	 (CREB)	and	nuclear	 factor	associated	with	T	cells	
(NFAT),	which	act	as	nuclear	transcription	factors.	Re-phosphorylation	of	NFAT	by	GSK3	
leads	to	its	export	from	the	nucleus	and	ending	of	its	activation	[53].	CAMKII	can	also	
activate	 nemo-like-kinase	 (NLK),	 which	 enters	 the	 nucleus	 and	 inhibits	 b-Catenin	
signalling	by	phosphorylation	and	degradation	of		TCF/LEF,	the	transcription	factors	of	
the	b-Catenin	dependent	signalling	pathway	[54].	Furthermore	Wnt-Fzd	interaction	can	
activate	phosphodiesterase	(PDE)	in	a	Ca2+	dependent	manner,	regulating	intracellular	
cyclic	nucleotide	concentrations	through	hydrolysis	of	cGMP	to	its	nucleoside	5-prime	
monophosphates	[55].		
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Fig.	 3:	 The	Wnt	 –	 Ca2+	 pathway.	 The	 graph	 summarises	 main	 interactions	 within	 the	 non-canonical	 Wnt-	 Ca2+-	
pathway.	Boxes	indicate	gene	products,	circles	additional	molecules	involved,	arrows	either	activation	or	inhibition	
and	“P”	phosphorylation	of	the	enzyme.	
1.4.3 Complexity	of	Wnt-signalling		
The	Wnt-signalling	pathway	is	a	complex	intracellular	signalling	network	with	cross-talk	
between	 different	 cascades	 and	 other	 signalling	 pathways,	 e.g.	 the	 Sonic	 Hedgehog	
pathway	[56],	rather	than	a	single	linear	signalling	pathway	[57].	In	order	to	achieve	this	
network	and	the	activation	of	differing	downstream	signalling	cascades,	a	number	of	
context	dependent	modifiers	are	required.	The	full	extent	of	this	network,	as	well	as	the	
exact	mechanisms	are	not	yet	fully	understood	and	are	still	under	continuing	research.		
A	 number	 of	 different	 mechanisms	 of	 cascade	 activation	 have	 been	 suggested.	
Following	 Grumolato	 et	 al.	 the	 activation	 of	 b-Catenin	 dependent	 versus	 b-Catenin	
independent	 signalling	 depends	 on	 the	 ability	 to	 couple	 a	 Fzd-receptor	 with	 an	
endogenous	 co-receptor	 [58].	 In	 this	 study	 it	was	 shown	 that	Dvl	 not	 only	 acts	 as	 a	
specific	 downstream	 scaffolding	 protein,	 but	 also	 as	 a	 switch	 between	 b-Catenin	
dependent	and	independent	signalling,	by	enabling	the	phosphorylation	and	activation	
of	specific	co-receptors,	LRP5/6	and	ROR1/2,	via	GSK3b	and	Axin.	Furthermore	 it	has	
been	 suggested	 that	 Wnt5a	 inhibits	 b-Catenin	 dependent	 signalling	 via	 ROR2	
signalling	[59]	 or	 the	 Siah/APC-cascade	 [60].	 Thrasivoulou	 et	 al.	 investigated	 the	
mechanisms	of	nuclear	translocation	of	b-Catenin	and	proposed	a	convergent	model	of	
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Wnt-signalling	in	which	an	increase	in	intracellular	and	nucleoplasmic	Ca2+	depolarizes	
the	nucleoplasmic	envelope	and	thereby	enables	and	increases	b-Catenin	translocation	
into	the	nucleus.	This	was	shown	for	a	number	of	Wnt	ligands	(3A,	4,	5A,	7A,	9B,	and	
10B)	in	different	mammalian	cell	lines	and	suggests	a	coupled	mechanism	of	Wnt/Ca2+	
and	b-Catenin	dependent	pathway	[61].	In	another	study	it	was	shown	that	JNK	inhibits	
Wnt3a-induced	b-Catenin	 signalling	by	 inducing	 the	nuclear	 export	 of	b-Catenin	 and	
thereby	inhibiting	the	b-Catenin	dependent	expression	of	target	genes	[62].	Although	
these	findings	seem	opposing	it	could	be	explained	by	further	mechanism	that	are	not	
yet	known	and	need	further	investigation.		
	
In	addition	to	intracellular	mechanisms,	that	decide	on	cascade	activation	or	inhibition,	
there	are	also	a	number	of	soluble	extracellular	proteins	that	influence	Wnt-signalling.	
This	includes	Wnt-inhibitors	such	as	the	Dickkopf-proteins	(DKK),	soluble	frizzled	related	
proteins	 (sFRP),	 Wnt-inhibitor	 factors	 (WIF)	 and	 Cerberus.	 DKK-proteins	 bind	 the	
Wnt-coreceptors	 LRP5/6	 and	 thereby	 modify	 b-Catenin	 dependent	 Wnt-signalling.	
While	DKK	4	acts	as	Wnt-	antagonist	[63],	DKK1,	DKK2	and	DKK3	can	either	antagonize	
or	potentiate	Wnt-signalling	depending	on	cell	type	and	receptor	profile	[64].	Kremen,	
a	single-pass	transmembrane	receptor,	can	negatively	regulate	Wnt-signalling	via	the	
LRP5/6	co-receptor	 in	the	presence	of	Dickkopf	by	mediating	LRP	 internalisation,	but	
can	also	facilitate	Wnt-signalling	in	the	absence	of	DKK	[65].		
Other	Wnt-antagonists,	such	as	sFRPs,	WIF	and	Cerberus	bind	to	Wnt-ligands	and	are	
thought	 to	 inhibit	 Wnt-signalling	 by	 competing	 with	 Fzd-receptors	 for	 Wnt-ligand	
binding	or	direct	interaction	with	Wnt-receptors.	The	sFRPs	have	a	Cystein	rich	domain	
(CRD),	which	is	similar	to	that	of	Fzd	receptors,	and	WIF	have	a	Wnt	interacting	domain	
similar	to	that	of	the	RYK-receptor,	which	allows	their	interaction	with	the	Wnt-ligand.	
However,	there	is	also	evidence	that	sFRPs	might	be	able	to	enhance	Wnt-signalling	by	
enabling	Wnt-ligand	distribution	[66]	and	LRP	phosphorylation	[67].	Hence,	the	view	of	
Wnt-antagonists	solely	acting	as	inhibitors	of	Wnt-signalling	has	to	be	renewed	and	a	
more	complex	system	should	be	applied.		
	
Positive	 influencers	 of	 Wnt-signalling	 are	 collagen	 triple	 helix	 repeat	 containing	 1	
(CTHRC1)	and	R-spondins.	CTHRC1,	a	secreted	glycoprotein	is	involved	in	the	selective	
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activation	of	 the	PCP-pathway	possibly	 by	 forming	 a	CTHRC1-Wnt-Fzd/Ror2	 complex	
[68]	 and	 thereby	 stabilizing	 ligand-receptor	 interaction.	 R-spondins	 can	 act	 as	Wnt-
agonists,	which	potentiate	Wnt-signalling	in	the	presence	of	Wnt-ligands.	A	number	of	
different	receptors,	such	as	the	syndecans	and	leucine-rich	repeat-containing	G	protein-
coupled	 receptors	 (LGRs),	 have	 been	 suggested	 for	 R-spondin	 interaction	 [37].	
Ohkawara	 et	 al.	 investigated	 a	 possible	 molecular	 mechanism	 for	 R-spondin	 and	
syndecan	 interaction,	 suggesting	 clathrin-mediated	 endocytosis	 of	 the	Wnt-receptor	
complex	 upon	 SDC4	 and	 R-spondin3	 binding,	 allowing	Wnt/PCP-activation	 [69].	 This	
ligand-receptor	internalisation	is	not	only	associated	with	Wnt/PCP-signalling,	but	also	
other	Wnt-cascades.	 Heparan	 sulphate	 proteoglycans	 (HSPG),	 notably	 glypicans	 and	
syndecans,	 can	 act	 as	Wnt-Coreceptors	 and	 enhance	Wnt-signalling	 by	 binding	 both	
ligand	 and	 receptor,	 allowing	 endocytosis	 and	 enhancement	 of	 Wnt-signalling	 [37].	
syndecans	 and	 glypicans	 can	 act	 as	 Co-receptors	 in	 a	 variety	 of	 different	 cellular	
signalling	cascades	by	interacting	with	e.g.	Fzd.	in	Wnt-signalling,	Hedgehog	receptors	
and	transforming	growth	factors	b	(TGF-b)	receptors	[70].		
	
In	 summary,	 it	 can	 be	 said	 that	 Wnt-signalling	 is	 represented	 by	 a	 complex	 set	 of	
different	signalling	cascades,	 including	extensive	cross-talk	within	these	cascades	and	
with	other	signalling	pathways.	There	are	19	different	Wnt-ligands,	over	15	receptors	
and	many	more	co-receptors	and	extracellular	as	well	as	intracellular	Wnt-modulators	
that	 make	 it	 difficult	 understand	 and	 predict	 Wnt-signalling.	 To	 simplify,	 one	 can	
distinguish	between	b-Catenin	dependent	and	b-Catenin	independent	signalling,	which	
in	 turn	 consists	 of	 Wnt-PCP	 and	 Ca2+	 signalling.	 However,	 making	 this	 distinction	
requires	a	profound	understanding:	Considering	that	this	is	only	a	simplified	model,	it	is	
clear	that	there	are	many	more	factors	and	interactions	that	are	not	yet	fully	understood	
and	under	on-going	research.	
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2 Aim	of	the	present	study	
Wnt-signalling	has	been	studied	in	the	context	of	a	variety	of	cellular	processes	and	has	
been	 linked	 to	 the	 development	 and	 differentiation	 of	 immune	 cells	with	 especially	
strong	ties	to	myeloid	biology.	The	aim	of	this	study	was	to	characterize	the	differences	
in	activation	status	of	Wnt-signalling	in	different	myeloid	cells	with	special	emphasis	on	
cDC	and	ercDC.	We	hypothesized	that	as	myeloid	cells	undergo	activation	to	different	
effector	subtypes	including	cDC	and	the	resident	ercDC,	they	alter	the	Wnt-activation	
status	and	that	these	changes	may	be	linked	to	their	effector	function.	As	a	first	step,	
we	therefore	performed	transcriptomic	analyses	on	primary	human	peripheral	blood	
monocytes	 from	 healthy	 donors	 and	 in	 vitro	 generated	 M1,	 M2,	 cDC	 and	 ercDC.	
Differential	 gene	 expression	 within	 the	 canonical	 and	 non-canonical	 Wnt-signalling	
cascades	was	selectively	investigated.		
The	 effects	 of	 altering	Wnt-signalling	 via	 inhibition	 or	 stimulation,	 on	 the	 functional	
abilities	 of	 cDC	 and	 ercDC,	 were	 evaluated	with	 special	 emphasis	 on	 their	 essential	
functional	abilities,	including	migration	and	cytokine	production.		
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3 Materials	
3.1 Instruments	
Name	 Manufacturer	
BD™	LSR	II	 Becton	 Dickinson	 (BD),	 Franklin	 Lakes	
(USA)		
Eppendorf	„Centrifuge“	5417	R		 Eppendorf,	Hamburg		
Fluorescence	Microscope	DMRBE		 Leica,	Wetzlar		
HERAcell®	240i	CO2-Incubator	 Heraeus	Instruments,	Hanau		
Irradiator	HWM-D-200,		
(radiation	source:	Caesium137)		
Gammacell®	40,	Ottawa	(Canada)		
Jenoptik	ProgRes	CCD	camera	 Jenoptik,	Jena	
Laminar	flow	working	bench		 BDK,	Sonnenbühl-Genkingen		
Leica	DM	IL	microscope		 Leica	Microsystems,	Wetzlar	
LightCycler®	Instrument	480	 Roche	Life	Science,	Unterhaching	
MACS	Multistand	(quadro	MACS)		 Miltenyi	Biotec,	Bergisch	Gladbach		
Magnetseparator,	 SPRIPlate	 Super	
Magnet	Plate		
Beckman	Coulter,	Brea	(USA)		
Milli-Q®	 Integral	 Water	 Purification	
System	
Merck	Millipore,	Billerica	(USA)		
	
Microwave	 Milestone	Medical,	Kalamazoo	(USA)	
Mikrozentrifuge	Biofuge	Pico		 Heraeus	Instruments	GmbH,	Hanau		
Multichannel	pipette		 Thermo	Scientific,	Waltham	(USA)		
Neubauer	Chamber	 GLW,	Würzburg	
Nitrogen	tank		 Messer	Griesheim,	Krefeld		
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Nunc-Immuno™	Washers	 Nunc,	Wiesbaden		
Pipetus®	battery		 Hirschmann	Laborgeräte,	Eberstadt	
Power	supply	PowerPac300	 Biorad,	München	
QubitTM	fluorometer	 Invitrogen,	Karlsruhe	
Rotator		 VWR	international,	Westchester	(USA)		
SpeedVac	Univapo	150	ECH		
	
Montreal	Biotech,	Montreal	(Canada)		
	
Spectrophotometer	sunrise		
	
Tecan	 Group	 AG,	 Männedorf	
(Switzerland)		
Thermomixer	comfort	 Eppendorf,	Hamburg	
UV	Transilluminator	 Bachofer,	Reutlingen	
Vortexer		 Heidolph	Instruments,	Schwabach		
Water	bath	 Köttermann,	Uetze	
Zentrifuge	Megafuge	2.0/2.0	R		 Heraeus	Instruments	GmbH,	Hanau		
	
3.2 Consumables	
Name		 Manufacturer	
Butterfly	(Ecoflo)		 Dispomed	Witt	oHG,	Gelnhausen		
Cell	scraper	S	(24cm)	 TPP,	Trasadingen	(Switzerland)		
Cell	scraper	mini	 LEAP	Biosciences	Corp.,	Palo	Alto	(USA)		
Cell	strainer	(700/100	μM)	 BD,	Franklin	Lakes	(USA)		
Cell	culture	flasks	(75/175cm2)	 Greiner	bio-one,	Kremsmünster	(Austria)		
ELISA	plates	 Greiner	bio-one,	Kremsmünster	(Austria)		
Eppendorf	tubes	(0,5/1,5/2	ml)		 Eppendorf,	Hamburg		
FACS-tubes	(1,5ml,	polypropylen)		 Greiner	bio-one,	Kremsmünster	(Austria)	
Falcon	tubes	(15/50	ml)		 BD,	Franklin	Lakes	(USA)		
MACS	Separation	Columns,	25	LS		 Miltenyi,	Biotec,	Bergisch	Gladbach		
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Nunc™	Well	Plates	(Flat	&	Round	Bottom	
(6-,	24-,	96-well)		
Nunc,	Wiesbaden		
	
Pasteurpipettes,	glas		 Peske	OHG,	Aindling		
Pipette	tips	 Eppendorf/Gilson,	Zentrallager	
Helmholtz-Zentrum,	Neuherberg		
QIAshredder		 QIAGEN,	Venlo	(Netherlands)		
“Safe-lock	tubes”	(1,5ml,	RNAse	free)	 Eppendorf,	Hamburg		
scalpel	 Aesculap	AG,	Tuttlingen		
Serological	Pipettes	(2	ml,	5	ml,	10	ml	und	
25	ml)	
Greiner	bio-one,	Kremsmünster	(Austria)		
µ-Slide	Chemotaxis	 Ibidi,	Planegg/Martinsried	
Syringe	(5/50ml)	 BD,	Franklin	Lakes	(USA)		
Taqman	plates	 Sarstedt,	Nümbrecht	
Taqman	cover	 Sarstedt,	Nümbrecht	
Trans-well	24	well	plate,	5	μM	pore	size	 Costar,	Corning	(USA)	
Vortexer	 neo-Lab,München	
	
3.3 Media,	chemicals,	reagents	and	additives	
Name		 Manufacturer	
AccuCheck	counting	beads	 Invitrogen,	Thermo	Fisher	Scientific,	
Waltham		
Acetic	acid	 Merck	KGaA,	Darmstadt		
Agarose,	ultrapure	 Invitrogen,	Thermo	Fisher	Scientific,	
Waltham	
AIM-V	 Life	Technologies,	Carlsbad	(USA)		
7-Amino-Actinomycin	D	(7-AAD)		 Sigma-Aldrich,	St.Louis	(USA)		
Aqua	ad	injectabilia	 Braun,	Melsungen	
ß-Mercaptoethanol	 Roth,	Karlsruhe	
Bovines	serumalbumin	(BSA)		 Sigma	Aldrich,	St.Louis	(USA)		
CD14	Microbeads		 Miltenyi	Biotec,	Bergisch-Gladbach		
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Collagen	I	Bovine	Protein,	5	mg/ml		 GIBCO,	 Thermo	 Fisher	 Scientific,	
Waltham	(USA)	
CompBeads	(anti-mouse/anti-rat	Ig,	κ;	
FCS)	
BD,	Franklin	Lakes	(USA)		
3,3'-diaminobenzidine	(DAB)	 Sigma	Aldrich,	Taufkirchen	
Dimethylsulfoxid	(DMSO)	 Merck	KGaA,	Darmstadt		
Dithiothreitol	(DTT)	 Invitrogen,	Karlsruhe	
Ethanol		 Merck	KGaA,	Darmstadt		
Ethylenediaminetetraacetic	acid	(EDTA)	 Sigma	Aldrich,	St.Louis	(USA)		
Ficoll®	(Biocoll,	concentration	1,077	
g/ml)		
Biochrom	AG,	Berlin		
First-strand	buffer	(5x)	 Invitrogen,	Thermo	Fisher	Scientific,	
Waltham	
Fetal	calf	serum	(FCS)	 Life	Technologies,	Carlsbad	(USA)		
Heparin	2500	IE		 Essex	Pharma	GmbH,	München	
HEPES,	1M	 Invitrogen,	Carlsbad		
Hexanucleotides	 Roche	Diagnostics,	Mannheim	
Human	serum	(HS)	(different	healthy	
donors)	
IMI	Helmholtzzentrum,	München	
Hydrogen	peroxide	solution,	30%	 Merck	KGaA,	Darmstadt	
Ibidi	freezing	medium	classic,	serumfree		 Ibidi,	Planegg/Martinsried		
L-Glutamine	 Life	Technologies,	Carlsbad	(USA)		
Lipopolysaccharid	(LPS)	E.coli		 Sigma	Aldrich,	St.Louis	(USA)		
Magnesiumchloride	 Fermentas,	St.Leon-Rot	
Methanol		 Merck	KGaA,	Darmstadt		
Methyl	green	 Fluka,	Schnelldorf	
MoDC-differentiation	medium,	human	
(contains	FCS,	RPMI	1640,	L-Glutamine,	
IL-4,	GM-CSF)	
Miltenyi	Biotec,	Bergisch-Gladbach		
	
Non-essential	amino	acids	(NEAA)	(100x)		 Life	Technologies,	Carlsbad	(USA)		
dNTP	set	 Fermentas,	St.Leon-Rot	
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Paraformaldehyd	(PFA)		 	 Merck	KGaA,	Darmstadt		
Penicilline/Streptomycine	(100x)		 Life	Technologies,	Carlsbad	(USA)		
Phosphate	buffered	saline	(PBS)	 Life	Technologies,	Carlsbad	(USA)		
Polysorbat-20	(Tween	20)		 Sigma	Aldrich,	St.Louis	(USA)		
Propidiumjodid	(PI)		 Sigma	Aldrich,	St.Louis	(USA)		
RNAsin	–	ribonuclease	inhibitor	 Promega,	Madison,	USA	
Rox	reference	dye	(25x)	 Invitrogen,	Thermo	Fisher	Scientific,	
Waltham	
RPMI	1640	Medium		 Sigma	Aldrich,	St.	Louis	(USA)		
Sodium	azide	 Sigma	Aldrich,	St.Louis	(USA)		
Sodiumcarbonat,	hydrogencarbonat		 Merck	KGaA,	Darmstadt		
Sodiumchloride		 Merck	KGaA,	Darmstadt	
Sodium	pyruvate	 Life	Technologies,	Carlsbad	(USA)		
SYBRgreen	I	(250x)	 Fluka,	Schnelldorf	
Trishydroxymethylaminomethan	(Tris)	 Merck	KGaA,	Darmstadt	
Trypan	blue	 ICN	Biomedicals	GmbH,	Eschwege		
Trypsin-EDTA	(10x)		 Life	Technologies,	Carlsbad	(USA)		
Taq	buffer	without	detergent	(10x)	 Fermentas,	St.Leon-Rot	
VectaMount	Permanent	Mounting	
Medium	
Vector	Laboratories,	Burlingame,	
Carlifornia	(USA)	
Xylol	 Merck	KGaA,	Darmstadt	
	
3.4 Prepared	buffers	and	solutions	
Name	 Preparation	
ELISA	–	blocking	buffer	 PBS	
+10%FCS	
ELISA	–	coating	buffer		
	
0,1	M	Carbonatebuffer	pH	9,5:		
8,4	g	NaHCO3		
3,56	g	Na2CO3		
ad	1	L	Milipore-water		
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ELISA	–	washing	Buffer		
	
PBS	
+	0,05%	Tween	20		
FACS	–	acid-buffer		
	
PBS	
+	2	mM	EDTA		
+	0,1%	sodium	azide		
+	2%	FCS		
MACS	–	buffer		
	
PBS	
+	2	mM	EDTA		
+	0,5%	FCS		
Trypsin	–	EDTA	–	solution	(2x)	
	
PBS	
+	20%	10x	Trypsin-EDTA		
Loading	buffer	 H2O	
+	0.25%	Bromphenol	blue	
+	0.25%	Xylene	cyanol		
+	30%	glycerol		
SYBRgreen	I	solution	 1:100	in	H2O	with	20%	DMSO,	(-20°C)	
SYBRgreen	Mastermix	 20%	Taq	buffer	without	detergent	
+	375	μM	NTPs	
+	4%	Rox	referencedye	
+	40%	PCR	Optimizer	
+	2%	BSA	
+	0.4%	SYBRgreen	I	solution		
+	6	mM	MgCl2	
	
3.5 Prepared	media	
Name	 Preparation	
RPMI	–	basismedium		
	
RPMI	1640		
+	2	mM	L-Glutamine	
+	1	mM	Sodium	pyruvate	
+	1	mM	NEAA	
LCL	–	medium		
(L929-CD40L-cells)		
RPMI	–	basismedium		
+	10%	FCS		
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RCC	–	medium		
(RCC-26-Zellen	)	
RPMI	–	basismedium		
+	12%	FCS		
AIM-V	–	medium		
(myeloid	cells)		
AIM-V	(serumfree)	
+	2	mM	L-Glutamine	
	
3.6 Enzymes	and	enzyme	solutions		
Name	 Manufacturer		
DNAse	I	 Qiagen,	Hilden	
RNase	A	(10	mg/ml)	 Roche	Diagnostics,	Mannheim	
Taq	DNA	–	polymerase	(5U/μl)	 NEB,	Frankfurt	a.M.	
Streptavidin-Horseradish	peroxidase	 Vector	Laboratories,	Burlingame,	USA	
	
3.7 Antibodyies	
Name	 Manufacturer	
Mouse	anti-Wnt5a	antibody		 abcamÒ,	Cambridge,	UK	
Biotinylated	goat	anti-mouse	IgG	 Jackson	ImmunoResearch	
Laboratories,	West	Grove,	USA	
	
3.8 qPCR	Primer		
Name	 Manufacturer	
Hs_CAMK2D_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_CELSR1_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_DAAM1_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_FRAT1_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_FRAT2_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_FZD5_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_GPC4_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_HIPK2_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
IL10,	 human,	 TaqMan®	 Gene	 Expression	
Assay	
Thermo	 Fisher	 Scientific,	 Waltham	
(USA)	
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IL12A,	 human,	 TaqMan®	 Gene	 Expression	
Assay	
Thermo	 Fisher	 Scientific,	 Waltham	
(USA)	
IL12B,	 human,	 TaqMan®	 Gene	 Expression	
Assay	
Thermo	 Fisher	 Scientific,	 Waltham	
(USA)	
Hs_NFATC1_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_RELA_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_RELB_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_SDC2_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_SDC3_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_TCF7L2_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
Hs_TLE3_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
TNFa,	 human,	 TaqMan®	 Gene	 Expression	
Assay	
Thermo	 Fisher	 Scientific,	 Waltham	
(USA)	
Hs_WNT5A_1_SG	QuantiTect	Primer	Assay	 Qiagen,	Hilden	
	
3.9 Cytokines,	chemokines	and	stimulants	
Name	 Manufacturer	
fMLP	 Sigma-Aldrich,	Taufkirchen	
rhu	CCL19		 Peprotech,	Hamburg	
rhu	IL-1ß	 PromoKine,	Heidelberg	
rhu	IL-6	 Promokine,	Heidelberg	
rhu	PGE2	 Sigma-Aldrich,	Taufkirchen	
rhu	TNF-α	 Sigma-Aldrich,	Taufkirchen	
Lipopolysaccharid	(LPS)	E.coli	 Sigma	Aldrich,	Taufkirchen		
rh-sFRP1	(250µg/ml)	 R&D	systems,	Minneapolis	(USA)	
rh-sFRP5	(100µg/ml)	 R&D	systems,	Minneapolis	(USA)	
rh/m-Wnt5a	(100µg/ml)	 R&D	systems,	Minneapolis	(USA)	
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3.10 Kits	
Name	 Manufacturer	
Avidin/Biotin	Blocking	kit	 Vector	Laboratories,	Burlingame,	
USA	
Human	IL-10	BD	OptEIATM	ELISA	Set		 BD,	Franklin	Lakes	(USA)		
Human	IL-12	(p70)	BD	OptEIATM	ELISA	Set		 BD,	Franklin	Lakes	(USA)		
Human	IL-12	(p40)	BD	OptEIATM	ELISA	Set		 BD,	Franklin	Lakes	(USA)	
Human	TNFa	BD	OptEIATM	ELISA	Set	 BD,	Franklin	Lakes	(USA)		
PureLink®	RNA	Mini	Kit	 Ambion,	Life	technologies,	Carlsbad	
(USA)	
Quant-iTTM	RNA	Assay	kit	 Invitrogen,	Karlsruhe	
RNeasy	Mini	(50)	kit	 Qiagen,	Hilden	
Taqman®	Universal	PCR	Master	mix	 Applied	Biosystems,	Darmstadt	
	
3.11 Cells	
Cells	 Description	 Source	 Medium	
„classical“	DC	(cDC)	 Differentiated	from	
monocytes	 of	
healthy	 human	
donors	
generated	 in	 the	
lab	
MoDC-Diff.-
Medium,	AIM-V-
Medium	(1%	HS)	+	
IL-4	+	GMCSF		
	
„enriched	 in	 renal	
cell	 carcinoma“	 DC	
(ercDC)	
Differentiated	from	
monocytes	 of	
healthy	 human	
donors	 through	
addition	of	RCC-26-
CM	
generated	 in	 the	
lab	
AIM-V-Medium		
(3%	HS),	VLE-
Medium	(6%	HS)		
with	 respectively	
25	%	RCC-26-CM		
L929-CD40L		 Mouse-fibroblast-
cell	 line,	
transfected	 with	
human	 CD40L,	
adherent	
P.	Garrone	(1995)		
	
LCL-Medium		
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Peripheral	blood	
mononuclear	cells	
(PBMC)	
Isolated	 from	
human	 whole	
blood	 of	 healthy	
donors	
Not	cultured		 Healthy	donors	
RCC-26		
	
Human	 renal	 cell	
carcinoma	cell	line,		
HLA-A2-positiv,	
adherent	
	
RCC-Medium		
	
IMI,	 Helmholtz	
Zentrum	München	
	
3.12 Blood	samples	
Whole	blood	samples	were	kindly	donated	by	healthy	human	donors.		All	blood	drawls	
were	performed	by	authorised	and	qualified	personnel.	The	donors’	informed	consents	
and	the	full	approval	of	the	ethics	commission	were	obtained	beforehand.		
	
3.13 Array	data	
For	 transcriptomic	 analysis	 in	 vitro	 and	 ex	 vivo,	myeloid	microarray	 expression	 data	
were	 kindly	 provided	 by	 the	 group	 of	 Prof.	 Dr.	 Elfriede	Nößner	 from	 IMI	 Helmholtz	
Zentrum	Munich.	Microarray	expression	data	of	healthy	kidney	samples	and	renal	cell	
carcinoma	samples	were	provided	by	PD	Dr.	Matthias	Maruschke	from	the	Department	
of	Urology	of	the	University	of	Rostock	[71].	Subsequent	analyses	were	performed	in	
the	laboratory	of	Prof.	Dr.	Peter	Nelson,	Klinische	Biochemie,	Medizinische	Poliklinik	der	
LMU.		
	
3.14 Kidney	sections	for	immunohistochemistry		
Kidney	sections	of	healthy	human	kidney	and	human	renal	cell	carcinoma	were	provided	
by	 Prof.	 Dr.	 Hermann-Josef	 Gröne,	 head	 of	 Department	 of	 Cellular	 and	 Molecular	
Pathology	at	the	DKFZ	Heidelberg.	Sample	preparation	and	immunohistochemistry	were	
performed	in	the	laboratory	of	Prof.	Dr.	Nelson.		
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3.15 Software	
Name	 Manufacturer	
Adobe	Illustrator		 Adobe,	San	Jose	(USA)		
Affymetrix®	Expression	Console™	 Affymetrix,	Santa	Clara	(USA)	
BD	FACSDivaTM		 BD,	Franklin	Lakes	(USA)		
Endnote	X7.0.2		 Thomson	Reuters,	New	York	(USA)		
FlowJo		 TreeStar	Inc.,	Ashland	(USA)		
Graph	Pad	Prism	6		 Graphpad	Software,	La	Jolla	(USA)		
ImageJ	1.49v	(Plugins:	Manual	Tracking,	
Chemotaxis	Tool)	
National	Institute	of	Health,	Bethesda	
(USA)	
MADMAX	 Bioinformatics,	 Wageningen	 UR,	
Wageningen	(Netherlands)	
Microsoft	Office	2010		 Microsoft,	Redmond	(USA)		
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4 Method		
4.1 Cell	culture	
4.1.1 General	cell	culture	
The	culture	of	cells	was	performed	with	a	laminar	flow	hood	and	only	sterile	materials,	
solutions	and	mediums	were	used	in	order	to	avoid	contamination.	Cells	were	cultivated	
in	an	 incubator	at	37°C,	6,5%	CO2	and	95%	air	humidity.	Unless	stated	otherwise,	all	
centrifugations	were	performed	at	1500rpm	for	5min	with	the	Heraeus	Megafuge	2.0.		
	
4.1.2 Freezing	and	thawing	of	cells	
The	 freezing	 medium	 was	 prepared	 by	 adding	 Dimethylsulfoxid	 (DMSO)	 to	 the	 cell	
medium.	As	DMSO	 is	 toxic	 to	 cells	 all	 steps	were	 performed	quickly	 on	 ice	 to	 avoid	
damage	of	the	cells.	Cells	were	centrifuged,	the	sediment	resuspended	in	500µl	cooled	
FCS	and	then	transferred	into	a	cryotube.	Thereafter,	another	500µl	20%DMSO	freezing	
medium	was	added	to	the	cryotube,	leading	to	a	final	concentration	of	10%	DMSO,	and	
cooled	down	to	-80°C	over	a	period	of	24	or	48h,	and	later	transferred	to	the	gas-phase	
of	 a	 liquid	nitrogen	 tank	 for	 long-term	 storage	 at	 approximately	 -196	 °C.	 In	 order	 to	
freeze	RCC-26-cells,	the	pellet	was	resuspended	in	1ml	Ibidi	freezing	medium,	which	also	
contains	DMSO.		
When	thawing	cells,	the	cryotube	was	rapidly	thawed	in	at	37°C	water	bath	until	2/3	of	
the	suspension	was	thawed,	which	indicated	a	temperature	of	4°C.	Immediately	2ml	of	
FCS	were	added	and	the	suspension	transferred	into	a	15ml	tube	for	centrifugation.	The	
pellet	was	then	resuspended	in	cell	medium	and	transferred	into	a	culture	plate.		
	
4.1.3 Counting	of	viable	cells	
Cells	 were	 counted	 using	 a	 Neubauer	 counting	 chamber.	 An	 aliquot	 of	 the	 cell	
suspension	was	taken	and	mixed	with	Trypan	Blue	in	the	required	ratio	in	order	to	stain	
dead	cells	blue.	When	preparing	whole	blood	for	PBMC	extraction,	3%	acetic	acid	was	
added	 to	 enable	 the	 bursting	 of	 Erythrocytes,	 which	 facilitates	 PBMC	 counting.	 The	
cover	slip	of	the	Neubauer	counting	chamber	had	to	be	attached	to	the	chamber	in	such	
a	way	so	that	the	“Newton	rings”	were	visible.	The	distance	between	chamber	and	slip	
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is	defined	and	enables	counting.	Only	living	cells	were	then	counted	in	all	quadrants	and	
cells	per	ml	could	be	calculated,	regarding	the	dilution	factor:		
Cell	no./ml	=	mean	cell	no.	of	the	4	large	quadrants	x	dilution	factor	x	104	
	
4.1.4 Cultivation	of	RCC-26	cells	
In	 order	 to	 in-vitro	 differentiate	 ercDC	 from	 CD14+	Monocytes,	 RCC-26	 conditioned	
medium	(RCC-26-CM)	was	required.	The	RCC-26	cell	line	is	an	adherent	growing	cell	line	
and	was	cultured	in	lying	cell	culture	flask	with	filter	cover.	Depending	on	the	size	of	the	
culture	flask	(T75	with	75	cm2	or	T175	with	175cm2	growing	surface)	respectively	10	or	
15ml	of	AIM-V	growth	medium	were	used	for	cultivation.	The	cell	medium	had	to	be	
renewed	every	3-4	days,	in	order	to	avoid	lack	of	nutrition.	Furthermore,	cells	were	split	
when	 80-100%	 confluence	 was	 reached	 to	 avoid	 overgrowth.	 For	 this	 purpose,	 the	
medium	was	completely	removed	and	cells	washed	with	5ml	PBS.	Then	1ml	(T75)	or	2ml	
(T175)	Trypsin-EDTA	solution	was	added	to	detach	cells	 from	the	surface,	which	was	
confirmed	by	microscopy.	Thereafter	fresh	culture	medium	with	FCS	was	added,	which	
inhibits	 Trypsin	 and	 its	 reaction,	 and	 the	 solution	 was	 transferred	 into	 a	 tube	 and	
centrifuged.	 The	 supernatant	 was	 then	 discarded,	 the	 pellet	 resuspended	 in	 fresh	
culture	medium	and	 the	 cells	 could	 be	 split	 and	 seeded	 into	 fresh	 flasks	 for	 further	
cultivation.		
In	order	to	obtain	RCC-26-CM,	2x106	RCC-26-cells	were	cultured	in	a	T75	flask	with	10ml	
AIM-V	medium	for	10	days.	Thereafter	the	supernatant	was	collected,	centrifuged	for	
10min	at	2000rpm,	sterile	filtered	through	a	0.2µm	pore	filter	and	frozen	at	-20°C.		
	
4.1.5 Isolation	of	peripheral	blood	mononuclear	cells	from	whole	blood	
Whole	blood	was	donated	from	healthy	donors	and	the	PBMCs	were	isolated	through	
FicollÒ	 density	 centrifugation.	 FicollÒ	 is	 a	 hydrophilic	 polysaccharide,	 which	 is	
commonly	used	to	separate	blood	into	its	components	and	the	isolation	of	PBMCs.	The	
FicollÒ	 density	 centrifugation	 is	 based	 upon	 the	 density	 differences	 between	 the	
mononuclear	cells	and	other	components	of	the	blood.	After	centrifugation	the	whole	
blood	is	separated	into	plasma	(top	layer,	very	low	density),	PBMCs	and	thrombocytes	
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(interphase,	 low	 density)	 and	 polymorphonuclear	 cells,	 such	 as	 neutrophils	 and	
eosinophils,	and	erythrocytes	(bottom	layer,	high	density).	
In	order	to	avoid	coagulation	of	the	whole	blood,	the	50ml	syringes	were	prepared	with	
1000	Units	Heparin/50ml	blood	(100μl	per	syringe)	previous	to	the	blood	draw.	Heparin	
is	an	anticoagulant,	which	inhibits	the	coagulation	of	blood	by	binding	to	and	activating	
antithrombin	and	thereby	inactivating	thrombin	and	other	proteases	involved	in	blood	
clotting.	The	whole	blood	was	 then	one-to-one	diluted	with	RPMI	1640-Medium,	 i.e.	
200ml	whole	blood	with	200ml	RPMI	1640-Medium,	and	each	35ml	of	the	diluted	blood	
layered	over	15ml	FicollÒ	 in	a	50ml	Falcon	tube.	Subsequently,	the	whole	blood	was	
separated	into	its	components	by	centrifugation	for	20min	at	2000rpm	without	break.	
The	interphases,	just	over	the	FicollÒ,	containing	the	PBMCs	were	collected	with	a	10ml	
pipette	into	a	50ml	Falcon-tube,	again	one-to-one	diluted	with	RPMI	1640-Medium	and	
remaining	FicollÒ	washed	away	through	centrifugation	for	12min	at	1900rpm.		
	
4.1.6 Isolation	of	CD14+	monocytes	
Magnetic	Cell	Sorting	(MACS)	was	used	to	isolate	CD14+	monocytes	from	PBMCs.	The	
Principle	of	MACS	separation	is	based	upon	the	magnetic	labelling	of	target	cells.	In	this	
case	monocytes	were	 labelled	with	CD14	Micro	beads.	 	The	CD14	 receptor,	which	 is	
strongly	expressed	on	most	monocytes	and	macrophages,	but	not	on	other	cells,	is	part	
of	 a	 LPS	 receptor	 complex,	 but	 does	 not	 transduce	 signalling	 due	 to	 its	 lack	 of	 a	
cytoplasmic	domain.	The	cell	suspension	is	separated	in	a	column,	which	is	placed	in	the	
magnetic	 field	 of	 the	 MACS	 separator.	 While	 the	 unlabelled	 cells	 pass	 through	 the	
column,	 the	CD14+	 labelled	 cells	 retain	 in	 the	 column	and	 can	 later	 be	 eluted	when	
removing	the	column	from	the	magnetic	field.		
The	 following	 steps	were	 carried	out	 on	 ice.	 The	 supernatant	 of	 the	washed	PBMCs	
isolated	 through	 Ficoll	 density	 centrifugation	was	 decanted	 and	 the	 pellets	 carefully	
resuspended	 in	 10ml	 cold	 MACS	 buffer	 and	 summed	 up	 in	 a	 50ml	 Falcon	 tube.	
Unnecessary	 pipetting	 was	 avoided	 in	 order	 to	 prevent	 cell	 activation	 and	 lump	
formation.	The	tubes	were	rinsed	again	with	10ml	MACS	buffer.	 	The	cell	suspension	
was	then	loaded	onto	a	cell	strainer	filter	(100μm	pore	size)	placed	on	a	50ml	falcon	
tube	in	order	to	eliminate	cell	aggregations	and	big	particles,	filled	up	to	50ml	with	MACS	
buffer	and	centrifuged	for	12min	at	1900rpm	and	4°C.	The	supernatant	was	decanted	
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and	 the	 pellet	 resuspended	 in	 80μl	MACS	 buffer/	 107	 cells.	 Hereafter	 10-15μl	 CD14	
Micro	beads/	107	were	added	and	thoroughly	mixed.	The	suspension	was	then	rotated	
for	15min	at	4°C.		
Surplus	unbounded	beads	were	removed	by	adding	10	times	volume	of	MACS	buffer	
and	12min	centrifugation	at	1900rpm	and	4°C.	The	supernatant	was	decanted,	the	pellet	
re-suspended	in	5ml	cold	MACS	buffer	and	then	loaded	onto	the	MACS	column,	which	
was	equilibrated	with	3ml	MACS	buffer	and	clamped	in	the	MACS	separator.	The	CD14	
negative	cells	were	collected	and	the	column	washed	three	times	with	3ml	MACS	buffer.	
The	column	was	then	removed	from	the	MACS	separator	and	placed	on	a	15ml	Falcon	
collecting	tube.	The	CD14+	cells	were	eluted	with	5ml	MACS	buffer	and	the	help	of	a	
piston.		Thereafter	the	cell	suspension	was	centrifuged	for	12min	at	1900rpm	and	4°C.		
Again	the	supernatant	was	discarded,	the	pellet	re-suspended	in	3ml	AIM-V	medium/1%	
L-glutamine	and	a	small	aliquot	was	taken	for	cell	number	determination.	The	CD14+	
yield	varied	between	15	x	106	to	30	x	106/100	ml	depending	on	the	blood	donor.	
	
4.1.7 In	vitro	generation	of	cDC	and	ercDC	
In	 order	 to	 generate	 CD209+	 CD14+	 conventional	 DC	 (cDC)	 the	 isolated	 monocytes,	
CD14+	 cells,	 were	 differentiated	 using	 Miltenyi’s	 Mo-DC	 differentiation	 medium.	
Miltenyi’s	differentiation	medium	is	based	on	RPMI	1640	Medium	and	contains	the	two	
cytokines	IL-4	and	GM-CSF.	The	monocytes	were	cultured	in	a	6	well	NuncÒ	plate	in	a	
concentration	of	5	x	106	cells/	5ml	Miltenyi’s	Mo-DC	differentiation	medium	per	well.	
On	 day	 three	 of	 culture	 another	 5ml	Miltenyi’s	 Mo-DC	 differentiation	 medium	 was	
added	 to	 each	well.	 The	 cells	were	 then	 either	 used	 as	 immature	 cells	 on	 day	 7	 or	
maturated	 using	 the	 “Jonuleit	 cocktail”	 [72]	 on	 day	 6.	 For	maturation	 on	 day	 6,	 the	
immature	 cDC	were	 harvested	 and	 re-suspended	 in	 1ml/1	 x	 106	 AIM-V	medium/1%	
L-glutamine	 plus	 “Jonuleit	 cocktail”.	 The	 “Jonuleit	 cocktail”	 is	 a	 defined	 cocktail	 of	
interleukin-1ß	 (IL-1ß,	 10ng/ml),	 TNF-α	 (25ng/ml),	 IL-6	 (1μg/ml)	 and	 prostaglandin	
E2(PGE2,	12.5ng/ml),	which	has	been	found	to	be	optimal	for	the	maturation	of	cDC.	
	
For	in	vitro	generation	of	triple	positive	CD209+CD14+CD163+	ercDC,	Figel	et	al.	showed	
that	RCC-26-CM	is	able	to	induce	this	phenotype.	Hence	isolated	CD14+	monocytes	were	
cultured	in	a	6	well	NuncÒ	plate	at	a	cell	density	of	7	x	106	cells/3ml	AIM-V/3%HS/1%	
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L-glutamine	 plus	 1ml	 RCC-26-CM	 per	 well.	 On	 day	 2	 and	 on	 day	 5	 respectively	 1ml	
RCC-26-CM	was	added	to	each	well.	ErcDC	were	harvested	as	immature	cells	on	day	7,	
or	maturated	adding	the	“Jonuleit	cocktail”	on	day	6.	After	adding	the	“Jonuleit	cocktail”	
on	day	6,	cells	were	harvested	24h	later	and	used	for	respective	experiments.		
Alternatively,	immature	ercDC	were	harvested	on	day	6	and	re-suspended	in	AIM-V/1%	
L-glutamine	 without	 RCC-26-CM	 and	 matured	 by	 adding	 “Jonuleit	 cocktail”.	 This	
variation	 allowed	 investigating	 the	 effects	 of	 stimulation	 with	 i.e.	 Wnt5a,	 without	
possible	inhibiting	factors	in	the	RCC-26-CM.		
Where	indicated,	recombinant	proteins,	such	as	Wnt5a	(250ng/ml),	sFRP5	(500ng/ml)	
and	 sFRP1	 (500ng/ml)	 were	 added	 to	 the	 cDC	 and	 ercDC	 suspension	 during	
differentiation.		
	
4.2 Functional	Tests	
4.2.1 Signal-3-Assay	
The	signal-3-assay,	previously	described	by	Mailliard	et	al.,	is	a	functional	test	of	DC	to	
determine	 the	 cytokine	production	of	DC	 after	 T-cell	 contact	 (signal-3)	 [73].	 For	 this	
purpose,	DC	were	co-cultured	with	stimulating	cells,	which	mimic	T-cells.	To	mimic	the	
interaction	with	CD40L-expressing	TH-cells,	the	mouse-fibroblast	cell	 line	L929-CD40L,	
which	was	transfected	with	human	CD40L	(CD40	ligand/CD154),	was	utilized.	To	ensure	
no	 further	proliferation	during	 the	 co-culture,	 the	 L929-CD40L-cells	were	 inactivated	
through	Caesium-irradiation	(100Gy)	and	thereafter	cultivated	for	48h	in	a	96-well-plate	
with	a	density	of	5x104cells/100µl	 LCL-medium.	The	medium	was	 then	 removed	and	
2x104	DC/200µl	AIM-V	medium	(1%HS)	added.	As	a	control	either	L929-Cd49L-cells	or	
DC	 alone	 were	 used.	 After	 24-h	 incubation	 at	 37°C	 and	 6.2%	 CO2,	 the	 cells	 were	
centrifuged	at	2000rpm	for	10min	and	the	supernatant	collected	for	further	cytokine	
determination	with	ELISA.		
	
4.2.2 LPS-Assay	
Lipopolysaccharide	 (LPS),	 which	 can	 be	 found	 in	 the	 membrane	 of	 gram-negative	
bacteria,	has	been	shown	to	be	able	to	induce	DC	maturation.	Upon	stimulation	with	
LPS,	 DC	 increase	 their	 Antigen	 uptake,	 migration	 ability	 and	 secretion	 of	 pro-
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inflammatory	 cytokines.	 Hence,	 LPS	 can	 be	 used	 as	 a	 good	 experimental	 set	 up	 to	
simulate	and	investigate	DC	changes	during	maturation.			
To	investigate	the	differences	between	cDC	and	ercDC	and	the	effects	of	Wnt5a,	sFRP5	
and	 sFRP1	 on	 cytokine	 levels,	 DC	 were	 differentiated	 and	 harvested	 on	 day	 6	 of	
differentiation.	 Thereafter	 the	 growth	 medium	 was	 removed	 and	 they	 were	
resuspended	in	AIM-V	(+1%HS	+	1%	L-Glutamine)	with	LPS	at	a	concentration	of	10µl/ml	
and	cultured	at	a	density	of	2x105	DC/200µl	in	a	96-well-plate	for	24h	hours	at	37°C	and	
6.2%	CO2.	As	a	control	DC	in	AIM-V	(+1%HS	+	1%	L-Glutamine)	without	LPS	were	used.	
After	 24h	 incubation	 the	 cells	 were	 centrifuged	 at	 2000rpm	 for	 10min	 and	 the	
supernatant	collected	for	further	cytokine	determination	with	ELISA.		
	
4.2.3 Enzyme-linked	immunosorbent	Assay		
The	Enzyme-linked	Immunosorbent	Assay	(ELISA)	is	commonly	used	for	the	detection	
and	quantification	of	proteins.	In	this	thesis,	the	so-called	“Sandwich	ELISA”	was	used.	
For	this	purpose,	the	target	protein	in	the	sample	is	captured	by	a	target	specific	capture	
antibody,	which	is	bound	onto	the	surface	of	an	ELISA	plate.	After	washing	to	remove	
any	 unbound	 target	 protein,	 a	 second	 specific	 detection	 antibody	 and	 an	 enzyme	
conjugate,	Streptavidin-horseradish	peroxidase	(SAv-HRP),	is	added,	which	also	binds	to	
the	captured	antigen.	After	another	washing	step	to	remove	unbound	antibody-enzyme	
conjugates	and	the	addition	of	a	substrate,	a	combination	of	hydrogen	peroxide	and	
3,3‘,5,5‘-Tetramethylbenzidin	(TMB),	a	colour	change	can	be	observed.	The	reaction	is	
stopped	 upon	 addition	 of	 phosphoric	 acid	 and	 the	 measured	 absorbance,	 with	 the	
Spectrophotometer	sunrise	at	450nm,	can	be	used	to	quantify	the	amount	of	antigen	
present.	For	this	purpose,	a	standard	curve	must	be	run	with	each	assay.	
The	cytokine	detection	of	IL-10,	IL12p40,	IL12p70	and	TNF-a	were	performed	with	the	
BD	OptEIATM	ELISA	Set	according	to	the	manufacturers‘	instructions.		
	
4.2.4 Boyden	chamber	assay	to	determine	DC	chemotaxis	
Upon	 maturation,	 through	 for	 example	 antigen	 uptake,	 DC	 express	 the	 chemokine	
receptor	 CCR7,	 which	 allows	 migration	 towards	 the	 chemokines	 CCL19	 and	 CCL21.	
Thereby	CCL19	and	CCL21	allow	DC	 trafficking	 towards	 lymphoid	organs	where	 they	
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then	 can	 interact	 with	 T-cells	 [74].	 In	 order	 to	 measure	 DC	 migration	 towards	 the	
chemoattractant	CCL19	the	Boyden	Chamber	Assay	was	used.	A	cylindrical	cell	culture	
insert,	acting	as	a	trans-well,	is	placed	inside	the	wells	of	a	24	well	cell	culture	plate	and	
thus	creating	a	two-compartment	system.	Cells	are	seeded	in	the	trans-well	insert	and	
can	migrate	through	the	porous	membrane	into	the	lower	compartment	towards	the	
chemoattractant.	The	bottom	of	the	polycarbonate	trans-well	insert	consists	of	a	thin,	
translucent	membrane	with	a	defined	pore	size.	Since	DC	chemotaxis	was	investigated,	
a	pore	size	of	5μm	was	chosen.	It	is	important	to	choose	the	correct	pore	size,	as	the	
pore	must	be	large	enough	to	allow	active	migration,	but	small	enough	to	avoid	passive	
passage.		
DC	used	for	 the	boyden	chamber	assay	were	maturated	on	day	6	and	harvested,	 re-
suspended	with	AIM-V/1%	L-glutamine	and	adjusted	to	1000	DC/μl	on	day	7.	The	trans-
well	 insert	was	 incubated	 for	 1	 hour	with	 100μl	 AIM-V/1%	 L-glutamine	 prior	 to	 the	
experiment.	 The	 base	well	 was	 then	 filled	with	 400μl	 AIM-V/1%L-glutamine	with	 or	
without	CCL19	(concentration	of	200ng/ml)	and	200μl	of	the	cell	suspension	were	added	
to	the	trans-well	insert	after	removal	of	the	incubation	medium.		For	migration	the	plate	
was	then	incubated	at	37°C	and	6.5%	CO2	in	the	cell	incubator	for	3	hours.	In	order	to	
release	the	 few	DC	which	might	be	stuck	on	the	trans-well	membrane,	50μl	of	0.1M	
EDTA	 was	 added	 to	 each	 well	 and	 the	 plate	 placed	 on	 a	 horizontal	 shaker	 (200	
shakes/min)	 at	 room	 temperature	 for	 10	 min.	 Thereafter	 the	 trans-well	 insert	 was	
removed	and	20μl	AccuCheck	 counting	beads	 (960	beads/μl)	were	added	 to	 the	 cell	
suspension	 in	 the	 base	well.	 The	 suspension	 containing	migrated	 cells	 and	 counting	
beads	was	then	transferred	into	a	1.5ml	FACS	tube	and	centrifuged	for	7min	at	538g.	
After	 aspiration	of	 the	 supernatant	 to	about	100μl,	 1μl	of	Propidium	 iodide	 (PI)	was	
added.	PI	is	a	fluorescent,	which	intercalates	with	double-stranded	nucleic	acids.	As	it	is	
excluded	by	viable	cells	and	can	only	penetrate	the	cell	membrane	of	dying	or	dead	cells,	
it	is	used	to	identify	dead	cells.		
Finally,	the	LSR-II	flow	cytometer	was	used	to	determine	the	number	of	migrated	cells.		
In	order	to	calculate	the	absolute	number	of	migrated	cells,	an	electronic	gate	counting	
all	 beads	 on	 forward	 scatter	 (FSC)	 and	 sideward	 scatter	 (SSC)	 dot	 plot	was	 created.	
AccuCheck	counting	beads	are	composed	of	two	different	fluorospheres,	A	and	B	beads.	
These	two	different	beads	are	used	as	a	double	internal	standard.	The	proportion	of	the	
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two	 beads,	 counted	 in	 two	 differentiate	 bead	 gates,	 should	 agree	 with	 the	
manufacture’s	indicated	proportion.	The	acquisition	of	events	was	stopped	when	10	000	
events	were	recorded	in	the	bead	gate.	Knowing	the	concentration	of	the	beads,	the	
absolute	number	of	cells	was	then	obtained	by	relating	the	number	of	cells	counted	to	
the	number	of	bead	events.	See	formula	below:		
	
𝑎𝑏𝑠. 𝑐𝑒𝑙𝑙	𝑛𝑜. =
𝑛𝑜. 𝑜𝑓	𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑	𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑	𝑐𝑒𝑙𝑙𝑠
𝑛𝑜. 𝑜𝑓	𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑	𝑏𝑒𝑎𝑑𝑠 ×𝑛𝑜. 𝑜𝑓	𝑏𝑒𝑎𝑑𝑠/𝑤𝑒𝑙𝑙	
	
The	number	of	beads	per	well	is	given	by	the	number	of	beads/μl	as	indicated	by	the	
manufacturer	(960	beads/μl).		
For	better	comparability	the	relative	migration	was	calculated	by	division	of	the	abs.	cell	
migration	by	the	abs.	cell	migration	of	cDC	without	stimulation.		
	
4.2.5 3D	Chemotaxis	assay	using	μ-Slide	Chemotaxis3D	
The	μ-Slide	Chemotaxis3D	by	IBIDI	can	be	used	for	observing	the	chemotactic	response	
of	cells	embedded	in	a	gel	matrix	and	exposed	to	a	chemical	gradient.	For	this	purpose,	
two	large-volume	reservoirs	are	connected	by	a	small	gap,	filled	with	the	gel	matrix.	By	
adding	a	chemoattractant,	CCL19,	to	one	of	the	reservoirs	and	not	the	other,	a	linear	
concentration	gradient	inside	the	gap	can	be	established	and	the	behaviour	of	the	cells	
within	 the	 gap	 observed	 by	 video	 microscopy.	 The	 aqueous	 gel	 matrix	 hinders	 the	
connective	flow	of	liquid,	but	at	the	same	time	allows	diffusion	in	order	to	establish	a	
concentration	 gradient.	 The	 experimental	 set	 up	 followed	 the	 instructions	 of	
Chemotaxis	3D	application	note	17	of	IBIDI.	For	DC	migration	a	1.6mg/ml	Collagen	gel	
based	on	RPMI	medium	was	used.	The	composition	of	the	gel	for	3	gaps	each	with	6µl	
is	shown	in	the	following	table:			
	 	
Method	
	 	 	 37	
	
1,6	mg/ml	Collagengel	 	 with	RPMI	
	 4,54	 µl	 H2O	
	 2,50		 µl	 10x	RPMI	
	 0,25	 µl	 200mM	L-Glutamin	
9µl	gelmedium	 0,67	 µl	 7,5%	NaHCO	
	 0,40		 µl	 1M	NaOH	
	 0,39		 µl	 HEPES	
	 0,25		 µl	 BSA	
	 	 	 		16	µl	Collagen	 	 	 Collagen	5mg/ml	
	 	 	 		25	µl	cells	 	 	 cell	suspension	
	
Experiments	were	performed	with	a	CCL19	concentration	of	1.25µg/ml.	The	obtained	
data	was	 analysed	with	 the	 ImageJ	 plugins	 “Manual	 tracking”	 and	 “Chemotaxis	 and	
Migration	tool”	by	IBIDI.		
	
4.3 Gene-expression	analysis		
Gene-expression	analyses	performed	in	this	thesis	are	based	upon	raw	Affymetrix	Gene	
Chip®	Array	data	kindly	provided	by	the	laboratory	of	Prof.	Dr.	Nößner	and	Prof.	Cohen.	
These	arrays	were	performed	on	“Affymetrix	GeneChip®	Human	Gene	1.0	ST“,	which	
allow	 the	 detection	 of	 29000	 genes	with	 an	 average	 of	 26	 probes	 per	 gene.	 	 These	
probes,	 which	 are	 artificially	 created	multiple	 short	 oligonucleotides	 specific	 for	 the	
transcript	of	interest,	are	able	to	hybridise	to	the	investigated	cDNA	by	complementary	
base	paring.	This	allows	to	detect	absolute	gene	expression	levels	through	the	emitted	
amount	of	fluorescence	during	hybridisation.		
Analysis	steps	included	quality	control,	normalization	using	the	RMA-algorithm	(Robust-
Multi-array-Average)	[75],	clustering	analysis,	annotation	of	individual	genes	based	on	
CustomCDF	 [76]	 and	 statistical	 analysis.	 All	 these	 steps	 were	 performed	 using	 the	
MADMAX	 (Management	 and	 Analysis	 Database	 for	 Multi-platform	 microArray	
eXperiments)	platform	(https://madmax.bioinformatics.nl),	University	of	Wageningen)	
[77].	Quality	control	and	normalisation	were	performed	in	order	to	assess	sample	and	
hybridization	 quality	 and	 to	 remove	non-biological	 variation	 to	 enable	 comparability	
between	 different	 microarrays.	 The	 RMA-algorithm	 used	 for	 normalisation	 includes	
background	 correction	 through	 perfect	match	 probes,	 log2	 transformation,	 quantile	
normalization	 and	 median	 polish.	 In	 order	 to	 compare	 average	 expression	 levels	
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between	the	different	groups,	Fold	Changes	based	on	mean	RMA	–	PLM	(probe	level	
model)	values	were	calculated.	A	Fold	Change	above	1.5	was	considered	a	differential	
gene	expression.	
In	addition,	the	arrays	were	analysed	using	Affymetrix	Expression	console	with	the	DABG	
algorithm	to	determine	genes	detected	above	background,	as	the	RMA-algorithm	only	
allows	 for	 the	 comparison	 between	 experimental	 groups.	 Individual	 DABG	 p-values	
were	filtered	using	a	cut-off	of	p<0.05	to	detect	statistically	significant	gene	expression.		
	
4.4 Verification	of	microarray	results	on	the	mRNA	level		
For	verification	of	microarray	data,	qPCRs	were	performed	for	a	chosen	set	of	genes.	
Therefore,	 cDC,	 ercDC	 and	 DC	 stimulated	 with	 Wnt5a	 were	 differentiated	 and	
stimulated	as	before.	Immature	cells	were	harvested	on	day	6	and	maturated	cells	on	
day	7	after	addition	of	the	“Jonuleit	cocktail”.		
	
4.4.1 RNA-Purification	
In	 order	 to	 isolate	 RNA,	 the	 PureLink®	 RNA	 Mini	 Kit	 was	 used	 according	 to	 the	
manufacturer	instructions.	This	kit	 includes	lysis,	homogenisation	and	isolation	of	the	
RNA.	 An	 optional	 digestion	 step	with	DNase	 I,	 following	 the	 RNeasy	Mini	Handbook	
instruction,	was	 included	instead	of	step	6	&	7,	to	ensure	high	quality	of	RNA	and	to	
remove	any	residual	DNA.	The	RNA	was	eluted	in	30	µl	RNase	free	water.		
	
4.4.2 Quantification	of	RNA	
For	quantification	of	RNA,	the	Quant-iTTM	RNA	assay	for	the	QubitTM	fluorometer	was	
utilised.	Measurements	followed	the	manufacturer’s	protocol.		
	
4.4.3 Reverse	transcription	
As	qPCR	only	allows	the	measurement	of	the	amount	of	cDNA,	the	isolated	RNA	was	
transcribed	into	cDNA	through	reverse	transcription.	Usually	primers	are	cDNA	specific	
and	do	not	measure	genomic	DNA.	However,	for	some	genes,	for	example	S18-RNA,	it	
is	not	possible	to	design	cDNA	specific	primers.	Considering	this	and	to	exclude	genomic	
DNA	 contamination	 of	 the	 sample,	 a	 RT-	 sample	was	 used	 as	 negative	 control.	 This	
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sample	contained	H2O	instead	of	the	of	the	reverse	transcription	enzyme,	Superscript	II.		
Any	produced	signal	in	this	sample	therefore	had	to	originate	from	a	combination	of	a	
cDNA	unspecific	primer	or	genomic	DNA	contamination.		
In	order	to	reversely	transcribe	2µg	of	RNA	into	cDNA	the	following	reverse	transcription	
reaction	mixture	was	prepared	for	each	sample.	The	RT-	reaction	mixture	only	contained	
0.2µg	of	RNA.		
	
Reagent	 RT+	 RT-	
RNA	
First-strand	buffer	(5x)	
2µg	
1x	
0.2µg	
1x	
dNTPs		 2mM	 2mM	
DTT		 0.5mM	 0.5mM	
Rnasin		 0.025U/µl	 0.025U/µl	
Acrylamid,	linear		 62.5ng/ml	 62.5ng/ml	
Hexamer	nucleotides	(10x)	 1x	 1x	
Superscript	II		
RNAse	free	water	
0.1 U/µl	
ad	40µl	
-	
ad	40µl	
	
The	reaction	tubes	were	then	incubated	at	42°C	and	slowly	shaken	on	a	thermo	block	
for	1.5h.	Thereafter	the	RT+	cDNA	was	1:10	diluted	for	further	qPCR	experiments	and	
all	tubes	stored	at	-20°C,	until	further	use.		
	
4.4.4 Quantitative	–	PCR	
The	quantitative	polymerase	chain	reaction	(qPCR),	also	called	real	time	PCR	(RT-PCR),	
allows	the	measurement/quantification	of	the	amount	of	specific	cDNA	in	a	sample.	This	
is	based	upon	a	fluorescent	signal	which	is	emitted	during	each	amplification	cycle	of	
the	sample	and	detected	by	the	thermal	cycler,	in	this	case	the	LightCycler®	Instrument	
480.	For	this	thesis	two	different	methods	for	qPCR	were	used,	the	Taqman	assay	and	
the	SYBRgreen	assay.	The	Taqman	assay	is	based	upon	the	annealing	of	a	primer	and	a	
probe,	which	is	labelled	with	a	quencher	and	a	fluorescent	dye,	to	the	cDNA.	Only	if	the	
primer	 and	 probe	 are	 bounded	 and	 the	 Taq-polymerase	 amplifies	 the	 strand,	 the	
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fluorescent	 dye	 is	 released	 from	 the	 quencher	 through	 hydrolysis	 of	 the	 probe.	 The	
quencher	free	probe,	which	is	labelled	with	FAM	or	VIC,	emits	a	fluorescent	signal	which	
is	then	detected	by	the	LightCycler.		
The	SYBRgreen	method	uses	the	ability	of	the	dye	to	intercalate	especially	with	double-
stranded	 cDNA.	 Through	 amplification	 of	 the	 cDNA	 product	 with	 each	 cycle,	 the	
intercalated	SYBRgreen	 increases	and	hence	 increases	 the	 fluorescent	 signal	emitted	
with	 each	 cycle.	 Performing	 a	 melting	 curve	 analysis	 after	 the	 amplification	 cycles,	
ensured	that	the	product	is	specific.		
For	the	SYBRgreen	reaction	mixture	1x	QuantiTectPrimer	and	0.03U/µl	Taq-Polymerase	
were	added	to	1x	SYBRgreen	mastermix,	as	described	in	materials,	and	H2O	was	added	
to	reach	a	final	volume	of	18µl.	For	the	TaqMan	Assays,	1x	TaqMan	Assay	was	mixed	
with	1x	TaqMan	Universal	PCR	Mastermix	and	again	H2O	added	to	reach	a	final	volume	
of	18µl.	2µl	of	either	RT+	(1:10)	dilution	or	RT-	sample	were	then	plated	to	the	ground	
of	a	taqman	plate	and	the	18µl	reaction	mixture	added	to	each	sample.	Each	sample	
was	tested	as	duplicate.		Experiment	were	performed	with	the	LightCycler®	Instrument	
480	and	expression	levels	normalized	to	the	reference	gene	18S	rRNA.		
The	 cycle	 threshold	 (CT)	 value	 calculated	 by	 the	 LightCycler	 software,	 describe	 the	
detected	fluorescence	above	a	certain	threshold,	which	is	individually	adjusted	for	every	
gene.	The	CT	values	can	then	be	used	representative	for	the	gene	expression.	A	high	CT	
value,	indicates	a	low	expression	of	the	gene,	as	a	signal	was	only	detected	in	a	late	cycle	
of	the	PCR.	The	opposite	can	be	applied	for	a	low	CT	value.		
	
4.5 Immunohistochemistry	
Immunohistochemistry	allows	the	detection	and	visualisation	of	an	Antigen	in	a	tissue	
sample	 by	 specific	 antibody	 binding.	 Paraffin	 embedded	 and	 formaldehyde-fixed	
samples	were	kindly	provided	by	Prof.	Dr.	Hermann-Josef	Gröne,	head	of	Department	
of	Cellular	and	Molecular	Pathology	at	the	DKFZ	Heidelberg.		
	
4.5.1 Sample	preparation	
In	order	to	remove	the	paraffin	from	the	tissue,	samples	were	washed	three	times	for	
five	minutes	in	xylol.	Thereafter	rehydration	was	performed	by	incubation	three	times	
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in	100%	Ethanol,	two	times	in	96%	Ethanol	and	once	in	70%	Ethanol	for	three	minutes	
each.	To	prevent	background	reactions	endogenous	peroxidase	was	blocked	 through	
incubation	in	a	dilution	of	20ml	H2O2	(30%)	in	180ml	Methanol	for	20	min.	To	remove	
any	residuals	a	washing	step	with	PBS	followed.	For	unmasking	of	the	antigen,	3	ml	of	
antigen	unmasking	solution	 in	300ml	distilled	water	were	brought	to	a	boil	and	then	
autoclaved	with	the	sample	for	20min	at	1bar.	Samples	were	then	cooled	down	to	room	
temperature	and	again	washed	in	PBS.	After	antigen	retrieval	samples	were	encircled	
with	a	liquid	blocker	pen	and	ready	for	antigen	detection.	
	
4.5.2 Detection	of	the	antigen	
All	steps	were	performed	in	a	humid	chamber,	consisting	of	a	metal	box	covered	with	a	
wet	pulp	and	a	cover,	to	prevent	dehydration	of	the	tissue	samples	during	incubation.	
Endogenous	 biotin	 was	 blocked	 using	 the	 Avidin/Biotin	 Blocking	 kit.	 The	 primary	
antibody,	 in	 this	case	Anti-Wnt5a	antibody,	was	 then	added	and	 incubated	 for	1h	at	
room	temperature	or	at	4°C	over	night.	The	samples	were	then	twice	washed	in	PBS	
before	the	secondary	biotinylated	antibody,	at	a	dilution	of	1:300	in	PBS,	could	be	added	
for	30	minutes.	The	secondary	antibody	was	again	washed	off	using	PBS.		To	increase	
sensitivity	of	the	staining	the	avidin-biotin-complex	method	was	employed	and	the	slide	
incubated	with	15µl	of	reagent	A	and	15µl	of	reagent	B	in	1ml	PBS	for	30	minutes	at	
room	temperature.	A	washing	step	in	PBS	and	one	in	Tris	for	5	minutes	each	followed.	
Staining	was	performed	using	a	mixture	of	500µl	3%	H2O2,	4ml	3,3'-diaminobenzidine	
(DAB)	and	1ml	NiCl	 in	200ml	Tris	pre-warmed	to	37°C.	Following	the	counterstaining	
with	ethyl	green,	the	slides	were	then	quickly	dehydrated	in	an	ascending	alcohol	series	
(from	96%	upwards)	and	washed	in	xylol.	In	a	final	step	the	samples	were	covered	with	
the	 mounting	 medium	 VectaMountTM	 for	 permanent	 preservation	 and	 ready	 for	
microscopy.			
	
4.6 Statistical	analyses	
Statistical	analyses	were	performed	using	the	Graphpad	Prism	6	software.	The	level	of	
significance	is	denoted	by	an	asterisk,	with	*	(p	<	0.05),	**	(p	<	0.01),	***	(p	<	0.001),	
****	 (p	 <	 0.0001)	 and	 ns	 for	 non-significant.	 Tests	were	 utilised	 as	 indicated	 in	 the	
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corresponding	result	section.	When	values	were	normally	distributed,	parametric	tests	
were	applied,	i.e.	the	paired	student	T-test	for	paired	data.	For	non-Gaussian	distributed	
data,	the	unpaired	Wilcoxon-Mann-Whitney-test	was	applied.		
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5 Results	
5.1 Array-analysis	
To	 investigate	 Wnt-signalling	 in	 myeloid	 cells,	 Affymetrix	 DNA-microarrays	 were	
performed	on	peripheral	blood	monocytes	(PBMs)	and	in	vitro	generated	Macrophage1	
(M1),	Macrophage2	 (M2),	GMCSF,	 cDC	and	ercDC	 in	 the	 laboratory	of	Prof.	Nößner.	
Quality	control,	clustering	analysis	and	normalisation	were	performed	as	described	in	
methods.	 The	 DABG	 algorithm	 was	 applied	 to	 detect	 statistically	 significant	 gene	
expression	and	 fold	 changes	 (FC)	were	 calculated	 in	order	 to	 compare	average	gene	
expression	 levels	 between	 different	 groups.	 A	 FC	 above	 or	 below	 1.5/-1.5	 was	
considered	a	differential	gene	expression.		
	
As	a	central	focus	of	the	study	was	to	investigate	Wnt	and	related	signalling	pathways	
in	the	context	of	myeloid	cell	differentiation,	a	gene	list	was	compiled	from	literature	
that	 included	 canonical	 and	 non-canonical	Wnt	 genes	 (ligands,	 receptors,	 inhibitors,	
pathway	 genes	 and	 downstream	 targets).	 As	 these	 pathways	 are	 not	 yet	 fully	
understood,	the	gene	lists	do	not	include	all	genes	that	have	ever	been	associated	with	
the	 pathways,	 but	 only	 the	 most	 essential	 genes.	 The	 objective	 was	 to	 identify	 all	
relevant	genes	in	respect	to	ligands,	receptors,	co-receptors	and	downstream	effector	
proteins,	 as	well	 as	modulators	 of	 the	 signalling	 pathway	 as	 they	 relate	 to	 different	
myeloid	subtypes,	but	with	a	specific	focus	on	the	ercDC	subtype	identified	ex	vivo	from	
human	 renal	 cell	 carcinoma	 samples.	 These	 gene	 lists	were	 then	 used	 as	 a	mask	 to	
analyse	the	array	data	in	respect	to	expression	levels	of	different	myeloid	subtypes	(see	
supplementary	table	1).			
	
5.1.1 Differential	expression	of	ligands,	receptors	and	extracellular	regulators	
The	Wnt-signalling	gene	list	consisted	of	198	genes.	It	quickly	became	apparent	that	the	
most	 significant	 differential	 gene	 expression	 was	 associated	 with	 the	 b-Catenin	
independent	 (non-canonical)	Wnt-pathway.	Altered	expression	within	 the	b-Catenin-
dependent	 pathway	 did	 not	 appear	 to	 affect	 the	 core-genes	 associated	 with	 this	
signalling	pathway,	but	rather	other	associated	target	genes.		
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Only	moderate	 differential	 gene	 expression	was	 detected	 for	most	 Fz-receptors,	 co-
receptors	and	no	significant	changes	were	found	for	LRP5/6.	By	contrast,	the	syndecans	
(SDC)	and	some	glypicans	(GPC)	were	strongly	regulated	in	the	activated	myeloid	cells	
(M1,	M2,	 ercDC,	 cDC)	 as	 compared	 to	 PBMs.	 Both,	 SDCs	 and	 GPCs,	 are	 part	 of	 the	
heparan	 sulphate	 proteoglycan	 family	 (HSPG)	 and	 are	 anchored	 to	 the	 cellular	
membrane	 either	 as	 type	 1	 transmembrane	 proteins	 or	 via	 a	
glycosylphosphatidylinositol	modification.	They	can	act	as	co-receptors	for	a	variety	of	
different	extracellular	ligands,	such	as	growth	factors,	chemokines,	angiogenic	factors	
and	for	morphogens	such	as	the	Wnt-	and	Hedgehog-ligands.	In	terms	of	Wnt-signalling,	
HSPG	are	thought	to	be	involved	in	ligand	gradient	formation	and	in	signal	transmission	
by	promoting	receptor-ligand	internalization	and	thereby	positively	as	well	as	negatively	
affecting	Wnt-signalling	 [70].	 In	 this	 array	 of	myeloid	 subsets,	 significant	 differential	
gene	expression	was	found	in	SDC2,	3,	4	and	GPC4,	but	not	 in	SDC1	and	other	GPCs.		
Especially	SDC2	was	highly	expressed	in	all	myeloid	subsets	compared	to	Monocytes.	
The	highest	FC	was	found	in	cDC	compared	to	Monocytes	(26.8)	and	in	M2	compared	to	
monocytes	with	25.5.	
With	regards	to	the	extracellular	and	membrane-bound	Wnt-antagonists	and	positive	
Wnt-modulators,	the	different	myeloid	subsets	showed	only	moderate	differential	gene	
expression.	 Only	 the	 Wnt-antagonists	 IGFBP4	 and	 TraB	 domain	 containing	 2A	
(TRABD2A)	showed	strong	differential	expression.	IGFBP4,	a	canonical	Wnt-antagonist,	
is	highly	expressed	in	the	M1	macrophages	and	showed	a	FC	of	27	compared	to	all	other	
subsets.	 TRABD2A,	 also	 known	 as	 Tiki,	 showed	 an	 over	 three-fold	 increase	 in	 cDC	
compared	to	the	other	subsets.		
Positive	extracellular	modulators	of	Wnt-signalling	are	Norrin	(NDP)	and	the	R-spondin	
family.	While	there	is	no	up-regulation	in	R-spondins,	Norrin	is	slightly	higher	expressed,	
with	a	FC	of	2.6,	in	cDC.	Norrin	is	a	secreted	protein	with	a	cysteine-knot	motif,	which	
acts	 as	 a	 high	 affinity	 ligand	 for	 Fz4	 and	 LRP5/6	 and	 thereby	 activates	 b-Catenin	
dependent	 signalling	 with	 downstream	 TCF/LEF	 transcription	 factors	 [78].	 This	 Fz4	
activation	is	Wnt-ligand	independent.		
Among	 the	 Wnt-ligands,	 Wnt5a	 was	 found	 to	 be	 strikingly	 differentially	 expressed	
within	the	myeloid	populations.	It	showed	a	five-fold	increase	in	cDC	as	compared	to	all	
other	 investigated	 subsets	 of	 myeloid	 cells	 including	 the	 ercDC.	 Furthermore,	
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application	of	the	DABG-Algorithm	showed	that	Wnt5a	was	only	expressed	in	cDC,	but	
not	 in	 the	other	 investigated	myeloid	subsets.	Wnt5a	 is	a	classic	non-canonical	Wnt-
ligand.	 It	 is	able	to	bind	to	a	number	of	different	Fz-receptors	and	co-receptors	 [79].	
Canonical	Wnt-ligands,	however,	were	not	differentially	regulated.		
Differential	 gene	 expression	 within	 the	 canonical	 Wnt-pathway	 is	 summarized	 in	 a	
schematic	 diagram	 in	 order	 visualize	 differences	 within	 different	 myeloid	
subsets	(Fig.	4).		
	
	
cDC	
	
	
ercDC	
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M1	
	
Fig.	4:	Microarray	analysis	of	b-Catenin	signalling	pathway.	The	scheme	display	microarray	data	integrated	into	a	
modified	version	of	the	b-Catenin	signalling	pathway.	Significant	differential	gene	expression	is	presented	by	green	
(up-regulation)	or	red	(down-regulation)	boxes	and	the	corresponding	fold	changes	in	comparison	to	monocytes.	Fold	
changes	were	generated	using	the	RMA-Algorithm	and	a	FC	>1.5	was	considered	significant	differential	expression.		
5.1.2 Non-canonical	Wnt-signalling	
The	molecular	mechanisms	underlying	the	PCP	and	the	Ca2+-signalling	cascade	are	not	
well	characterized.	The	gene	lists	used	to	study	their	regulation	included	the	20	most	
well-known	and	investigated	genes	linked	to	the	PCP-cascade,	and	37	genes	associated	
with	the	Ca2+-cascade.	Within	the	PCP-cascade,	differential	gene	expression	was	found	
in	the	M1	transcriptome.	Dishevelled-associated	activator	of	morphogenesis	1	(DAAM1)	
is	a	downstream	target	of	Dvl,	and	is	activated	by	Dvl	upon	e.g.	Wnt5a	binding	to	a	Fzd	
or	 the	 Co-receptor	 ROR2.	 DAAM1	 can	 activate	 RHO,	 Rac	 and	 Cdc42	 and	 thereby	
influence	cytoskeletal	rearrangements,	cell	migration	and	polarity.	The	array	showed	a	
cDC	up-regulation	of	DAAM1	by	two	fold	compared	to	monocytes,	whereas	M1	showed	
a	-2.4	fold	down-regulation.	Furthermore,	M1	also	showed	a	-2.8	fold	down-regulation	
of	 RHOB	 and	 a	 -6.7	 fold	 down-regulation	 of	 RAC2.	 RHOB	 was	 also	 slightly	 down-
regulated	by	two	fold	 in	cDC	and	M2.	Again,	 this	could	suggest	a	down-regulation	of	
Wnt-signalling	within	the	M1.	However,	the	regulations	of	the	PCP-cascade	are	not	as	
strong	 as	 for	 the	 other	 cascades	 and	 assumptions	 have	 to	 be	 drawn	 carefully,	 also	
because	not	all	regulating	genes	are	yet	known	and	included	in	this	analysis.			
	 	
Results	
	 	 	 47	
cDC	
	
ercDC	
	
M1	
	
Fig.	 5:	 Microarray	 analysis	 of	 PCP-signalling	 pathway.	 The	 scheme	 displays	 microarray	 data	 integrated	 into	 a	
modified	version	of	 the	PCP-signalling	pathway.	Significant	differential	gene	expression	 is	presented	by	green	(up-
regulation)	or	 red	 (down-regulation)	boxes	and	 the	corresponding	 fold	changes	 in	comparison	 to	monocytes.	Fold	
changes	were	generated	using	the	RMA-Algorithm	and	a	FC	>1.5	was	considered	significant	differential	expression.	
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Within	 the	 Ca2+-signalling	 cascade	 differential	 gene	 expression	 was	 found	 for	 key	
regulating	 genes.	 Phospholipase	 C	 beta1	 (PLCB1),	 which	 forms	 inositol	
1,4,5-trisphosphate	 (IP3)	 and	 diacylglycerol	 (DAG)	 from	 phosphatidylinositol	
4,5-bisphosphate	upon	Wnt-receptor	binding,	is	strongly	down-regulated	in	all	myeloid	
subsets	compared	to	monocytes.	Furthermore,	PLCB2	is	also	very	strongly	suppressed	
in	M1	(FC	-15.9)	and	slightly	in	GMCSF	(FC	-2.9).	The	formation	of	IP3	initiates	the	release	
of	Ca2+	from	the	endoplasmic	reticulum,	which	in	turn	activates	proteinkinase	C	(PRKC),	
calcium	sensitive	calmodulin-dependent	protein	kinase	II	(CAMKII)	or	calcineurin.	While	
PRKCA	is	3.4	fold	up-regulated	in	cDC,	PRKCB	is	down-regulated	in	all	myeloid	subsets	
and	strongest	again	in	M1	with	a	FC	of	-6.1.	M1	also	showed	a	-2.7	fold	down-regulation	
of	CAMK2G	and	a	-4.4-fold	suppression	of	calcineurin	(PPP3CA).	Moreover,	NFkB2,	RELA	
and	RELB,	which	are	downstream	effector	transcription	factors	of	the	Wnt-Ca2+-cascade,	
were	up-regulated	in	M1	with	a	FC	of	3.0,	3.5	and	2.5	respectively.	NFATC1	and	NFATC2,	
however,	were	slightly	up-regulated	with	a	FC	of	2.3	in	M2	and	cDC.	It	has	been	shown	
that	the	non-canonical	cascades	can	inhibit	the	canonical-signalling	cascade	via	different	
mechanism.	One	mechanism	is	the	TAK1-NLK	pathway,	which	is	activated	by	CAMKII	in	
the	 Ca2+-cascade.	 The	 NLK,	 which	 is	 2.2	 fold	 up-regulated	 in	 cDC,	 phosphorylates	
TCF/LEF	 and	 thereby	 inhibits	 TCF/LEF	 transcriptional	 activation	 upon	 ß-Catenin	
binding	[54].		
cDC	
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ercDC	
	
M1	
	
Fig.	6:	Microarray	analysis	of	the	Ca2+-signalling	pathway.	The	scheme	displays	microarray	data	integrated	into	a	
modified	version	of	the	Ca2+-signalling	pathway.	Significant	differential	gene	expression	is	presented	by	green	(up-
regulation)	or	 red	 (down-regulation)	boxes	and	 the	corresponding	 fold	changes	 in	comparison	 to	monocytes.	Fold	
changes	were	generated	using	the	RMA-Algorithm	and	a	FC	>1.5	was	considered	significant	differential	expression.	
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Transcriptomic	analysis	identified	differential	gene	expression	within	the	Wnt-signalling	
pathway.	 While	 only	 moderate	 changes	 in	 expression	 were	 found	 within	 the	 PCP-
signalling	 cascade,	 the	differential	 expression	was	 found	 in	 the	b-Catenin-dependent	
and	the	Ca2+-cascade	pathways.	Changes	in	pathway	regulation	was	strongly	associated	
with	cDC	and	M1	myeloid	subtypes.	A	potential	reduction	in	canonical	Wnt	signalling	
with	 a	 corresponding	 increase	 in	 the	 Ca2+-signalling	 pathway	 was	 seen	 in	 cDC.	 The	
dysregulation	 in	M1	macrophages	was	difficult	 to	 assign	 to	 specific	 pathways,	 but	 it	
could	be	concluded	that	regulation	is	evident.	Interestingly,	only	few	differential	gene	
expressions	 could	be	observed	when	 comparing	 ercDC	 to	monocytes,	 suggesting	 for	
similarities	and	a	possible	explanation	for	differences	between	ercDC	and	cDC.		
Among	 the	 ligands,	 only	 Wnt5a,	 a	 non-canonical	 Wnt-activator,	 was	 strongly	 up-
regulated	 in	 cDC.	 A	 strong	 up-regulation	 of	 syndecans	 and	 glypicans	 in	 all	 myeloid	
subsets	was	also	found	as	compared	to	monocytes.	These	HSPG	are	thought	to	act	as	
Wnt-Co-receptors	and	have	been	shown	to	be	involved	in	non-canonical	signalling,	e.g.	
by	influencing	Wnt5a	autocrine	signalling	and	signal	transduction.		
As	 average	 expression	 levels	 of	 the	 different	 myeloid	 subsets	 were	 compared	 to	
monocytes,	and	all	myeloid	subsets	were	generated	from	peripheral	blood	monocytes,	
it	 becomes	 evident	 that	 Wnt-signalling	 changes	 during	 myeloid	 differentiation.	
Depending	on	the	myeloid	subset	Wnt-signalling	varies	and	canonical	or	non-canonical	
signalling	pathways	show	either	activation	or	suppression.	Hence	we	hypothesize,	that	
Wnt-signalling	 is	 of	 importance	 in	 myeloid	 differentiation	 and	 functioning.	 As	 Wnt-
ligands	are	lipid-modified	glycoproteins,	they	mainly	signal	in	a	paracrine	or	autocrine	
manner.	While	cDC	showed	very	strong	differential	regulation	within	the	Wnt-pathway,	
ercDC	revealed	only	little	regulation.	Baring	this	 in	mind,	the	question	arose	whether	
Wnt-signalling	 could	 in	 part	 be	 responsible	 for	 the	 functional	 differences	 and	
impairment	between	cDC	and	ercDC.		 	
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5.2 RT-PCR		
In	order	 to	validate	 the	data	obtained	by	 transcriptomic	analysis,	qPCRs	of	key	Wnt-
signalling	 genes	 were	 performed	 on	 immature	 cDC,	 ercDC	 and	 maturated	 cDC.	
Additionally,	 immature	 cDC	 and	 ercDC	 stimulated	 with	 Wnt5a	 on	 day	 zero	 of	
differentiation	 were	 investigated	 to	 assess	 the	 effect	 of	 Wnt5a-signalling	 on	 gene-
expression	levels.	As	differential	gene-expression	was	especially	found	within	the	non-
canonical	pathways,	investigated	genes	were	chosen	subsequently.		
All	obtained	qPCR	results	supported	our	findings	 in	the	DNA-microarrays	 (see	Fig.	7).	
Wnt5a	could	be	 shown	 to	be	only	expressed	 in	 cDC,	but	not	 in	ercDC.	 Furthermore,	
evidence	of	decreased	expression	of	Wnt5a	in	maturated	cDC	was	found.	Contrary,	the	
Wnt-receptor	Fzd5,	a	suggested	Wnt5a	receptor,	was	expressed	in	both	cDC	as	well	as	
ercDC,	suggesting	the	presence	of	non-canonical	Wnt-signalling	machinery	in	ercDC.	The	
results	of	SDC2,	which	was	shown	to	be	strongly	differentially	expressed	within	cDC,	
ercDC	and	monocytes	in	the	microarray,	could	be	validated	by	qPCR	and	showed	higher	
expression	in	cDC,	than	ercDC.	SDC3	and	GPC4,	also	belonging	to	the	family	of	HSPG,	
showed	similar	expression	levels	for	cDC	and	ercDC.	DAAM1,	part	of	the	PCP-signalling	
pathway,	 and	NFATC2,	belonging	 to	 the	Ca-Pathway,	were	both	up-regulated	 in	 cDC	
compared	 to	ercDC.	All	 other	by	qPCR	 investigated	genes	 showed	 similar	expression	
levels	between	cDC	and	ercDC	(not	shown	here).		
Furthermore,	a	tendency	of	down-regulation	in	maturated	cDC	compared	to	immature	
cDC	was	 found	 for	 several	 genes,	 including	 for	 example	Wnt5a,	 CAMK2D,	 SDC2	 and	
SDC3.	 This	 could	 suggest	 a	 possible	 change	 within	 the	 Wnt-signalling	 cascade	 and	
consequently	in	the	Wnt-response	of	cDC	during	maturation.	Addition	of	Wnt5a	on	day	
zero	 of	 differentiation	 of	 cDC	 as	 well	 as	 ercDC	 did	 not	 result	 in	 changes	 of	 gene-
expression	levels	for	investigated	genes.		
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Fig.	 7:	 Validation	 of	 gene	 expression.	 Expression	 data	 of	 Wnt-signalling	 genes	 after	 qPCR	 advanced	 relative	
quantification	analysis	of	immature	and	maturated	cDC,	ercDC	and	stimulation	with	Wnt5a(d0).	Graphs	display	ΔΔCT-
values,	mean	and	the	standard	error	of	mean	(SEM).	The	grey	bar	at	10-9	indicates	borderline	expression	and	values	
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at	 10-10	 non-detectable	 expression	 levels.	 For	 statistical	 analysis	 the	 unpaired	 Mann-Whitney-test	 was	 applied.	
Significant	differences	are	denoted	by	an	asterisk.		
5.3 Immunohistochemistry	
As	we	detected	high	levels	of	Wnt5a	in	cDC,	but	not	 in	ercDC,	we	hypothesized,	that	
Wnt5a	might	affect	DC	differentiation	and	functioning.	As	it	has	previously	been	shown	
that	Wnt5a	is	expressed	in	other	tumours,	we	wondered	whether	Wnt5a	is	also	present	
in	 RCC.	 Immune-histological	 staining	 of	 Wnt5a	 in	 RCC	 samples	 revealed	 a	 strong	
overexpression	 of	 Wnt5a	 in	 these	 samples,	 hence	 suggesting	 a	 possible	 source	 of	
Wnt5a.	This	Wnt5a	could	act	in	an	autocrine,	paracrine	and	juxtacrine	manner	and	affect	
the	differentiation	of	myeloid	cells	within	the	RCC.	Subsequently,	we	aimed	to	examine	
the	effects	of	Wnt5a	on	DC	function.		
	
A	 	 B	 	
Fig.	8:	Immunohistochemical	staining	of	Wnt5a.	Immunohistochemical	staining	of	Wnt5a	in	normal	kidney	(A)	and	
RCC	(B),	showing	a	strong	overexpression	of	Wnt5a	and	hence	suggesting	a	possible	source	for	Wnt5a.	
	
5.4 Cytokine	pattern	on	gene	expression	level	
As	we	found	that	cDC	and	ercDC	differ	in	Wnt-gene	expression	pattern,	we	hypothesized	
that	Wnt-signalling	may	influence	their	differentiation	and	functionality.	In	a	first	step,	
we	 investigated	 cytokine	 gene	expression	 levels	of	 cDC	 compared	 to	ercDC,	 and	 the	
impact	of	Wnt-signalling	modulation.	We	therefore	performed	qPCRS	of	 IL-10,	TNF-α	
and	 the	 subunits	 IL12A	 (syn.	 IL12p35)	 and	 IL12B	 (syn.	 IL12p40)	of	 the	heterodimeric	
cytokine	 IL-12	(syn.	 IL12p70)	on	cDC	and	ercDC	 in	an	 immature	as	well	as	maturated	
state	 and	 upon	 stimulation	with	Wnt5a	 on	 day	 zero.	Maturation	was	 performed	 by	
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addition	of	the	“Jonuleit	cocktail”	on	day	6	of	differentiation	(see	methods).	Interestingly	
no	differences	 in	 cytokine	expression	 levels	were	 found	between	 immature	 cDC	and	
ercDC.	 Upon	 maturation,	 however,	 the	 cytokine	 expression	 levels	 of	 cDC	 changed	
significantly.	 TNF-α	 levels	were	 lowered	 significantly	 (p-value:	 0.0159)	 and	 also	 IL-10	
levels	showed	a	decreased	tendency,	but	could	not	be	shown	to	be	significant	(p-value	
0.057).	 IL12B	 levels	 of	maturated	 cDC	were	 increased	 significantly	 (p-value	 0.0159).	
Contrary	to	maturated	cDC,	maturated	ercDC	did	not	change	the	gene	expression	levels	
of	these	cytokines.	Hence,	suggesting	an	altered	response	of	ercDC	towards	maturation	
and	a	probable	maintaining	of	a	 rather	 immature	state.	 Interestingly,	Wnt5a	did	not	
show	a	significant	effect	on	the	gene	expression	levels	in	neither	cDC	or	ercDC	in	the	
immature	or	maturated	state.	Evaluation	of	IL12A	levels	was	difficult	as	the	obtained	
data	often	showed	values	below	detection	level.	
		
		
Fig.	9:	Cytokine	gene	expression	levels.	Gene	expression	levels	of	IL-10,	TNF-α,	IL12A	and	IL12B	after	qPCR	advanced	
relative	 quantification	 analysis	 of	 immature	 and	maturated	 cDC,	 ercDC	 and	 stimulation	with	Wnt5a(d0).	 Graphs	
display	ΔΔCT-values,	mean	and	the	standard	error	of	mean	(SEM).	The	grey	bar	at	10-9	indicates	borderline	expression	
and	 values	at	10-10	 non-detectable	 expression	 levels.	 For	 statistical	 analysis	 the	unpaired	Mann-Whitney-test	was	
applied.	Significant	differences	are	denoted	by	an	asterisk.	
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5.5 Cytokine	secretion	
In	a	next	step	we	investigated	the	cytokine	secretion,	as	protein	levels,	of	cDC	compared	
to	 ercDC,	 and	 the	 impact	 of	 Wnt-signalling	 modulation	 with	 enzyme-linked	
immunosorbent-assays	 (ELISA).	 Hence	 the	 secretion	 of	 IL12p70,	 IL12p40,	 IL-10	 and	
TNF-a	 were	 measured	 upon	 LPS	 and	 CD40L	 stimulation.	 	 IL-12	 is	 a	 heterodimeric	
cytokine,	which	acts	as	a	link	between	innate	and	adaptive	immune	response.		It	is	able	
to	 induce	IFN-g	production	by	CTL	and	NK	and	activate	their	phagocytic	capacity,	but	
also	 to	 induce	 the	 generation	 of	 	 TH1	 CD4+	 cells	 [80,	 81].	 IL-10,	 however,	 acts	 as	 a	
regulator	and	suppressor	of	the	immune	system	and	can	counteract	IL-12	production	
[82].	 It	 reduces	 inflammation	 and	 prevents	 overshooting	 immune	 reactions.	
Furthermore,	it	has	been	implicated	in	CD8+	T-cell	priming	and	suggested	as	a	possible	
mechanism	for	cancers	to	escape	immune	surveillance	[83].	TNF-a	is	a	pro-inflammatory	
cytokine	 and	 involved	 in	 immune	 regulation,	 inflammation,	 cellular	 homeostasis	 and	
inhibition	of	tumourigenesis	and	viral	replication.			
A	 first	 general	 comparison	 between	 cDC	 and	 ercDC	 revealed	 that	 ercDC	 produce	
significantly	more	IL-10	and	TNF-a	when	stimulated	with	LPS	than	cDC.	This,	however,	
could	 not	 be	 shown	 for	 CD40L	 stimulation,	 as	 no	 distinctive	 results	 were	 obtained.	
Contrary,	 IL12p40	 secretion	 upon	 CD40L	 stimulation	 was	 higher	 in	 cDC	 than	 ercDC,	
although	this	could	not	be	shown	to	be	significant	by	paired	t-test.	These	differences	
between	 cDC	 and	 ercDC	 could	 in	 part	 explain	 findings	 of	 impaired	 ercDC	 ability	 to	
activate	and	induce	proliferation	of	T-cells	and	to	escape	immune	surveillance.	While	
TNF-a	 is	 mainly	 known	 to	 carry	 out	 antitumourigenic	 properties,	 low	 dose,	 chronic		
secretion	of	TNF-a	has	been	detected	in	RCC	and	suggested	to	promote	tumour	growth	
and	metastasis.		Furthermore,	the	detection	of	TNF-a	in	RCC	has	been	associated	with	
poor	prognosis	[84].	Our	findings	could	hence	suggest	a	possible	source	of	TNF-a	in	RCC	
by	ercDC.		
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A:	LPS	 	 	 	 	 	 B:	CD40L	
	 	
Fig.	10:	Enzyme	linked	immunosorbent	assay.	IL-10,	TNF-α	and	IL12p40	secretion	of	cDC	and	ercDC	upon	LPS	(A)	and	
CD40L	(B)	stimulation	for	24h.	The	graphs	display	mean	and	SEM	of	several	experiments.	For	the	purpose	of	statistical	
analysis,	the	parametric	paired	t-test	was	applied.	
Following	 these	 findings,	 Wnt-signalling	 modulation	 with	 the	 non-canonical	 agonist	
Wnt5a	and	the	antagonists	sFRP1	and	sFRP5	were	performed.	Wnt5a,	sFRP1	and	sFRP5	
were	 respectively	 added	 to	 the	growth	medium	on	day	 zero	of	differentiation	 to	be	
present	throughout	the	whole	differentiation	process.		
As	Wnt5a	was	up-regulated	in	cDC	compared	to	ercDC,	it	was	expected	that	addition	of	
Wnt5a	 to	 ercDC,	 or	 blockage	 of	Wnt5a	 by	 sFRP5	 and	 sFRP1	 in	 cDC,	would	 alter	 the	
cytokine	secretion	pattern.		Yet,	addition	of	Wnt5a	did	not	show	any	significant	effects	
on	 ercDC.	 The	 obtained	 data	 was	 not	 distinct	 and	 no	 tendency	 could	 be	 detected.	
Contrary,	 however,	 Wnt5a	 showed	 significant	 effects	 regarding	 IL-10,	 TNF-a	 and	
IL12p40	secretion	in	cDC.	Addition	of	Wnt5a	to	cDC	showed	increased	secretion	levels	
of	IL-10	upon	LPS	as	well	as	CD40L	stimulation.	Increased	levels	upon	addition	of	Wnt5a	
could	 also	 be	 detected	 for	 IL12p40	 stimulated	with	 CD40L.	 A	 tendency	 of	 increased	
levels	were	also	seen	for	 IL12p70	upon	CD40L	stimulation,	but	were	not	found	to	be	
significant.	Furthermore,	Wnt5a	did	decrease	TNF-a	secretion	upon	LPS,	but	not	upon	
CD40L	stimulation.	While	the	effects	of	Wnt5a	on	IL-10	secretion	of	cDC	did	resemble	
the	 higher	 secretion	 of	 ercDC	 compared	 to	 cDC,	 the	 effects	 on	 TNF-a	 and	 IL-12,	
however,	were	rather	contrary.	Hence,	Wnt5a	within	the	tumour	milieu	could	only	in	
part	be	responsible	for	the	altered	phenotype	of	ercDC	differentiated	from	monocytes.		
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A:	cDC+Wnt5a(d0)	 	 	 	 B:	ercDC+Wnt5a(d0)	
	 	
Fig.	11:	Enzyme	linked	immunosorbent	assay.	Wnt5a(d0)	effect	on	IL-10,	TNF-α	and	IL12p40	secretion	of	cDC	(A)	and	
ercDC	(B)	upon	LPS	and	CD40L	stimulation	for	24h.	The	graphs	display	the	geometric	mean	FC	of	cDC	and	ercDC	+	
Wnt5a(d0)	in	comparison	to	control	cDC	and	the	95%	Confident	interval	of	several	experiments.	Statistical	significance	
was	tested	by	one-sample	t-test	of	log-transformed	FCs.		
Through	their	cysteine	rich	domain	(CRD)	sFRPs	can	physically	interact	with	Wnt-ligands	
and	act	as	inhibitors	of	Wnt-signalling.	sFRP5	and	sFRP1	have	both	been	proposed	as	
possible	inhibitors	of	Wnt5a.	In	this	work,	addition	of	either	sFRP5	or	sFRP1	did	not	have	
any	 significant	 effects	 on	 IL-10,	 IL-12	 and	 TNF-a	 secretion	 in	 cDC	 or	 ercDC.	 Unlike	
expected,	 they	 did	 not	 influence	 cytokine	 patterns	 in	 cDC,	 which	 secrete	 Wnt5a	
themselves	 or	 ercDC,	 which	 might	 be	 influenced	 through	 Wnt-signalling	 within	 the	
tumour	milieu.		
Furthermore,	 sFRP5	 and	 sFRP1	 did	 not	 abrogate	 the	 effects	 of	 Wnt5a	 on	 cDC,	 as	
combination	of	Wnt5a	and	sFRP5	or	sFRP1	respectively	did	not	reduce	the	IL-10,	IL-12	
or	TNF-a	effects	of	Wnt5a.	
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A:	cDC+sFRP5(d0)	 	 	 	 B:	cDC+sFRP1(d0)	
	 	
	
C:	ercDC+sFRP5(d0)	 	 	 	 D:	ercDC+sFRP1(d0)	
	 	
	Fig.	12:	Enzyme	linked	immunosorbent	assay.	sFRP5	and	sFRP1(d0)	effect	on	IL-10,	TNF-α	and	IL12p40	secretion	of	
cDC	(A,	B)	and	ercDC	(C,	D)	upon	LPS	and	CD40L	stimulation	for	24h.	The	graphs	display	the	geometric	mean	FC	in	
comparison	to	control	cDC	and	ercDC	and	the	95%	Confident	interval	of	several	experiments.	Statistical	significance	
was	tested	by	one-sample	t-test	of	log-transformed	FCs.		
	
	
Fig.	13:	Enzyme	linked	immunosorbent	assay.	Effect	of	Wnt5a	and	its	combination	with	sFRP5	and	sFRP1(d0)	on	
IL-10,	TN-Fα	and	IL12p40	secretion	of	cDC	upon	LPS	and	CD40L	stimulation	for	24h.	The	graphs	display	the	
geometric	mean	FC	in	comparison	to	control	cDC	and	ercDC	and	the	95%	Confident	interval	of	several	experiments.	
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5.6 Migration	assay	
An	 important	 function	 of	 DC	 is	 their	 migration	 towards	 regional	 lymph	 nodes	 after	
antigen	uptake	and	consequent	maturation.	This	enables	the	DC	to	move	from	the	site	
of	inflammation	to	the	site	of	activation	of	the	adaptive	immune	system,	i.e.	activation	
of	T-cells.	CCL19	is	one	of	the	key	chemokines	involved	in	recirculation	and	homing	of	
lymphocytes.	By	binding	to	the	chemokine	receptor	CCR7	on	target	cells,	e.g.	DC,	B-cells	
and	 T-cells,	 it	 enables	 their	 trafficking	 towards	 the	 thymus	 and	 secondary	 lymphoid	
organs.	
	
5.7 Boyden	chamber	migration	assay	
Using	 the	Boyden	chamber	migration	assay	 (MA),	we	 investigated	 the	differences	of	
migration	 ability	 of	 cDC	 as	 compared	 to	 ercDC,	 and	 the	 potential	 influence	 of	Wnt-
signalling	 modulation	 on	 the	 ability	 of	 these	 DC	 subtypes	 to	 respond	 to	 migration	
stimuli.	 It	 could	 be	 shown	 that	 cDC	migrate	 strongly	 towards	CCL19,	whereas	 ercDC	
where	 not	 attracted	 by	 this	 chemokine	 (but	 do	 express	 the	 CCR7	 receptor).	
Furthermore,	by	addition	of	CCL19	in	the	trans	well,	as	well	as	in	the	base	well,	we	could	
verify	 that	 the	 migration	 of	 cDC	 towards	 CCL19	 was	 a	 directed	 migration,	 i.e.	
chemotaxis,	and	not	chemokinesis.		
cDC	 produce	 Wnt5a,	 but	 not	 ercDC.	 However,	 as	 was	 shown	 earlier,	 RCC	 strongly	
produce	Wnt5a.	Thus,	Wnt5a	stimulation	of	ercDC	may	occur	within	the	tumour	milieu	
through	 paracrine	 signalling.	 To	 test	 the	 effect	 of	 Wnt5a	 signalling	 on	 the	 ercDC	
phenotype,	 it	was	 added	 to	 the	 cells	 on	 day	 5,	 just	 before	 onset	 of	 the	maturation	
process.	While	 some	experiments	 showed	a	 slight	 increase	 in	 the	ability	of	ercDC	 to	
migrate,	this	effect	could	not	be	shown	to	be	consistent	and	significant.	Hence,	based	
on	the	Boyden	chamber	MA,	no	significant	effect	of	Wnt5a	on	the	migration	ability	of	
ercDC	could	be	shown.		
In	order	to	inhibit	the	Wnt5a	produced	by	cDC,	and	investigate	the	potential	importance	
of	Wnt5a	regarding	cDC	migration,	sFRP1	and	sFRP5	were	added	to	cDC	differentiation	
medium	 on	 day	 3.	 Again	 no	 significant	 effect	 could	 be	 detected	 with	 the	 Boyden	
chamber	MA.		
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Fig.	14:	Boyden	chamber	migration	assay.	Two	representative	examples	of	Boyden	chamber	MA.	The	graphs	display	
fold	changes	in	comparison	to	unstimulated	cDCm	without	CCL19.	Addition	of	CCL19	to	the	base	well	results	in	strong	
directed	Migration	of	cDCm,	but	not	of	ercDCm.	No	significant	effect	of	Wnt5a,	sFRP1,	sFRP5,	on	day	3,	5	or	6	(d3,	d5,	
d6),	on	cDCm	or	ercDCm	could	be	detected.	By	addition	of	CCL19	to	the	base	well	and	the	transwell	(+/+),	a	chemotactic	
effect	and	not	only	chemokinetic	effect	could	be	verified.		
	
5.8 Ibidi-migration	assay	
The	Boyden	chamber	MA	only	enables	detection	of	chemotaxis,	by	contrast,	the	µ-Slide	
Chemotaxis3D	by	IBIDI	also	allows	investigation	of	directionality,	distance	and	velocity.	
DC	were	 first	 embedded	 into	 gel	matrices	 and	 their	migration	 towards	 a	 chemokine	
gradient,	in	this	case	CCL19,	was	observed	by	video	microscopy	every	2	minutes	for	3.5h.		
Analysis	steps	included	the	manual	tracking	of	the	cells	and	hence	allowing	calculation	
of	accumulated	as	well	as	euclidean	distance	[µm],	velocity	[µm/min],	directness,	the	
center	 of	 mass	 and	 the	 forward	 migration	 index	 (FMI),	 using	 the	 chemotaxis	 and	
migration	tool	plugin	for	ImageJ.			
The	first	aim	was	to	validate	the	results	of	the	Boyden	chamber	MA,	and	to	then	gain	
further	insight	into	DC	migration	behaviour.	For	the	IBIDI-MA,	the	DC	required	a	higher	
chemokine	 concentration	 of	 1.25µg/ml,	 than	 the	 Boyden	 chamber	 MA.	 Lower	
concentrations	were	not	able	to	 induce	migration	 in	this	assay.	Matured	cDC	(cDCm)	
migrated	strongly	towards	CCL19.	This	was	represented	by	a	high	parallel-FMI	(FMI	II	or	
y-FMI),	i.e.	of	0.29,	compared	to	the	control	without	CCL19	(y-FMI	around	“0”),	and	a	
perpendicular	 FMI	 (FMI	^	 or	 x-FMI)	 that	 is	 close	 to	 “0”.	 The	 center	 of	mass,	which	
represents	the	spatial	averaged	point	of	all	cell	endpoints,	was	shifted	strongly	along	the	
y-axis.	Furthermore,	the	directionality,	calculated	by	comparing	the	euclidean	distance	
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to	the	accumulated	distance,	was	slightly	increased.	Though	the	directness	cannot	be	
used	as	a	parameter	for	judging	chemotaxis,	it	can	be	used	to	characterize	the	path	of	
migration.	The	velocity	of	the	cDC	stimulated	with	CCL19	was	only	slightly	increased.		
	
	
Fig.	15:	µ-Slide	Chemotaxis3D.	cDCm	migration	with	and	without	the	Chemoattractant	CCL19.	cDCm	show	a	strong	
chemotactic	 response	 to	 a	 CCL19-gradient	 with	 1.25µg/ml.	 Without	 CCL19,	 i.e.	 medium	 in	 both	 chambers,	
chemokinesis,	but	no	chemotaxis	could	be	observed.	The	blue	cross	represents	the	center	of	mass,	which	is	shifted	
upwards	on	the	y-Axis	upon	CCL19	stimulation.	(Analysis	with	Chemotaxis	and	Migration	tool	plug-in	for	ImageJ)	
In	contrast,	maturated	ercDC	(ercDCm)	did	not	increase	their	y-FMI	or	directionality,	and	
did	not	shift	their	center	of	mass	when	stimulated	with	CCL19.	Their	accumulated	and	
euclidean	distance	and	velocity,	however,	did	slightly	increase	upon	CCL19	stimulation.		
These	findings	basically	confirm	the	results	of	the	Boyden	chamber	MA,	as	ercDC	do	not	
respond	 to	 CCL19	 stimulation.	 Compared	 to	 cDCm,	 ercDCm	 showed	 reduced	
chemokinesis	as	well	as	reduced	chemotaxis	(Fig.	16).		
	
As	ercDCm	did	not	migrate	towards	CCL19	(but	still	express	the	CCR7	receptor	on	their	
surface),	the	question	was	posed	whether	they	have	impaired	migration	abilities.	To	test	
this,	the	migration	of	ercDC	towards	formyl-methionyl-leucyl-phenylalanine	(fMLP)	was	
investigated.	 fMLP,	 a	 cleavage	 product	 of	 bacteria	 binds	 to	 formyl	 peptide	 receptor	
(FPR)	and	FPR-like	1	and	2,	and	acts	as	a	chemoattractant	for	leukocytes	to	attract	them	
to	the	site	of	inflammation	[85].	It	was	shown	that	while	monocytes	and	immature	DC	
express	FPR,	FPR	was	down-regulated	during	maturation	and	maturated	DC	lost	their	
responsiveness	towards	fMLP	[86].		This	could	also	be	shown	with	the	IBIDI	MA.	While	
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cDCm	did	migrate	 strongly	 towards	 CCL19,	 they	 did	 not	migrate	 towards	 fMLP.	 The	
y-FMI	was	only	 slightly	higher	upon	 fMLP	stimulation	 than	unstimulated	and	did	not	
reach	the	level	of	stimulation	with	CCL19.	The	center	of	mass	was	only	slightly	shifted	
along	 the	 y-axis.	 Accumulated	 and	 euclidean	 distance	 as	 well	 as	 velocity	 of	 fMLP	
stimulation	 were	 similar	 to	 CCL19	 stimulation.	 Interestingly,	 ercDCm	 did	 migrate	
strongly	 towards	 fMLP.	The	y-FMI	and	 the	Directionality	 increased	and	 the	center	of	
mass	shifted	along	the	y-axis	upon	fMLP	stimulation.	Also	accumulated	and	euclidean	
distance	and	velocity	increased	slightly.	It	can	therefore	be	concluded,	that	ercDCm	do	
not	have	impaired	migration	abilities,	but	impaired	abilities	to	respond	towards	CCL19.	
While	 cDCm	 down-regulate	 their	 fMLP-receptors	 during	 maturation,	 it	 seems	 that	
ercDCm	do	not	and	rather	retain	an	immature	response	towards	chemoattractants.			
	
	
Fig.	 16:	 µ-Slide	 Chemotaxis3D.	 Chemotactic	 response	 of	 ercDCm	 (A)	 and	 cDCm	 (B)	 towards	 CCL19	 and	 fMLP	
respectively.	While	 ercDCm	 show	no	 chemotactic	 and	 chemokinetic	 response	 towards	CCL19,	 they	 show	a	 strong	
response	 towards	 fMLP.	 Contrary,	 cDCm	 do	 not	 respond	 towards	 fMLP,	 but	 only	 towards	 CCL19	 with	 directed	
migration.	This	suggests	that	ercDCm	retain	the	immature	response	of	DC	towards	CCL19,	and	do	not	have	overall	
impaired	migration	abilities.	Furthermore,	it	can	be	noted,	that	cDCm	are	more	chemokinetic	active	than	ercDCm.		
In	a	next	 step,	we	sought	 to	determine	whether	 immature	cDC	are	 less	mobile	 than	
mature	cDC,	or	generally	more	mobile	than	immature	ercDC,	and	whether	treatment	
with	 Wnt5a	 could	 influence	 this	 mobility.	 For	 this	 experimental	 setup,	 µ-Slide	
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Chemotaxis3D	MAs	were	performed	with	 cells	 from	 the	 same	donor,	 in	an	 immature	
state	 and	 after	 maturation.	 As	 expected,	 immature	 cDC	 were	 not	 able	 to	 migrate	
towards	CCL19,	and	they	only	gained	the	ability	of	directional	migration	towards	CCL19	
through	maturation.	Wnt5a	 stimulation	 showed	 no	 significant	 effect	 on	 the	 general	
mobility	of	immature	cDC.	Velocity	and	accumulated	distance	were	slightly	decreased	
in	 immature	 cDC	 stimulated	 with	 Wnt5a	 (d0)	 compared	 to	 immature	 cDC	 without	
Wnt5a.	In	their	immature	state	cDC	behaved	similarly	to	immature	ercDC,	which	even	
seemed	 to	 be	 slightly	 more	 mobile	 than	 cDC	 with	 an	 increased	 velocity	 and	 mean	
distance.		
	
	
Fig.	17:	µ-Slide	Chemotaxis3D.	Chemotactic	response	of	 immature	cDC	(A)	and	ercDC	(B)	towards	CCL19,	with	A	c.	
being	immature	cDC	+	Wnt5a(d0).	Neither	immature	cDC	nor	ercDC	show	directed	migration	towards	CCL19.	In	their	
immature	state	cDC	present	similarly	to	immature	ercDC.	Addition	of	Wnt5a(d0)	did	not	show	any	effect	on	migration	
behaviour	of	immature	cDC.		
Once	maturated,	 cDC	were	able	 to	migrate	directional	 towards	CCL19	and	 increased	
their	accumulated	distance	and	velocity	 significantly.	As	expected,	 the	maturation	of	
ercDC	did	not	influence	their	migration	towards	CCL19	as	compared	to	their	immature	
state.	They	showed	no	directed	migration	and	also	distance	and	velocity	remained	the	
same	compared	to	their	immature	state.		
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Fig.	18:	µ-Slide	Chemotaxis3D.	Chemotactic	response	of	maturated	cDC	(A)	and	ercDC	(B)	towards	CCL19.	Cells	were	
derived	 from	 the	 same	 donor	 at	 the	 same	 time	 as	 experiment	 Fig.	 12.	While	maturation	 of	 cDC	 enabled	 strong	
directional	migration	towards	CCL19,	no	directional	migration	could	be	observed	for	maturated	ercDC.		
5.8.1 Migratory	effect	of	Wnt5a,	sFRP5	and	sFRP1	on	cDC		
In	 order	 to	 investigate	 the	 specific	 effects	 of	 modulation	 of	 Wnt-signalling	 on	 the	
migratory	behaviour	of	cDCm,	Wnt5a,	sFRP1,	sFRP5	or	the	combination	of	Wnt5a	and	
sFRP1	were	added	to	the	growth	medium	during	differentiation.	 	All	stimulants	were	
added	on	day	0	to	ensure	their	presence	throughout	the	whole	differentiation	process.	
Thereafter	 µ-Slide	 Chemotaxis3D	 MAs	 towards	 CCL19	 was	 performed	 and	 the	 FMI,	
directionality,	 distances	 and	 velocity	 evaluated.	 As	 a	 negative	 control,	 cDCm	
medium-medium	migration	was	performed	with	each	experimental	setup.	For	statistical	
purposes,	 the	 results	of	 several	experiments,	with	different	donors	were	pooled	and	
statistical	significance	determined	using	the	Mann-Whitney	U-test	for	two-tailed	data	
and	cDCm	as	a	reference	group.	Even	though	donor	specific	differences	were	observed	
in	 these	 experiments,	 histogram	 analysis	 (by	 Kolmogorov-Smirnov-Test)	 confirmed	
Gaussian-distribution	of	pooled	data,	justifying	their	further	analysis.	
	
As	 we	 previously	 showed	 that	 cDC,	 but	 not	 ercDC,	 produce	Wnt5a,	 we	 expected	 a	
positive	 effect	 of	 Wnt5a	 and	 a	 possible	 negative	 effect	 of	 Wnt5a-inhibition	 on	 the	
migratory	behaviour	of	cDCm.	Unexpectedly	however,	Wnt5a	significantly	reduced	the	
y-FMI,	directionality,	distances	and	the	velocity.	Stimulated	with	Wnt5a,	cDCm	showed	
reduced	 motility	 and	 directed	 migration	 towards	 CCL19.	 Furthermore,	 attempted	
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inhibition	of	Wnt5a	with	sFRP5	and	sFRP1	did	not	counteract	the	effects	of	Wnt5a,	but	
also	showed	an	inhibitory	effect	on	migration,	with	reduced	FMI,	directionality,	distance	
and	 velocity.	 The	 simultaneous	 stimulation	 with	 Wnt5a	 and	 sFRP1	 also	 inhibited	
migration,	although	this	effect	was	not	additive.	Overall	 it	could	be	shown	that	Wnt-
signalling	 modification	 seemed	 to	 inhibit	 the	 migration	 of	 cDCm	 in	 all	 investigated	
aspects.	 When	 stimulated	 the	 cells	 showed	 reduced	 motility,	 velocity	 and	 directed	
migration.		
	
Fig.	19:	µ-Slide	Chemotaxis3D.	Chemotactic	and	chemokinetic	effect	of	Wnt5a,	sFRP5,	sFRP1	on	cDCm.	All	stimulants	
were	added	on	day	0	of	 differentiation.	 For	 statistical	 analysis	 the	Mann-Whitney	U-test	 for	 two-tailed	data	was	
applied	and	cDC	used	as	a	reference	group.		
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5.8.2 Migratory	effect	of	Wnt5a,	sFRP1	and	sFRP5	on	ercDC	
The	same	experimental	setup	was	used	to	investigate	the	effects	of	Wnt5a,	sFRP1	and	
sFRP5	on	ercDCm.	Again	all	stimulants	were	added	on	day	0	of	differentiation.	Data	of	
several	 experiments	were	 pooled	 and	 the	Mann-Whitney	U-test	 for	 two-tailed	 data,	
with	 ercDCm	 as	 reference	 group,	 applied	 in	 order	 to	 test	 for	 statistical	 significance.		
Contrary	 to	 cDCm,	 however,	 no	 significant	 effects	 regarding	 distances,	 velocity	 and	
directionality	could	be	detected.	The	significant	effects	on	yFMI	have	to	be	evaluated	
carefully,	as	ercDCm	only	showed	marginal	migration,	with	very	short	distances,	and	
therefore	rather	have	to	be	considered	as	an	experimental	error.		
	
Fig.	20:	µ-Slide	Chemotaxis3D.	Chemotactic	and	chemokinetic	effect	of	Wnt5a,	sFRP5,	sFRP1	on	ercDCm.	All	stimulants	
were	added	on	day	0	of	 differentiation.	 For	 statistical	 analysis	 the	Mann-Whitney	U-test	 for	 two-tailed	data	was	
applied	and	cDC	used	as	a	reference	group.		
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5.9 Microarray	analysis	of	ex	vivo	cDC	and	ercDC	
All	initial	experiments	were	performed	with	in	vitro	generated	PBMC	derived	cDC,	ercDC	
and	MΦ.	 In	 a	 final	 step	 we	 therefore	 aimed	 to	 validate	 the	 in	 vitro	 transcriptomic	
analysis	with	ex	vivo	derived	data.	“Affymetrix	GeneChip®	Human	Gene	1.0	ST”	array	
data	of	ex	vivo	cDC,	ercDC	and	MΦ	were	kindly	provided	by	Dorothee	Brech.	Ex	vivo	
ercDC	RCC	(CD209+CD14+CD163+)	and	MΦ	(CD209+CD14+CD163+)	were	obtained	from	
tissue-suspensions	of	clear	cell	RCC	samples,	while	CD1c+	DC	(CD11c+,	CD1c+,	CD19-)	and	
slanDC	 (CD11c+,	 slan+,	 CD19-)	were	 obtained	 from	blood	 samples	 of	 healthy	 donors.	
Again	quality	 control,	 clustering	 analysis	 and	normalisation	using	 the	RMA-algorithm	
were	performed	using	the	MADMAX	platform.	Fold	changes	were	calculated	as	before	
comparing	CD1c+	DC,	slanDC	and	MΦ	to	ercDC_RCC	and	a	fold	change	>1.5	or	<-1.5	was	
considered	differential	gene	expression.	For	better	comparability,	FCs	of	 in	vitro	cDC	
compared	to	ercDC	were	included	in	the	chart	(see	supplementary	table	2).		
Interestingly	CD1c+	DC	and	slanDC	compared	to	ercDC_RCC	showed	a	lot	of	regulation	
for	canonical	as	well	as	non-canonical	Wnt-signalling	pathways.	These	differential	gene	
expressions	did	however,	not	necessarily	resemble	the	gene	expression	pattern	found	
for	the	in	vitro	cDC	compared	to	ercDC.		
Contrary	to	the	in	vitro	data,	no	differential	gene	expression	could	be	observed	for	any	
of	 the	 Wnt-ligands	 or	 receptors	 and	 only	 little	 for	 co-receptors,	 agonists	 and	
antagonists.	 Unlike	 in	 vitro	 cDC,	 ex	 vivo	 CD1c+	 DC	 or	 slanDC	 did	 not	 show	 higher	
expression	of	Wnt5a	compared	to	ercDC.	Interesting,	was	the	differential	expression	of	
SDC2,	3	and	4,	which	showed	higher	expression	in	ercDC_RCC	compared	to	CD1c+	DC	or	
slanDC.		
Even	though	this	data	does	not	support	our	findings	of	increased	expression	of	Wnt5a	
in	in	vitro	cDC,	compared	to	ercDC,	differential	expression	for	core	signalling	genes	of	
canonical	 as	 well	 as	 non-canonical	 signalling	 was	 evident	 and	 suggest	 possible	
mechanism	for	impaired	ercDC	functioning.		
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Fig.	21:	Microarray	analysis	of	CD1c+	DC.	The	scheme	displays	microarray	data	integrated	into	a	modified	version	of	
the	canonical	(A),	Ca2+	(B)	and	PCP	(C)	Wnt	pathway.	FC	were	calculated	comparing	CD1c+	DC	(CD11c+,	CD1c+,	CD19-)	
to	ercDC_RCC	(CD209+CD14+CD163+).	Significant	differential	gene	expression	is	presented	by	green	(up-regulation)	or	
red	 (down-regulation)	boxes	and	 the	corresponding	 fold	changes	 in	comparison	 to	monocytes.	Fold	changes	were	
generated	using	the	RMA-Algorithm	and	a	FC	>1.5	and	<-1.5	was	considered	significant	differential	expression.	
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Fig.	22:	Microarray	analysis	of	slanDC.	The	scheme	displays	microarray	data	integrated	into	a	modified	version	of	the	
canonical	 (A),	 Ca2+	 (B)	 and	PCP	(C)	Wnt	pathway.	 FC	were	 calculated	 comparing	 slanDC	 (CD11c+,	 slan+,	 CD19-)	 to	
ercDC_RCC	(CD209+CD14+CD163+).	Significant	differential	gene	expression	is	presented	by	green	(up-regulation)	or	red	
(down-regulation)	 boxes	 and	 the	 corresponding	 fold	 changes	 in	 comparison	 to	 monocytes.	 Fold	 changes	 were	
generated	using	the	RMA-Algorithm	and	a	FC	>1.5	and	<-1.5	was	considered	significant	differential	expression.	
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5.10 Wnt-signalling	in	renal	cell	carcinoma	
In	order	to	further	analyse	Wnt-signalling	in	RCC,	we	performed	transcriptomic	analysis	
of	the	Wnt-signalling	pathways	in	normal	kidney	and	samples	of	RCC	with	G1	and	G3	
nuclear	grade,	3-tiered	WHO.	Data	was	kindly	provided	by	PD	Dr.	Matthias	Maruschke	
from	the	Department	of	Urology	of	the	University	of	Rostock.	Analysis	and	FC	calculation	
were	performed	concordant	with	previous	data	(see	supplementary	table	3).		
Supporting	the	 immune-histological	 findings	Wnt5a	was	strongly	up	regulated	 in	RCC	
and	even	more	expressed	with	higher	WHO	nuclear	grading.	Other	Wnt-ligands	were	
not	differentially	expressed,	suggesting	a	possible	key	role	of	Wnt5a	signalling	in	RCC.	
An	up-regulation	could	also	be	observed	for	Fzd1	and	2	receptors	in	RCC,	especially	G3.			
Interestingly,	the	RCC	showed	a	strong	down	regulation	of	HSPG,	especially	glypicans	3	
and	4.	Our	in	vitro	data	of	activated	myeloid	cells	(cDC,	ercDC,	M1	and	M2),	however,	
showed	high	expression	of	SDC2,	3,	4	and	GPC4.	High	expression	for	SDC2,	3	and	4	were	
also	observed	for	ercDC_RCC	compared	to	CD1c+	DC	and	slanDC.	As	discussed	earlier,	
HSPG	are	discussed	to	be	involved	with	Wnt-ligand	gradient	formation	and	can	act	as	
co-receptors,	especially	for	non-canonical	signalling.	The	RCC	could	hence	be	a	possible	
source	of	Wnt5a	and	thereby	affect	myeloid	cells	differentiation.		
Strong	differential	expression	was	also	found	for	several	Wnt-antagonists,	suggesting	
strong	regulation	of	specific	Wnt-signalling.	DKK3,	sFRP2,	3,	4,	CTHRC1	and	IGFBP1	were	
for	 example	 up-regulated,	 whereas	 WIF1,	 sFRP1,	 Shisa	 2,	 3	 and	 SOST	 were	
down-regulated.	
Differential	expression	of	core	Wnt-signalling	genes	was	found	for	b-Catenin-dependent	
as	well	as	b-Catenin-independent,	PCP	and	Ca,	-signalling.	Even	though	regulation	was	
evident,	 data	 was	 not	 suggestive	 of	 specific	 activation	 of	 either	 canonical	 or	 non-
canonical	signalling.	
In	conclusion,	 it	can	be	said	that	strong	differential	expression	of	core	Wnt	signalling	
genes	and	associated	genes	could	be	found	in	clear	cell	RCC,	and	differences	could	also	
be	found	depending	on	grading	of	the	tumour.	Interesting	was	the	high	expression	of	
Wnt5a	in	RCC	compared	to	normal	kidney.	This	could	suggest	a	possible	mechanism	for	
impaired	 DC	 functioning	 in	 RCC	 and	 even	 be	 in	 part	 responsible	 for	 altered	
differentiation	of	ercDC.		
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6 Discussion	
6.1 Renal	cell	carcinoma	and	ercDC	
As	immunogenic	tumours,	RCC	and	especially	clear	cell	RCC	(ccRCC)	are	usually	highly	
infiltrated	 by	 leukocytes.	 However,	 a	 negative	 correlation	 of	 increased	mononuclear	
cells	in	the	infiltrate	with	prognosis	has	been	observed,	suggesting	that	the	immune	cells	
do	not	properly	function	in	their	role	as	anti-tumour	defence	[87].	Recent	studies	have	
attempted	 to	 investigate	 the	 composition	 of	 this	 infiltrate	with	 special	 emphasis	 on	
subtype	 identification	and	 functionality.	A	deeper	understanding	of	RCC	 immunology	
and	the	factors	involved	in	tumour	escape	from	an	eliminating	immune	response,	could	
reveal	 prognostic	 factors	 and	 identify	 new	 therapeutic	 approaches.	 Schleypen	 et	 al.	
investigated	the	influence	of	cytotoxic	marker	expression	and	the	frequency	of	natural	
killer	 cell	 infiltrates	 in	 samples	of	RCC,	with	 regards	 to	 their	 functional	 capacity	 [88].	
Their	findings	suggested	the	potential	use	of	NK-infiltrates	in	RCC	as	prognostic	marker	
for	the	clinical	outcome	of	RCC	patients.	DC,	which	can	function	as	a	switch	between	
immune	activation	and	tolerance,	have	also	been	suggested	as	predictive	markers	of	
disease	 progression.	 The	 granulocyte/DC	 ratio,	 for	 example,	 was	 proposed	 as	 a	
biomarker	 for	 immune	monitoring	 of	 RCC	 patients	 [89].	 SlanDC,	 a	 proinflammatory	
subset	of	myeloid	DC,	have	been	shown	 to	accumulate	 in	primary	ccRCC,	metastatic	
lymph	nodes	and	metastases	[90].	These	RCC	infiltrating	slanDC,	however,	differ	from	
slanDC	 found	 in	healthy	human	blood,	 as	 they	present	 an	 immature	phenotype	 and	
show	 impaired	 ability	 to	 induce	 T-cell	 proliferation	 and	 polarization,	 and	 produce	
reduced	levels	of	proinflammatory	cytokines	such	as	TNF-a	and	IL-12,	but	higher	levels	
of	anti-inflammatory	IL-10.	While	healthy	blood	slanDC	may	contribute	to	an	antitumour	
immune	response,	these	tolerogenic	slanDC	seem	to	be	involved	in	tumour	growth	and	
immune	escape	and	hence	may	be	used	as	prognostic	marker.		
Another	DC	subtype	identified	in	RCC	tissue	are	the	so	called	ercDC,	which	co-expresses	
the	DC	marker	CD209	and	the	macrophage	markers	CD14	and	CD163.	This	“DC”	subtype	
was	 found	 to	 be	 enriched	 in	 RCC	 and	 with	 increasing	 density	 in	 advanced	 tumour	
stages	[91].	Although	initially	referred	to	as	DC-subtype,	further	work	by	D.	Brech	have	
positioned	the	ercDC	phenotype	within	the	continuum	of	the	mononuclear	phagogocyte	
system,	where	DC	and	Mf	 represent	opposite	extremes.	 In	her	work,	she	has	shown	
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that	ercDC	resemble	DC	as	well	as	Mf,	but	based	on	gene	expression	analysis,	appear	
to	show	more	similarities	to	Mf,	especially	to	an	inflammatory	Mf	subtype	found	within	
the	 ascites	 produced	 by	 ovarian	 cancer.	 ErcDC	 can	 be	 generated	 in	 vitro	 through	
addition	 of	 CXCL8/IL-8,	 IL-6	 and	 VEGF,	 which	 are	 highly	 expressed	 by	 RCC	 [91].	
Furthermore,	D.	Brech	has	shown	that	PGE2,	glucocorticoids	(GC)	and	palmitic	acid	(PA),	
or	a	 combination	of	TNF,	PGE2	and	Pam3CysSerLys4	 found	within	 the	 tumour	milieu	
influence	 the	 differentiation	 of	 ercDC	 and	 thus	 could	 explain	 the	 proangiogenic	 and	
invasive	gene	expression	of	ercDC,	which	promote	tumour	progression.	Moreover,	she	
identified	 signs	of	 tolerogenic	 and	protumoural	 characteristics,	 such	 as	 the	 impaired	
ability	of	ercDC	to	induce	T-cell	proliferation.		
In	the	present	work,	my	goal	was	to	further	identify	differences	between	ercDC	and	cDC.	
As	 cytokine	 production	 plays	 a	 pivotal	 role	 in	 influencing	 cell	 signalling,	 immune	
responses	and	especially	 the	activation	or	 inhibition	of	other	 immune	cells,	 cytokine	
levels	of	IL-12,	TNF-a	and	IL-10	were	measured.	IL-12	and	TNF-a	are	pro-inflammatory	
cytokines	associated	with	antitumourogenic	properties.	IL-10	is	referred	to	as	an	anti-
inflammatory	cytokine	and	high	levels	are	assumed	to	play	a	role	in	the	tumours	escape	
from	 an	 immune	 response	 [83].	 Recent	 studies	 reported	 a	 low,	 chronic	 secretion	 of	
TNF-a	 in	RCC	and	showed	that	this	correlates	with	poor	prognosis	[84].	In	support	of	
these	findings,	my	work	could	show	that	ercDC	produce	significantly	more	TNF-a	and	
IL-10	 upon	 LPS	 stimulation,	 and	 hence	 could	 represent	 a	 possible	 source	 of	 these	
cytokines	in	RCC.	IL-12,	however,	was	detected	at	decreased	levels	in	ercDC	compared	
to	cDC.	These	findings	support	the	hypothesis	of	ercDC	being	a	myeloid	subset,	found	
especially	in	RCC,	which	facilitates	the	tumours	escape	from	the	immune	surveillance	
and	furthermore	possibly	promotes	tumour	growth.		
In	a	next	step,	the	ability	of	ercDC	to	migrate	towards	CCL19	was	investigated.	CCL19	is	
an	important	chemokine	involved	in	the	homing	of	maturated	DC	towards	peripheral	
lymph	nodes.	Homing	to	lymph	nodes	is	crucial	in	DC	biology,	as	this	is	where	DC	activate	
and	 prime	 T-cells	 for	 a	 directed,	 adaptive	 immune	 response.	 While	 cDC	 migrated	
strongly	 towards	 CCL19,	 ercDC	 did	 not	 respond	 to	 CCL19	 stimulation	 although	 they	
express	 the	 receptor	 CCR7.	 To	 ensure	 that	 ercDC	 have	 the	 ability	 to	migrate,	 ercDC	
migration	towards	fMLP	was	tested.	fMLP	is	a	cleavage	product	of	bacteria	and	attracts	
leukocytes	 to	 the	 site	of	 inflammation.	 FPR,	 the	 receptor	 for	 fMLP,	was	 found	 to	be	
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expressed	on	monocytes	and	immature	DC,	but	down-regulated	on	maturated	DC	[86],	
thereby	enabling	a	switch	between	site	of	inflammation	and	site	of	adaptive	immune	
response	activation.	Here	we	could	show	that	unlike	maturated	cDC,	“maturated”	ercDC	
migrate	strongly	towards	fMLP,	but	not	towards	CCL19.	This	suggests	that	ercDC	retain	
a	rather	immature	response	towards	chemoattractants	or	do	not	maturate	in	the	same	
way	as	cDC.	This	prohibits	 the	migration	of	ercDC	towards	 lymph	nodes,	where	 they	
could	potentially	initiate	an	adaptive	immune	response.	We	hypothesize	that	this	is	a	
second	mechanism	by	which	the	tumour	escapes	immune	response	in	which	ercDC	play	
a	decisive	role.		
In	summary,	we	found	further	evidence	to	support	the	hypothesis	that	ercDC	may	be	
involved	 in	 the	 tumours	 ability	 to	 escape	 immune	 surveillance.	We	 could	 show	 that	
ercDC	produce	high	levels	of	IL-10	and	TNF-a,	but	lower	levels	of	IL-12.	Furthermore,	
maturated	ercDC	are	not	able	to	migrate	towards	CCL19.	As	a	next	step,	we	attempted	
to	go	deeper	 into	the	biology	of	ercDC,	specifically	as	 it	relates	to	their	regulation	by	
signalling	pathways	linked	to	tumour	biology.	
		
6.2 Wnt-signalling	in	renal	cell	carcinoma		
While	 Wnt-signalling,	 especially	 β-catenin	 dependent	 signalling,	 has	 been	 studied	
extensively	 in	other	cancers,	such	as	colorectal	cancer,	breast	cancer	and	melanoma,	
only	 little	 is	 known	 about	 its	 involvement	 in	 RCC.	 Controversial	 results	 of	 β-Catenin	
expression	levels	have	been	detected,	yet	all	of	these	studies	confirm	the	importance	of	
β-Catenin-signalling	 in	 RCC.	Multilayer-omics	 	 studies	 identified	 gene	mutations	 and	
epigenetic	 as	 well	 as	 mRNA	 expression	 alterations	 of	 canonical	 Wnt-signalling	 in	
RCC	[92].	 Increased	 expression	 levels	 of	Wnt	 receptors	 Fzd5,	 7	 and	 8	 [93]	 and	Wnt-
ligands,	 such	 as	Wnt1	 and	Wnt10A	 could	 be	 detected	 [94].	 Furthermore,	 decreased	
expression	levels	were	detected	for	extracellular	Wnt-antagonists,	such	as	DKK,	IGFBP4	
and	 sFRPs,	 which	 result	 in	 increased	 β-Catenin	 stabilisation	 [95].	 Downstream	
alterations	 include	the	activation	of	ubiquitin	protein	 ligase	E3C	(UBE3C)[96]	and	the	
oncogene	MYC	[93].	Potential	implications	of	Wnt	signalling	in	RCC	include	changes	in	
apoptosis,	proliferation	and	migration	[97].		
As	little	was	known	about	non-canoncial	signalling	in	RCC	our	one	goal	of	this	study	was	
to	 further	 elucidate	 its	 potential	 involvement.	 Immunohistochemistry	 demonstrated	
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that	Wnt5a	is	highly	expressed	within	the	RCC.	Furthermore,	 it	was	possible	to	verify	
Wnt5a	expression	in	RCC	by	transcriptomic	analysis,	and	that	Wnt5a	expression	appears	
to	increase	with	tumour	progression	suggesting	a	possible	role	for	Wnt5a.		
Although,	 Shiina	 et	 al.	 and	 Kruck	 et	 al.	 detected	 increased	 levels	 of	 canonical	 Fzd-
receptors	and	Wnt-ligands,	these	findings	could	not	be	verified	in	our	gene	array	analysis	
performed	on	RCC	samples.	In	addition,	no	differential	expression	of	β-Catenin	and	only	
slight	 variations	 in	 other	 genes	 linked	 to	 canonical	 Wnt	 signalling	 were	 observed.	
Possible	 reasons	 for	 these	 deviations	 from	 the	 published	 literature	 include	 differing	
sample	 acquisition,	 tumour	 stages	 and	 other	 factors	 associated	 with	 protocol	
differences.	Noteworthy,	was	the	strong	up	regulation	of	RAC2,	which	showed	a	positive	
correlation	with	progressive	tumour	grading.	RAC2	is	a	small	Rho-like	GTPase	and	part	
of	the	Wnt	PCP	pathway.	It	is	involved	in	cytoskeletal	rearrangement	by	regulating	cell	
adhesion,	migration	and	polarity.	Differential	expression	was	also	seen	for	other	genes	
of	the	Wnt	PCP	and	Ca2+-pathways,	suggesting	a	possible	role	of	non-canonical	signalling	
in	RCC.	Strong	regulation	was	observed	for	Wnt-antagonists.	While	a	previous	study	by	
Ueno	et	al.	showed	an	epigenetical	down-regulation	of	DKK3	[98],	we	could	detect	an	
up-regulation	of	DKK3.	DKK3	has	been	shown	to	influence	canonical,	e.g.	in	lung	cancer,	
as	well	as	non-canonical	Wnt	signalling	in	for	example	prostate	cancer,	via	interference	
with	Wnt	receptors	and	co-receptors.	An	increase	in	expression	of	sFRP2,	3	and	4	in	RCC	
was	also	seen	as	compared	to	normal	kidney	tissue.		sFRP1	and	WIF1,	both	important	
inhibitors	of	Wnt-signalling,	were	down-regulated	in	RCC,	which	is	 in	agreement	with	
previous	findings	by	others	[99].		
Interesting	was	 the	 differential	 expression	 of	 HSPG,	 and	 especially	 the	 strong	 down	
regulation	of	glypicans	3	and	5	found	in	RCC	as	compared	to	healthy	kidney.	Glypicans	
are	 HSPGs	 that	 are	 covalently	 bound	 to	 the	 plasma	 membrane	 through	 a	
glycosylphosphatidylinositol	 anchor.	 They	 can	 regulate	 signalling	 pathways	 through	
ligand-receptor	interaction	and	thereby	exhibit	inhibitory	as	well	as	stimulatory	effects.	
Similarly	to	Wnt5a,	GPC3	is	up-regulated	during	development,	but	down	regulated	in	
most	 adult	 tissues,	with	 the	 exception	 of	mesothelium,	 breast	 and	 ovarian	 epithelia	
[100].	GPC3	up-regulation	was	detected	in	hepatocellular	carcinoma	(HCC)	and	has	been	
shown	 to	 promote	 β-Catenin	 dependent	 signalling	 through	 direct	 ligand	 receptor	
interaction,	e.g.	with	Wnt3a	and	Fzd8,	and	increased	ligand	concentration	at	the	cellular	
Discussion	
	 	 	 75	
membrane	[101].	Furthermore,	 it	was	shown	to	be	involved	in	cellular	migration	and	
motility	 in	HCC	 [102].	GPC3	has	 been	 shown	 to	have	 inhibitory	 effects	 on	β-Catenin	
dependent	signalling,	and	promote	activation	of	non-canoncial	PCP	signalling	in	breast	
cancer.	 In	this	context,	 it	 is	thought	to	promote	mesenchymal-epithelial	transmission	
(MET),	 and	 thereby	 inhibit	metastasis	 and	 the	 invasiveness	 of	 tumours	 [100].	 These	
contrary	effects	of	GPC3	on	Wnt-signalling	could	be	explained	in	part	by	cellular	context,	
as	well	as	the	ligands	and	receptors	involved.	Castillo	et	al.	have	suggested	that	GPC3	
expression	 patterns	 depend	 on	 the	 tumour	 tissue	 and	 its	 origin.	 GPC5	 shows	 high	
homology	to	GPC3.	However,	only	little	is	known	about	its	exact	role.	It	has	been	shown	
to	 promote	 rhabdomyosarcoma	 proliferation	 via	 hedgehog	 and	Wnt1	 signalling,	 but	
also	to	exhibit	a	protective	effect	on	lung	cancer	[103].	It	would	be	interesting	to	further	
elucidate	the	biologic	mechanisms	of	GPC3	and	GPC5	in	RCC.		
Summarizing,	we	detected	strong	differential	regulation	of	non-canonical	Wnt-signalling	
in	RCC.	Striking	was	the	up	regulation	of	Wnt5a	at	the	protein	and	mRNA	level,	and	the	
differential	expression	of	GPC	3,	5	and	Wnt-antagonists.	Not	all	of	our	findings	were	in	
concordance	with	previous	studies,	especially	with	regards	to	the	differential	expression	
of	Wnt-antagonists.	This	 is	also	seen	across	the	 literature	research	where	sometimes	
contrary	 results	 and	 functions	 were	 described	 for	 the	 same	 gene.	 These	 results	
underscore	 the	 diversity	 and	 complexity	 of	 Wnt-signalling	 in	 tumour	 biology.	 The	
activation	of	these	pathways	depend	on	the	intricate	interplay	of	ligands,	receptors,	co-
receptors	 and	 down-stream	 signalling	 pathways.	 The	 detection	 of	mRNA	 expression	
levels	alone	does	not	allow	 for	prediction	of	mechanism	or	effects.	 Further	 research	
would	be	necessary	to	identify	causes	explaining	these	differences.	In	addition,	patient	
differences,	tumour	stages	and	other	unknown	factors	such	as	sample	acquisition	and	
experimental	error	have	to	be	kept	in	mind.	As	complex	and	difficult	as	this	seems,	it	is	
still	vitally	important	to	better	understand	this	biology	in	the	context	of	RCC	biology.		
	
6.3 Wnt-signalling	and	dendritic	cells	
The	major	goal	of	 this	 thesis	was	 to	 study	 the	potential	 role	of	Wnt-signalling	 in	 the	
context	 of	 myeloid	 biology	 and	 specifically,	 during	 development	 of	 the	 ercDC	
phenotype.	We	hypothesized,	that	Wnt-signalling	may	differ	between	myeloid	subsets	
and	that	the	tumour	milieu	of	the	RCC	may	be	able	to	influence	the	differentiation	of	
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myeloid	 cells	 and	 thereby	 promote	 RCC	 growth.	 Transcriptomic	 analysis	 of	 in	 vitro	
generated	monocyte	derived	DC	and	Mf	was	used	to	identify	potential	differences	in	
Wnt-signalling	 associated	 gene	 expression	 levels.	 Interestingly,	 high	 expression	 of	
Wnt5a	was	identified	in	cDC,	while	it	was	largely	absent	in	monocytes,	Mf	and	ercDC.	
Other	Wnt	ligands,	however,	were	not	found	to	be	differentially	expressed	between	the	
myeloid	subsets.	According	to	the	DABG	algorithm,	many	of	the	Wnt-ligands,	e.g.	Wnt2,	
3a,	 8a,	 8b,	 10a	 and	 11	were	 not	 detected	 above	 background	 in	 any	 of	 the	myeloid	
subsets.	Differential	expression	was	found	within	the	Ca2+-	and	the	β-Catenin	dependent	
Wnt	-signalling	pathways	and	moderate	changes	were	also	seen	in	the	PCP-pathway.	A	
striking	up-regulation	of	SDC2,	4	and	GPC4	was	seen	in	activated	myeloid	cells	compared	
to	peripheral	blood	monocytes.	These	HSPGs	have	been	shown	to	enhance	and	inhibit	
canonical,	as	well	as	non-canonical	signalling,	depending	on	ligand	and	receptor	context.	
These	proteins	are	thought	to	help	concentrate	Wnt-ligands	at	the	cellular	membrane	
and	thereby	promote	direct	ligand-receptor	interaction	[70].	SDC4	has	been	implicated	
in	Wnt/PCP	as	well	as	Ca2+-signalling	and	SDC2	in	moderating	RhoGTPase	activity	[104].	
Furthermore,	SDC4	expression	has	been	shown	to	correlate	with	Wnt5a	 levels	and	 is	
thought	 to	 be	 essential	 for	 Wnt5a	 autocrine	 signalling,	 internalization	 and	 signal	
transduction,	especially	in	non-canonical	signalling	of	melanoma	cells	[105].	GPC4	has	
recently	 been	 shown	 to	 inhibit	 β-Catenin	 signalling	 in	 cardiomyocytes	 by	 possibly	
affecting	Wnt-ligand	 gradient	 formation	 and	 interaction	 with	Wnt-inhibitor	 factor	 1	
(WIF-1)	[106].	However,	there	is	also	evidence	that	GPC4	binds	to	Wnt11	and	enhances	
Wnt-induced	migration	and	that	GPC4	can	positively	and	negatively	regulate	Wnt3a	as	
well	as	Wnt5a-signalling	depending	on	its	membrane	localization	[107].	The	biology	of	
HSPGs	is	clearly	complex	and	very	little	is	understood	about	their	exact	role	in	myeloid	
cell	biology.		
Based	on	the	results	of	 the	transcriptomic	and	pathway	analysis,	differences	 in	Wnt-
signalling	 pathways	 were	 seen	 between	 the	 myeloid	 subsets.	 Activation,	 as	 well	 as	
suppression	of	canonical	and	non-canonical	signalling	was	observed	depending	on	the	
specific	 myeloid	 subset.	 While	 a	 more	 robust	 differential	 expression	 was	 observed	
between	cDC	and	M1,	when	compared	to	monocytes,	only	slight	differences	were	seen	
when	comparing	ercDC	to	monocytes.	This	suggests	that	Wnt-signalling	in	ercDC	more	
closely	resembles	peripheral	blood	monocytes,	but	not	with	cDC	or	M1	cells.	Hence,	this	
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led	 to	 the	 question	whether	 the	 differences	 seen	 in	Wnt-signalling	 could	 in	 part	 be	
responsible	for	the	functional	differences	between	cDC	and	ercDC.		
	
6.4 The	role	of	Wnt5a	in	dendritic	cells	
The	high	expression	of	Wnt5a	of	in	vitro	generated	myeloid	DC,	but	not	of	monocytes	
and	Mf,	 has	 been	 previously	 shown	 by	 others	 [108].	 Furthermore,	Wnt5a	 addition	
during	 the	differentiation	of	monocyte	 derived	DC,	 has	 been	 shown	 to	 increase	 IL-6	
secretion,	which	in	turn	inhibits	DC	differentiation	resulting	in	increased	CD14+/++	CD16+	
monocytes	[109].	As	Wnt5a	has	previously	also	been	shown	to	induce	inflammatory,	as	
well	as	anti-inflammatory	cytokines,	and	to	inhibit	IL-6	secretion	[110],	Bergenfelz	et	al.	
proposed	that	Wnt5a	may	act	as	a	cytokine	inducer	with	differing	effects	depending	on	
the	 cellular	 and	 tissue	 context.	 Wnt5a	 secretion	 by	 melanoma	 cells,	 for	 example,	
influences	 DC	 to	 induce	 Treg	 development	 via	 β-Catenin	 dependent	
indoleamine	2,3-dioxygenase-1	 activation	 [111],	 highlighting	 that	Wnt5a	 can	 activate	
canonical	 as	 well	 as	 non-canonical	 signalling	 in	 a	 cell	 and	 receptor	 specific	manner.	
Activation	 of	 β-Catenin	 dependent	 signalling	 through	 Wnt5a	 promotes	 DC	 with	
tolerogenic	features,	so	called	semi-maturate	DC	[112].	Valencia	et	al.	describe	Wnt5a	
signalling	 in	 DC,	 but	 distinguish	 between	 effects	 of	 Wnt5a	 stimulation	 during	 DC	
differentiation,	maturation	and	function.	This	emphasises	the	assumption	that	Wnt5a	
signalling	 is	 complex,	 and	 its	 effects	 may	 differ	 depending	 on	 different	 cellular	
conditions.	 They	 show	 that	 non-canonical	Wnt5a	 signalling	 skews	 the	 cells	 toward	 a	
tolerogenic	 phenotype	 during	 monocyte-derived	 DC	 differentiation	 [113].	 They	 also	
showed	that	Wnt5a	stimulation	could	induce	IL-12	secretion	and	enhance	CD4+	T-cell	
priming	with	IFN-g	and	IL-2	secretion.	Interestingly,	the	authors	showed	that	the	Fzd5	
receptor	is	expressed	only	during	early	DC	differentiation	and	that	immature	DC	express	
an	array	of	Wnt	receptors,	but	show	reduced	Fzd5	expression,	while	maturated	DC	show	
regulation	 of	 Fzd1	 and	 4.	 Ryk,	 a	 nonconventional	Wnt	 receptor	 and	 co-receptor,	 is	
expressed	by	monocytes	and	DC	[114].	It	is	thought	that	this	helps	to	conduct	differing	
effects	of	Wnt5a	through	changes	in	receptor	status.		
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6.5 Wnt5a	effect	on	functional	abilities	of	cDC	and	ercDC		
Following	the	previous	results	by	others	and	our	findings	of	strong	Wnt5a	expression	in	
RCC,	a	goal	of	this	thesis	was	to	elucidate	potential	effects	of	Wnt5a	signalling	on	DC	
subtypes,	 specifically	 on	 the	 ercDC	 subtype	 associated	 with	 RCC.	 Although	 we	
hypothesized	 that	Wnt5a	may	 enhance	 the	migratory	 ability	 of	 cDC,	 we	 found	 that	
Wnt5a	addition	during	differentiation	of	peripheral	blood	monocyte	derived	cDC	had	
the	 opposite	 effect,	 leading	 to	 reduced	 motility,	 velocity	 and	 directed	 migration.	
Furthermore,	 the	 addition	 of	 sFRP5	 or	 sFRP1,	 both	 inhibitors	 of	 Wnt5a,	 could	 not	
counteract	the	Wnt5a-driven	effects,	but	instead	also	led	to	inhibition	of	cDC	migration.	
Simultaneous	addition	of	Wnt5a	and	sFRP5	or	sFRP1	respectively	inhibited	the	directed	
migration	of	cDC,	but	not	in	an	additive	manner,	suggesting	that	they	might	act	via	a	
similar	mechanism.	Moreover,	we	examined	whether	addition	of	Wnt5a	during	ercDC	
differentiation	might	restore	their	migratory	capacity	towards	CCL19.	Again,	no	positive	
effect	of	Wnt5a	addition	during	ercDC	differentiation	could	be	observed	and	their	ability	
to	migrate	towards	CCL19	remained	poor.		
Similarly,	Wnt5a	 did	 not	 exert	 any	 effects	 on	 cytokine	 secretion	 of	 ercDC.	However,	
addition	of	Wnt5a	to	cDC	resulted	in	increased	IL-10,		IL12p40,	IL12p70,	but	decreased	
TNF-a	levels.	While	the	high	secretion	of	IL-10	upon	Wnt5a	stimulation	resembled	the	
high	 secretion	 of	 unstimulated	 ercDC,	 the	 effects	 on	 TNF-a	 and	 IL-12	 were	 rather	
contrary.	Hence,	addition	of	Wnt5a	can	only	 in	part	explain	the	 impaired	functioning	
and	altered	phenotype	of	ercDC.	Interestingly,	immature	cDC	and	ercDC	did	not	show	
any	 differences	 in	 cytokine	 secretion	 regarding	 IL-10,	 IL-12	 and	 TNF-a,	 while	 cDC	
changed	their	cytokine	secretion	pattern	upon	maturation.	By	contrast,	ercDC	appeared	
to	remain	in	an	immature	state,	suggesting	impaired	maturation	of	ercDC.		
		
Although	a	high	expression	of	Wnt5a	was	detected	in	cDC	and	not	in	ercDC,	we	could	
only	show	an	effect	of	Wnt5a	addition	on	cDC.	Wnt5a	was	found	to	inhibit	the	directed	
migration	of	the	cells,	and	to	alter	the	cytokine	expression	of	cDC.	These	results	support	
the	hypothesis	that	Wnt5a	stimulation	can	skew	DC	towards	a	tolerogenic	phenotype	
[113]	and,	in	this	context,	may	help	facilitate	tumour	escape	from	immune	surveillance.	
Contrary	to	what	was	expected,	 the	addition	of	 the	Wnt	 inhibitors	sFRP5	and	sFRP1,	
showed	a	similar	effect	to	that	seen	with	Wnt5a.	These	factors	have	been	previously	
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reported	to	 inhibit	Wnt5a	signalling.	 In	 the	context	of	 this	experiment,	however,	 the	
agents	appear	to	act	as	agonists.	sFRPs	exert	their	function	via	a	similar	CRD	as	the	Wnt-
ligands.	 This	 could	 be	 a	 possible	mechanism	 for	 the	 agonistic	 function.	 It	 would	 be	
interesting	to	further	elucidate	whether	the	agonistic	or	antagonistic	function	of	sFRP5	
and	sFRP1	might	be	dose	dependent.	Valencia	et	al.	previously	showed	not	only	a	time-
dependent	response,	but	also	a	dose	dependent	effect	of	Wnt5a.	They	propose	that	the	
dose	dependent	 response	of	Wnt5a	 is	due	 to	 its	different	affinity	 towards	particular	
receptors	[114].	As	little	is	known	about	the	mechanism	of	action	of	sFRPs,	this	would	
be	an	interesting	approach	to	further	understand	their	functioning.		
In	our	experiments,	ercDC	did	not	respond	to	Wnt5a,	sFRP1	or	sFRP5	treatment	during	
in	vitro	differentiation.	It	would	be	interesting	to	further	evaluate	Wnt5a	levels	during	
ercDC	differentiation.	Valencia	et	al.	showed	that	addition	of	Wnt5a	to	immature	cDC	
did	 not	 exert	 the	 same	 effect	 as	 at	 earlier	 stages.	 They	 propose	 that	 the	 decreased	
response	is	due	to	low	level	autocrine	Wnt5a	signalling	of	cDC.	Thus,	the	lack	of	effect	
seen	here	could	in	part	be	due	to	a	window	of	sensitivity.	
We	could	show	that	immature	cDC	express	Wnt5a	and	respond	to	Wnt5a	stimulation	
during	 differentiation	 by	 decreased	 migratory	 capacity	 towards	 CCL19	 and	 TNF-a	
secretion,	but	increased	production	of	IL-10	and	IL-12.	By	contrast,	ercDC	did	not	express	
Wnt5a	and	did	not	show	any	measurable	effects	upon	Wnt5a	addition.	Their	migratory	
capacity	remained	poor,	and	the	cytokine	secretion	pattern	of	ercDC	remained	similar	
to	that	of	immature	ercDC.	
	
6.6 In	vitro	generated	dendritic	cells	versus	ex	vivo	derived	dendritic	cells	
Dendritic	cell	development	is	influenced	through	a	number	of	different	factors	including	
cytokines	 and	 adhesion	 molecules	 that	 act	 in	 a	 paracrine,	 autocrine	 and	 juxtacrine	
manner.	Thus,	 the	tissue	environment	helps	define	the	development	of	DC	[115].	To	
study	DC	biology,	a	well-established	method	involving	in	vitro	differentiation	of	DC	from	
peripheral	blood	monocytes	was	used	[116].	In	the	present	study	we	used	the	MO-DC	
differentiation	 medium	 provided	 by	 Miltenyi	 Biotec.	 This	 medium	 contains	 FBS,	
RPMI	1640,	 L-Glutamine,	 GM-CSF	 and	 IL-4	 and	 allows	 a	 lot-to-lot	 consistent	
standardized	 protocol	 for	 DC	 differentiation.	 However,	 even	 though	 this	 protocol	 is	
often	 used,	 the	 relevance	 of	monocytes	 as	 in	 vivo	 precursors	 of	 DC	 is	 not	 yet	 fully	
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understood	and	other	protocols	exist	[117].	A	number	of	different	maturation	protocols	
including	addition	of	LPS,	CD40L	and	TNF-a	or	the	combination	of		TNF-a,	IL-1ß,	IL-6	and	
PGE2	have	been	used	for	the	preparation	of	immunogenic	DC.	A	tolerogenic	phenotype	
can	be	induced	through	the	addition	of	IL-10,	TGF-b,	corticosteroids	or	Vitamin	D3.	This	
exemplifies	how	complex	DC	biology	is	and	that	the	exact	mechanisms	of	relevant	DC	
differentiation	and	maturation	are	still	unknown.	Hence,	any	strong	conclusion	based	
on	 in	 vitro	 generated	DC	 should	be	made	 carefully,	 especially	when	 transferring	 the	
acquired	knowledge	to	biology	of	in	vivo	DC.		
In	order	to	validate	our	transcriptomic	analysis	data	based	on	in	vitro	generated	cDC	and	
ercDC,	we	 compared	 the	 obtained	 results	with	 recent	 array	 data	 from	 ex	 vivo,	 RCC	
derived	cDC	and	ercDC.	While	strong	differential	gene	expression	between	ex	vivo	cDC	
and	ercDC	regarding	canonical	and	non-canonical	Wnt-signalling	was	evident,	it	did	not	
fully	 resemble	 the	 differential	 expression	 found	 in	 the	 in	 vitro	 data.	 No	 differential	
expression	was	found	for	neither	Wnt-ligands	nor	receptors	and	only	moderate	changes	
for	co-receptors,	agonists	and	antagonists.	Striking	was	 the	differential	expression	of	
SDC2,	3	and	4,	which	showed	higher	expression	in	ercDC_RCC	compared	to	CD1c+	DC	or	
slanDC.	Even	though	the	high	expression	of	Wnt5a	of	in	vitro	generated	cDC	could	not	
be	validated	by	the	ex	vivo	data,	the	results	of	the	ex	vivo	data	analysis	suggest	a	possible	
role	of	Wnt	signalling	 in	DC	biology,	which	could	 in	part	explain	differences	between	
subtypes,	e.g.	cDC	compared	to	ercDC.		
Following	these	results,	the	question	arose	of	how	representative	the	in	vitro	generated	
DC	are	and	whether	 results	based	upon	 in	vitro	 studies	 can	be	 transferred	 to	better	
understand	 the	 complex	 in	 vivo	 DC	 biology.	 Royer	 et	 al.	 investigated	 the	 effect	 of	
differing	culture	media	and	adjuvant	proteins	on	DC	phenotype	and	immune	capacity.	
They	could	show	that	depending	on	culture	medium	and	supplements,	e.g.	HSA	or	FCS,	
DC	 differed	 regarding	 surface	 markers,	 such	 as	 CD80,	 CD83	 and	 HLA-ABC,	 but	 also	
regarding	their	functional	abilities,	such	as	IL12p70	secretion	[118].	While	they	pointed	
out,	that	standardized	protocols	are	important	regarding	DC	differentiation	in	terms	of	
DC-based	vaccines	in	immunotherapies,	we	would	go	further	and	highlight	that	results	
based	on	in	vitro	studies	should	only	carefully	be	transferred	to	the	in	vivo	situation.	
Even	more,	D.	Brech	notes	in	her	thesis	that	cluster	analysis	of	externally	available	data	
from	“GEO”	or	the	“Array	Express”	homepage	with	her	own	data	of	CD1c+	DC,	slanDC	
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and	Monocytes	showed	clustering	depending	on	the	laboratory	but	not	the	cell	type.	
This	further	suggests	that	not	only	the	in	vitro	generation	of	DC	depends	on	the	protocol	
applied,	but	also	the	ex	vivo	acquisition	of	DC.		
In	conclusion,	our	results	show	differences	in	Wnt-signalling	between	different	myeloid	
and	especially	DC	subtypes.	Furthermore,	we	could	show	effects	of	Wnt5a-signalling	on	
migration	and	cytokine	secretion	pattern	of	DC.	These	could	in	part	explain	impaired	DC	
functioning	 in	 the	 tumour	milieu	of	RCC	and	suggest	a	possible	 role	of	Wnt5a	 in	 the	
tumours	 escape	 from	 immune	 surveillance.	 However,	 further	 experiments	 regarding	
exact	downstream	signalling	of	Wnt5a	and	the	relevance	of	Wnt5a	signalling	in	the	in	
vivo	situation	would	be	interesting	to	perform.		
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7 Abbreviations	
7-AAD	 7-Amino-Actinomycin	
APC	 Antigen	presenting	cells	
APC	 Adenomatosis	polyposis	coli	
BSA	 Bovines	serumalbumin	
CAMK	 Calmodulin-dependent	protein	kinase	
CCL	 CC-	Chemokine	ligand	
CCR	 Chemokine	CC-motif	receptor	
CD	 Cluster	of	differentiation	
cDC	 classical	Dendritic	cells	
CDC42	 Cell	division	control	protein	42	homolog	
cDNA	 copy	deoxyribonucleic	acid	
CK	 Casein	kinase	
CRD	 Cysteine-rich	domain	
CREB	 cAMP	responsive	element	binding	protein	
CTHRC	 Collagen	triple	helix	repeat	containing		
CTLA	 Cytotoxic	T-lymphocyte	antigen	
CXCL	 Chemokine	(C-X-C	motif)	ligand	
DAAM	 Dishevelled-associated	activator	of	morphogenesis	
DAB	 3,3'-diaminobenzidine	
DABG	 Detection	above	background	
DAG	 Diacylglycerol	
DC	 Dendritic	cells	
DKK	 Dickkopf-protein	
DMSO	 Dimethylsulfoxid	
dNTP	 Desoxyribonukleosidtriphosphate	
DTT	 Dithiothreitol	
Dvl	 Dishevelled	
EDTA	 Ethylenediaminetetraacetic	acid	
ELISA	 Enzyme-linked	immunosorbent	assay	
EMT	 Epithelial-mesenchymal	transmission	
ercDC	 enriched	in	RCC	Dendritic	cells	
FACS	 Fluorescence	activated	cell	scanning	
FC	 fold	change	
FcR	 Fc-Receptor	
FCS	 Fetal	calf	serum	
FDR	 Formyl	peptide	receptor	
FMI	 Forward	migration	index	
fMLP	 N-Formylmethionyl-leucyl-phenylalanine		
FOXP3	 Forkhead	box	P3	
FRAT	 Frequently	rearranged	in	advanced	T-cell	lymphomas		
FSC	 Forward	scatter	
Fzd	 Frizzled-receptor	
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GM-CSF	 Granulocyte-macrophage	colony-stimulating	factor	
GPC	 Glypican	
GPI	 Glycosylphosphatidylinositol	
GSK	 Glycogen	synthase	kinase		
HEPES	 4-(2-hydroxyethyl)-1-piperazineethanesulfonic	acid	
HIPK	 Homeodomain	interacting	protein	kinase		
HLA	 Humane	leucocyte	antigen	
HRP	 Horeseradish	peroxidase	
HS	 Human	serum	
HSPG	 Heparan	sulphate	proteoglycans	
IFN	 Interferon	
Ig	 Immunoglobuline	
IL	 Interleukin		
IP3	 Inositol-1,4,5-triphosphate	
JNK	 c-JUN	N-terminal	kinase	
LAMP	 Lysosomal	associated	membrane	protein	
LEF	 Lymphoid	enhancer	binding	factor	
LPS	 Lipopolysaccharid	
LRP	 Lipoprotein	receptor-related	protein	
M	 Molar	
M-CSF	 Macrophage	colony-stimulating	factor	
MA	 Migration	assay	
MACS	 Magnetic	activated	cell	sorting	
MADMAX	 Management	and	Analysis	Database	for	Multi-platform	microArray	
eXperiments	
MDSC	 Myeloid-derived	suppressor	cells	
mg	 Milligram	
MHC	 Major	histocompatility	complexes	
min	 Minutes	
ml		 Milliliter	
mm	 Millimeter	
mM	 Millimole	
MMP	 Matrix	metalloproteinase	
MoDC	 Monocyte-derived	dendritic	cell	
MPS	 Mononuclear	phagocyte	system	
mRNA	 messenger	Ribonucleic	acid	
MUSK	 Muscle-specific	receptor	tyrosine	kinase	
MΦ	 Macrophage	
NEAA	 Non-essential	amino	acids	
NFAT	 Nuclear	factor	associated	with	T-cells	
NFkB	 Nuclear	factor	kappa-B	
ng	 nanogram	
NK	 Natural	Killer	cells	
NLK	 Nemo-like-kinase	
NUSK	 Neuronal	specific	kinase	
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PAMP	 Pathogen	associated	molecular	patterns	
PBS	 Phosphate	buffered	saline	
PCP	 Planar	cell	polarity	
PCR	 Polymerase	chain	reaction	
PD1	 Programmed	death	1	receptor	
pDC	 plasmacytoid	Dendritic	cells	
PDE	 Phosphodiesterase	
PFA	 Paraformaledhyd	
PGE	 Prostaglandin	E	
pH	 potentia	hydrogenia	
PI	 Propidiumjodid	
PKC	 Proteinkinase	C	
PLCB	 Phospholipase	C	beta	
PLM	 Probe	level	model	
PRC	 Pathogen	recognition	receptors	
PTK	 Protein	tyrosine	kinase	
RCC	 Renal	Cell	Carcinoma	
RCC-26-CM	 Renal	cell	carcinoma-26	conditioned	medium	
RHOA	 Ras	homolog	familiy	member	A	
Rhu	 Recombinant	human	
RMA	 Robust	Multi-array	Average	
RNA	 Ribonucleic	acid	
ROCK	 Rho-associated,	coiled-coil	containing	protein	kinase	
ROR	 Receptor	Tyr	kinase-like	orphan	receptor	
rpm	 Rounds	per	minute	
RPMI	 Roswell	Park	Memorial	Institute	
RT	 Room	temperature	
RYK	 Receptor-like	tyrosine	kinase	
SDC	 Syndecan	
sec	 Seconds	
SEM	 Standard	error	of	the	mean	
sFRP	 soluble	Frizzled	related	protein	
slandDC	 6-sulfo	LacNAc	dendritic	cells	
SSC	 Sideward	scatter	
STAT	 Signal	transducer	and	activator	of	transcription		
T-regs	 Regulatory	T-cells	
TAM	 Tumour-associated	macrophages	
TCF	 Transcription	factor	
TCR	 T-cell	receptor	
TGF	 Transforming	growth	factor	
TLR	 Toll-like	receptor	
TNF	 Tumour	necrosis	factor	
Tris	 Trishydroxamethylaminomethan	
VANGL	 VANGL	planar	cell	polarity	protein	
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VEGF	 Vascular	epithelial	growth	factor	
WHO	 World	health	organization	
WIF	 Wnt-inhibitor	factor	
WNT	 Wingless-related	integration	site	
μg	 microgram	
μl	 microliter	
μm	 micrometer	
μM	 micromole	
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9 Supplementary	data	
9.1 Supplementary	table	1:	Microarray	data	of	in	vitro	generated	myeloid	cells	
Supplementary	table	1	displays	the	microarray	data	of	the	in	vitro	generated	myeloid	cells.	It	displays	calculated	Fold	
changes	(FC)	of	cDC,	ercDC,	M1,	M2	and	GMCSF-macrophages	compared	to	monocytes	for	the	canonical	and	non-
canonical	Wnt-pathways.	Genes	are	represented	by	gene-IDs	and	official	gene-symbols.	The	green	colour	indicates	an	
up	regulation	compared	to	monocytes	with	an	FC	of	>1.5.	The	red	colour	a	down	regulation	with	a	FC	of	<-1.5.		
Gene:	 Entrez-ID:	 FC:	cDC/Mono	
FC:	
M2/Mono	
FC:	
M1/Mono	
FC:	
GMCSF/Mono	
FC:	
ercDC/Mono	
Wnt-ligands	
Wnt	1	 7471	 1.0478	 1.1137	 -1.0599	 -1.0485	 1.0120	
Wnt	2	 7472	 -1.1159	 -1.1643	 1.0786	 -1.0346	 -1.1793	
Wnt	2b	 7482	 1.2493	 1.3829	 1.8945	 1.6519	 1.5486	
Wnt3	 7473	 -1.0657	 -1.0621	 -1.2824	 -1.1541	 -1.0118	
Wnt	3a	 89780	 -1.0484	 1.0263	 -1.1117	 -1.0742	 1.0057	
Wnt	4	 54361	 -1.0149	 -1.0366	 1.0241	 1.0444	 1.0382	
Wnt	5a	 7474	 5.0499	 1.3656	 1.2981	 -1.0402	 -1.0651	
Wnt	5b	 81029	 1.2944	 1.1507	 -1.0462	 -1.1872	 -1.0099	
Wnt	6	 7475	 -1.0217	 -1.0908	 1.0183	 1.0577	 1.0700	
Wnt	7a	 7476	 -1.0942	 -1.1713	 1.0001	 -1.1834	 -1.0997	
Wnt	7b	 7477	 -1.1037	 1.0378	 -1.0600	 -1.0944	 -1.1809	
Wnt	8a	 7478	 1.0791	 1.2026	 1.0383	 1.1184	 1.0286	
Wnt	8b	 7479	 -1.1196	 -1.2019	 -1.1273	 -1.1105	 -1.1273	
Wnt	9a	 7483	 -1.0643	 -1.0670	 -1.0760	 1.0467	 -1.0709	
Wnt	9b	 7484	 -1.0681	 1.0270	 -1.1525	 -1.0818	 -1.0741	
Wnt	10a	 80326	 -1.1058	 1.0172	 -1.0888	 -1.0502	 1.0937	
Wnt	10b	 7480	 -1.1798	 -1.1405	 1.0292	 -1.2164	 -1.0193	
Wnt	11	 7481	 1.0567	 1.0421	 -1.0120	 1.0235	 -1.0042	
Receptors	
Fzd1	 8321	 -1.1940	 -1.0202	 1.1876	 -1.5238	 1.0084	
Fzd2	 2535	 1.0362	 -1.1441	 -1.1968	 -1.2572	 -1.1570	
Fzd3	 7976	 1.6825	 1.2213	 -1.0577	 -1.0286	 -1.0129	
Fzd4	 8322	 -1.0758	 -1.1363	 1.0001	 -1.0596	 1.0678	
Fzd5	 7855	 1.6328	 1.6570	 2.3540	 1.3563	 1.5308	
fzd6	 8323	 -1.1244	 -1.0507	 1.1862	 -1.1625	 1.0726	
Fzd7	 8324	 1.2094	 1.1684	 -1.0433	 1.6801	 1.0872	
Fzd8	 8325	 -1.1847	 -1.0675	 1.1257	 -1.1052	 -1.0865	
Fzd9	 8326	 -1.1324	 -1.0036	 -1.1307	 -1.2065	 -1.1476	
Fzd10	 11211	 -1.0362	 -1.0641	 -1.1107	 -1.0839	 -1.0057	
Co-receptors	
LRP5	 4041	 1.0425	 1.0545	 1.0456	 -1.1117	 -1.0982	
LRP6	 4040	 1.0442	 -1.1025	 1.2047	 -1.0164	 -1.1069	
LRP1	 4035	 1.0983	 1.1279	 -4.4389	 1.2263	 1.1907	
Kremen	1	 83999	 -1.0562	 -1.2954	 1.3496	 1.1663	 -1.1561	
Kremen	2	 79412	 -1.1588	 -1.0619	 -1.1339	 -1.2653	 -1.0823	
RYK	 6259	 1.5829	 1.1947	 1.0334	 1.2196	 1.0210	
ROR1	 4919	 1.2579	 1.1067	 -1.0999	 1.0407	 1.1640	
ROR2	 4920	 1.0097	 1.0564	 1.1123	 1.0182	 1.1341	
VANGL1	 81839	 -1.0065	 -1.0374	 -1.0785	 1.0427	 1.0967	
VANGL2	 57216	 -1.1272	 -1.1182	 -1.1037	 -1.0352	 -1.0528	
CELSR1	 9620	 1.3749	 1.6053	 1.0304	 1.6621	 1.8117	
CELSR2	 1952	 -1.0571	 -1.1768	 -1.3285	 -1.2005	 -1.1994	
CELSR3	 1951	 -1.0029	 -1.0239	 -1.0833	 1.0057	 1.0126	
PTK7	 5754	 -1.1457	 -1.0947	 -1.0110	 -1.0483	 -1.0982	
SDC1	 6382	 -1.1248	 -1.0977	 1.0042	 1.0102	 -1.0464	
SDC2	 6383	 26.8547	 25.5374	 6.6457	 17.9097	 9.5164	
SDC3	 9672	 2.3762	 2.6069	 1.4328	 1.4247	 2.7031	
SDC4	 6385	 6.4081	 10.8838	 11.2835	 9.3504	 7.7408	
GPC2	 221914	 -1.1221	 -1.0885	 -1.0545	 -1.0461	 -1.1324	
GPC3	 2719	 -1.0980	 -1.0464	 1.1636	 1.0768	 -1.0608	
GPC4	 2239	 5.7710	 4.9093	 8.9275	 7.3588	 6.9322	
GPC5	 2262	 1.0140	 1.0747	 1.5207	 1.1036	 1.1229	
GPC6	 10082	 -1.1176	 -1.1559	 -1.1314	 -1.0030	 -1.1989	
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GPC1	 2817	 -1.0188	 -1.0845	 -1.3223	 -1.0810	 -1.1129	
CD44	 960	 1.1727	 1.0178	 1.2675	 1.2640	 -1.1106	
Inhibitors	
Dkk1	 22943	 -1.2269	 -1.1954	 -1.1426	 -1.0695	 -1.2161	
Dkk2	 27123	 -1.1293	 1.4759	 -1.0151	 -1.0348	 -1.1505	
Dkk3	 27122	 -1.1490	 -1.1092	 1.0491	 -1.0099	 -1.0352	
Dkk4	 27121	 -1.0170	 -1.1018	 1.1006	 1.0211	 -1.0639	
WIF1	 11197	 -1.1668	 -1.0380	 1.0095	 1.0290	 -1.0021	
sFRP1	 6422	 -1.1427	 -1.0632	 1.0010	 1.0126	 -1.2376	
sFRP2	 6423	 -1.0946	 1.0135	 -1.1346	 1.0345	 -1.0707	
sFRP3	 2487	 -1.1410	 -1.1193	 1.0137	 1.0502	 -1.1478	
sFRP4	 6424	 1.1390	 1.2671	 1.0846	 1.0664	 1.1427	
sFRP5	 6425	 1.0184	 -1.0106	 -1.0684	 -1.0486	 1.0179	
Shisa2	 387914	 -1.3154	 -1.1454	 -1.3957	 -1.2841	 -1.2513	
Shisa3	 152573	 1.0578	 1.0007	 1.2062	 -1.0021	 1.1512	
CTHRC1	 115908	 -1.0945	 -1.1229	 1.0315	 -1.1654	 1.0169	
IGFBP1	 3484	 -1.1135	 -1.0935	 1.1107	 -1.0644	 1.0712	
IGFBP2	 3485	 2.0006	 1.2833	 1.0485	 2.5624	 1.1074	
IGFBP4	 3487	 1.0751	 1.2708	 27.7678	 -1.0669	 1.4595	
IGFBP6	 3489	 1.2435	 -1.0573	 1.0969	 -1.0126	 1.0371	
CER1	 9350	 -1.2912	 -1.1755	 1.0267	 1.0636	 -1.1883	
SOST	 50964	 -1.1291	 -1.0781	 -1.1195	 -1.1004	 -1.1172	
SOSTDC1	 25928	 -1.1406	 -1.2441	 -1.0490	 -1.1310	 -1.0812	
TPBG		 7162	 -1.1712	 -1.0196	 -1.0649	 1.0571	 1.0392	
APCDD1	 147495	 -1.7306	 -1.8358	 -1.6678	 -2.0023	 -1.9006	
TRABD2A		 129293	 3.7015	 -1.0753	 -1.0146	 1.4683	 1.0429	
agonists/	positive	modulators	
NDP	 4693	 2.6809	 1.1334	 1.6308	 1.3193	 1.1137	
RSPO1	 284654	 -1.0356	 1.0406	 1.0656	 -1.0297	 -1.0627	
RSPO2	 340419	 -1.0377	 -1.0174	 -1.1584	 -1.1436	 -1.0729	
RSPO3	 84870	 -1.2312	 -1.0773	 -1.0881	 1.0941	 -1.0633	
RSPO4	 343637	 -1.2118	 -1.2918	 -1.2725	 -1.1669	 -1.2664	
ß-Catenin	dependent	signalling	
Dvl1	 1855	 -1.0077	 -1.0212	 -1.1000	 -1.0158	 -1.0566	
Dvl2	 1856	 1.1384	 1.1115	 1.0360	 1.4196	 1.2250	
Dvl3	 1857	 1.0678	 1.0474	 1.2670	 1.0842	 1.1509	
GSK3ß	 2932	 -1.1435	 -1.2545	 -1.0061	 -1.0254	 -1.0594	
Axin	1	 8312	 -1.0020	 1.1640	 1.0146	 1.1054	 -1.1066	
Axin	2	 8313	 -1.1370	 1.0114	 -1.1245	 1.0421	 -1.1323	
APC	 324	 -1.0674	 -1.4986	 -1.2794	 -1.0184	 -1.1618	
CSNK1A1	 1452	 -1.0028	 -1.0073	 -1.2442	 -1.1706	 -1.2162	
CSNK1E	 1454	 1.8168	 2.2686	 -1.0147	 1.9968	 1.4481	
CSNK1D	 1453	 -1.3106	 -1.1585	 -1.1473	 -1.0886	 -1.2703	
CSNK2A1	 1457	 1.7151	 1.4747	 1.1542	 1.4473	 -1.0620	
CSNK2A2	 1459	 1.3787	 1.4801	 1.1321	 1.5653	 1.1586	
CSNK2B	 1460	 1.5749	 1.5673	 -1.1649	 1.2529	 1.0740	
CTNNB1	 1499	 1.0325	 1.3101	 2.1273	 -1.0417	 1.1365	
CTNNBIP1	 56998	 -1.2974	 -1.2827	 -1.4591	 -1.3467	 -1.0918	
NDRG1	 10397	 1.2263	 -1.0287	 1.0248	 2.3875	 1.3126	
NDRG2	 57447	 3.2720	 -1.2540	 -1.4075	 1.2947	 -1.3170	
FRAT1	 10023	 -2.0934	 -4.2753	 -4.8864	 -1.9421	 -2.5590	
FRAT2	 23401	 -1.0051	 -1.8382	 -2.4926	 1.0518	 -1.5536	
PAK4	 10298	 -1.0559	 -1.0419	 1.0545	 -1.0362	 -1.0467	
AKT1	 207	 1.0727	 1.0076	 -1.2579	 -1.2273	 1.0050	
AKT2	 208	 -1.0234	 -1.0023	 1.2957	 -1.0031	 -1.0020	
AKT3	 10000	 -1.0556	 1.2061	 2.7455	 2.1395	 1.7693	
ILK	 3611	 -1.3309	 -1.2260	 1.1650	 -1.4029	 -1.0632	
CXXC4	 80319	 -1.0795	 -1.0460	 -1.1647	 -1.0098	 -1.1332	
SUMO1	 7341	 1.2422	 1.0634	 1.0334	 -1.0801	 1.0897	
RANBP2	 5903	 1.1914	 1.4217	 -1.0105	 1.0314	 -1.0073	
SENP2	 59343	 -1.2144	 -1.3138	 -1.0094	 1.0007	 -1.4116	
BTRC	 8945	 1.5230	 1.1182	 1.0634	 1.3534	 1.0955	
SKP1	 6500	 1.0463	 -1.1129	 -1.0360	 1.0865	 -1.1832	
CUL1	 8454	 1.0682	 1.1666	 3.5811	 1.2519	 -1.2846	
NKD1	 85407	 -1.0889	 -1.0214	 1.1297	 -1.0088	 -1.0119	
ARRB1	 408	 -1.5309	 -1.5627	 -1.0906	 -1.6392	 -1.2186	
ARRB2	 409	 -1.8236	 -1.3505	 -1.9410	 -1.7086	 -1.2804	
MACF1	 23499	 1.0032	 1.4368	 3.1303	 -1.4268	 1.4177	
PPP1CA	 5499	 -1.0971	 -1.2032	 -1.6766	 -1.2980	 -1.0472	
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PPP1CB	 5500	 -1.3857	 -1.2836	 -1.1046	 -1.4058	 -1.4033	
PPP1CC	 5501	 1.0556	 -1.0985	 -1.5390	 1.2284	 -1.0003	
PPP2R5B	 5526	 -1.4492	 -1.5188	 1.0017	 -1.2962	 -1.2832	
PPP2CB	 5516	 1.1577	 1.4632	 1.9676	 1.2064	 1.3461	
PPP2CA	 5515	 -1.3256	 -1.1105	 -1.1280	 -1.3437	 -1.3523	
PPP3CB	 5532	 -1.1929	 -1.1702	 -1.2772	 -1.0798	 -1.0620	
DAB2	 1601	 6.8342	 8.9126	 3.3473	 8.9411	 11.2741	
TCF1	 6927	 1.0999	 1.0152	 -1.0610	 -1.0259	 1.0979	
TCF3	 6929	 1.1808	 1.2276	 -1.3194	 1.0366	 1.0088	
TCF4	 6925	 2.0252	 2.7192	 5.1342	 -1.8166	 2.1165	
LEF1	 51176	 -1.1706	 -1.2622	 -1.1247	 -1.0747	 1.4940	
TCF7L1	 83439	 -1.1656	 -1.1750	 1.2834	 -1.0844	 -1.1102	
TCF7L2	 6934	 -5.6145	 -5.3457	 -4.0381	 1.9644	 -2.7601	
TLE1	 7088	 4.2189	 3.5446	 1.3227	 1.6946	 1.2847	
TLE2	 7089	 -1.1592	 1.0052	 -1.2013	 1.0606	 -1.0114	
TLE3	 7090	 -1.7896	 -1.2458	 -5.6279	 -1.4681	 -1.0852	
TLE4	 7091	 -1.9182	 -1.7843	 -1.8317	 -1.7156	 -2.0216	
CDX1	 1044	 -1.2265	 -1.1330	 -1.2034	 -1.1406	 -1.0821	
BCL9	 607	 1.2041	 1.1923	 -1.4637	 -1.1155	 -1.2702	
PIAS4	 51588	 -1.1180	 -1.1361	 -1.1656	 1.0687	 -1.1316	
FHL2	 2274	 -1.1385	 -1.0177	 -1.0116	 -1.0242	 -1.1351	
TAX1BP3	 30851	 1.1900	 1.1222	 -1.1825	 1.0423	 1.0370	
SALL1	 6299	 -1.0629	 1.0353	 -1.1064	 -1.0805	 -1.1476	
SALL4	 57167	 -1.0078	 -1.0791	 -1.0304	 -1.0509	 -1.0910	
MAP1B	 4131	 -1.0230	 1.0534	 1.0761	 -1.0505	 1.0295	
PCP	signalling	
ANKRD6	 22881	 1.3379	 1.2828	 1.1069	 1.4564	 1.6408	
DAAM1	 23002	 2.0291	 1.2277	 -2.4222	 -1.6253	 -1.2703	
DAAM2	 23500	 -1.1115	 -1.1538	 -1.0051	 -1.0658	 -1.0630	
RHO	A	 387	 -1.0749	 -1.1261	 -1.2114	 -1.2304	 -1.1508	
RHO	B	 388	 -1.9047	 -2.0169	 -2.8387	 -1.5755	 -1.4729	
ROCK1	 6093	 -1.3520	 -1.4745	 -1.7087	 -1.3189	 -1.5281	
ROCK2	 9475	 1.2736	 1.0840	 1.0213	 1.0924	 -1.1808	
RAC1	 5879	 -1.0341	 -1.1305	 1.4357	 1.1597	 1.0920	
RAC2	 5880	 1.1084	 -1.4144	 -6.7489	 -1.0065	 -1.3686	
RAC3	 5881	 -1.0337	 -1.0597	 -1.0107	 -1.0068	 -1.1778	
MAP2K7	 5609	 -1.3565	 -1.1139	 -1.0733	 -1.0140	 -1.3529	
MAP2K4	 6416	 1.1980	 1.0955	 1.3847	 1.0420	 -1.0306	
MAP3K4	 4216	 1.0504	 -1.1367	 -1.7921	 -1.0399	 -1.3015	
MAPK8	 5599	 -1.5394	 -1.1032	 -1.2819	 -1.2300	 -1.1249	
MAPK9	 5601	 1.4818	 1.1390	 -1.1602	 1.0375	 1.1043	
MAPK10	 5602	 -1.1782	 -1.0914	 -1.0572	 -1.1085	 -1.0427	
JUN	 3725	 1.0972	 1.5890	 1.3903	 1.4314	 -1.0270	
ATF2	 1386	 1.0705	 1.1227	 1.2299	 -1.0230	 1.2329	
CDC42	 998	 -1.6011	 -1.4475	 -1.2920	 -1.3913	 -1.4254	
MARK2	 2011	 -1.5442	 -1.7883	 -1.7048	 -1.7351	 -1.8013	
Ca-Signalling	
PLCB1	 23236	 -6.1276	 -7.2183	 -8.6383	 -9.5319	 -8.8037	
PLCB2	 5330	 -1.3916	 -1.7778	 -15.9277	 -2.8603	 -1.7213	
PLCB3	 5331	 -1.2168	 1.0497	 -1.1470	 -1.2337	 -1.1461	
PLCB4	 5332	 -1.1066	 -1.1022	 1.0774	 -1.0391	 -1.0927	
PLCG1	 5335	 1.4294	 1.0326	 1.0172	 1.0453	 1.2639	
PLCG2	 5336	 -1.1341	 -1.6673	 -2.1837	 -1.4115	 -1.2078	
PLCD1	 5333	 1.4100	 1.1912	 -1.0767	 2.0738	 1.3305	
PLCD3	 113026	 -1.0531	 -1.0058	 -1.1065	 -1.0824	 -1.1213	
PLCD4	 84812	 -1.2495	 -1.0002	 -1.0473	 -1.0208	 -1.0271	
PLCE1	 51196	 1.1222	 1.1445	 1.0809	 1.1054	 1.1868	
PRKCA	 5578	 3.3514	 1.6840	 -1.6743	 1.3901	 1.8637	
PRKCB	 5579	 -3.2992	 -4.1438	 -6.1427	 -3.6640	 -1.9495	
PRKCG	 5582	 -1.1439	 -1.1418	 -1.1841	 -1.0150	 -1.0262	
CAMK1	 8536	 1.6321	 1.0665	 -3.3369	 -1.3655	 1.1039	
CAMK1D	 57118	 1.6759	 1.4681	 -3.3233	 -1.4166	 1.3677	
CAMK1G	 57172	 -1.0030	 1.0487	 3.4686	 -1.0618	 1.1956	
CAMK2A	 815	 -1.2510	 -1.3186	 -1.0654	 -1.2583	 -1.2725	
CAMK2B	 816	 -1.2008	 -1.0613	 1.0337	 -1.0812	 -1.0314	
CAMK2G		 818	 -1.5428	 -1.9162	 -2.6514	 -1.6674	 -1.4086	
CAMK2D	 817	 1.3780	 -1.8171	 -1.0562	 -1.4306	 -1.3717	
CAMK4	 814	 1.1173	 -1.0041	 1.0244	 1.0170	 1.4807	
PPP3CA	 5530	 -1.0679	 -1.1391	 -4.4206	 -1.0901	 -1.1414	
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NFkB1	 4790	 -1.8829	 1.6466	 1.8537	 -1.3429	 -1.1220	
NFkB2	 4791	 -1.9227	 1.1474	 3.0284	 -1.3349	 -1.4022	
RELA	 5970	 1.0161	 1.3137	 3.5154	 1.4552	 -1.0315	
RELB	 5971	 -1.4547	 1.3258	 2.4936	 1.0235	 -1.0003	
REL	 5966	 -1.0572	 1.2662	 -1.3225	 1.0080	 1.0842	
NFATC1	 4772	 1.0171	 2.2826	 1.1181	 1.0658	 1.3799	
NFATC2	 4773	 2.2980	 1.9122	 -1.0952	 -1.2216	 1.4803	
NFATC3	 4775	 1.4524	 1.1518	 -1.5166	 1.2830	 1.2650	
NFATC4	 4776	 -1.1882	 -1.1059	 -1.2274	 -1.2375	 -1.1479	
CREB1	 1385	 -1.5866	 -1.7637	 -1.2734	 -1.3750	 -1.4478	
MAPK1	 5594	 1.1860	 1.0449	 -1.4963	 -1.2695	 -1.4842	
MAP3K7	 6885	 1.0506	 1.0291	 -1.0495	 1.2353	 1.0365	
NLK	 51701	 2.2148	 1.0336	 1.1425	 1.7717	 1.0901	
HIPK2	 28996	 1.8257	 -1.0352	 -1.7297	 1.3915	 1.1315	
MYB	 4602	 -1.9721	 -1.7544	 -1.7517	 1.2062	 -1.0282	
	
9.2 Supplementary	table	2:	Microarray	data	of	ex	vivo	derived	myeloid	cells	
Supplementary	table	2	displays	the	microarray	data	of	the	ex	vivo	obtained	myeloid	cells.	It	displays	calculated	Fold	
changes	(FC)	of	cD1c+DC,	slan_DC	and	MΦ	_RCC	compared	to	ercDC_RCC	for	the	canonical	and	non-canonical	Wnt-
pathways.	Additionally,	it	also	displays	the	FC	of	in	vitro	generated	cDC	compared	to	ercDC.		Genes	are	represented	
by	gene-IDs	and	official	gene-symbols.	The	green	colour	indicates	an	up	regulation	compared	to	ercDC_RCC	with	an	
FC	of	>1.5.	The	red	colour	a	down	regulation	with	a	FC	of	<-1.5.		
Gene:	 Entrez-ID:	 FC:	cD1c+DC/ercDC_RCC	
FC:	
slanDC/ercDC_RCC	
FC:	
MΦ_RCC/ercDC_RCC	
FC:	cDC/ercDC	in	
vitro	
Wnt-ligands	
Wnt	1	 7471	 1.0097	 -1.1544	 -1.1480	 1.0021	
Wnt	2	 7472	 -1.0224	 -1.0892	 -1.0734	 -1.0600	
Wnt	2b	 7482	 -1.0438	 -1.3770	 -1.2097	 -1.3406	
Wnt3	 7473	 -1.0000	 -1.0751	 -1.0061	 -1.0227	
Wnt	3a	 89780	 1.0786	 1.1578	 -1.0093	 -1.0189	
Wnt	4	 54361	 -1.0034	 1.0307	 -1.0648	 -1.0823	
Wnt	5a	 7474	 -1.0080	 -1.0503	 1.2209	 6.2926	
Wnt	5b	 81029	 -1.0824	 -1.1094	 -1.0041	 1.1526	
Wnt	6	 7475	 -1.1454	 -1.2974	 -1.2274	 -1.1001	
Wnt	7a	 7476	 -1.0903	 1.0194	 -1.0115	 1.0568	
Wnt	7b	 7477	 -1.0664	 1.1921	 1.0045	 1.2180	
Wnt	8a	 7478	 1.1079	 1.0210	 1.1149	 1.0452	
Wnt	8b	 7479	 1.0430	 -1.0117	 1.0118	 1.0170	
Wnt	9a	 7483	 1.0289	 -1.2044	 -1.0915	 -1.0406	
Wnt	9b	 7484	 -1.0428	 -1.1106	 -1.0676	 1.0624	
Wnt	10a	 80326	 -1.3670	 -1.1560	 -1.3498	 -1.3330	
Wnt	10b	 7480	 -1.2812	 -1.1624	 -1.2105	 -1.1946	
Wnt	11	 7481	 -1.1320	 -1.1984	 -1.0435	 1.0661	
Receptors	
Fzd1	 8321	 -1.0349	 -1.0299	 -1.0823	 -1.0394	
Fzd2	 2535	 -1.1635	 -1.4565	 -1.1449	 1.3873	
Fzd3	 7976	 1.3665	 1.0812	 -1.0461	 1.7617	
Fzd4	 8322	 -1.0897	 -1.1428	 1.0094	 -1.1865	
Fzd5	 7855	 -1.2693	 -1.4711	 -1.1802	 1.0222	
fzd6	 8323	 1.0141	 1.0409	 -1.0227	 -1.1573	
Fzd7	 8324	 -1.0589	 -1.0328	 -1.0418	 1.1079	
Fzd8	 8325	 -1.3583	 -1.2150	 -1.1282	 -1.0574	
Fzd9	 8326	 -1.0458	 -1.2537	 -1.0551	 1.0256	
Fzd10	 11211	 1.0678	 -1.3507	 -1.0507	 -1.1383	
Co-receptors	
LRP5	 4041	 1.0912	 1.0100	 -1.0408	 1.1721	
LRP6	 4040	 -1.0158	 -1.0174	 -1.0934	 1.3216	
LRP1	 4035	 -2.4504	 -1.6889	 -1.1696	 -1.0803	
Kremen	1	 83999	 1.0218	 1.0004	 -1.0258	 1.0948	
Kremen	2	 79412	 -1.0196	 -1.1387	 -1.0224	 -1.1078	
RYK	 6259	 -1.4538	 1.5468	 1.1389	 1.5257	
ROR1	 4919	 -1.0267	 -1.1371	 -1.0253	 1.0990	
ROR2	 4920	 -1.0104	 -1.0176	 1.0526	 -1.2039	
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VANGL1	 81839	 1.0120	 -1.1749	 -1.0265	 -1.0991	
VANGL2	 57216	 -1.0823	 -1.0346	 1.0867	 -1.0855	
CELSR1	 9620	 -1.2823	 1.0675	 -1.0670	 -1.1313	
CELSR2	 1952	 -1.0539	 -1.1833	 -1.1143	 1.1074	
CELSR3	 1951	 -1.0653	 -1.1039	 -1.0586	 -1.0636	
PTK7	 5754	 -1.0413	 -1.2401	 -1.0548	 1.0258	
SDC1	 6382	 -1.1586	 -1.2876	 -1.1446	 -1.1348	
SDC2	 6383	 -2.0238	 -3.0293	 1.1840	 2.4422	
SDC3	 9672	 -13.9840	 -17.7616	 -2.2844	 -1.2611	
SDC4	 6385	 -3.3641	 -5.2096	 -1.1604	 -1.2838	
GPC2	 221914	 1.0280	 -1.1169	 1.0218	 -1.0776	
GPC3	 2719	 1.0086	 1.0355	 -1.0112	 -1.0938	
GPC4	 2239	 -1.0581	 -1.0137	 1.0073	 -1.2177	
GPC5	 2262	 1.0165	 1.0211	 -1.0607	 -1.0976	
GPC6	 10082	 -1.0489	 1.0607	 1.0356	 1.1023	
GPC1	 2817	 -1.2736	 -1.1863	 -1.1308	 1.0234	
CD44	 960	 1.7607	 2.3867	 1.6069	 1.3199	
Inhibitors	
Dkk1	 22943	 -1.1640	 1.0137	 -1.0596	 1.0133	
Dkk2	 27123	 1.0489	 -1.0804	 1.0889	 1.0432	
Dkk3	 27122	 -1.1317	 -1.1360	 -1.0182	 -1.1449	
Dkk4	 27121	 -1.1292	 -1.0598	 -1.1939	 1.1142	
WIF1	 11197	 -1.0493	 1.0038	 1.0410	 -1.2619	
sFRP1	 6422	 -1.1710	 1.0444	 -1.1043	 1.0285	
sFRP2	 6423	 -1.1927	 -1.2204	 -1.2165	 -1.0340	
sFRP3	 2487	 -1.1185	 -1.0538	 -1.0984	 -1.0177	
sFRP4	 6424	 -1.0741	 -1.0741	 -1.1922	 -1.0948	
sFRP5	 6425	 -1.0412	 -1.1051	 1.0468	 -1.0391	
Shisa2	 387914	 1.0506	 -1.0021	 1.0746	 1.0431	
Shisa3	 152573	 -1.0619	 -1.1272	 -1.1695	 -1.1468	
CTHRC1	 115908	 -1.2800	 -1.2979	 -1.1785	 -1.0866	
IGFBP1	 3484	 -1.0606	 -1.0005	 -1.1331	 -1.0923	
IGFBP2	 3485	 -1.0713	 -1.1487	 -1.0785	 1.5769	
IGFBP4	 3487	 -2.1345	 -2.3517	 -1.7152	 -1.2767	
IGFBP6	 3489	 -1.1611	 1.7273	 -1.0471	 1.2318	
CER1	 9350	 1.0559	 -1.1610	 1.0868	 -1.1534	
SOST	 50964	 -1.0677	 -1.0641	 -1.0556	 1.0414	
SOSTDC1	 25928	 -1.1579	 1.0825	 -1.0490	 -1.0792	
TPBG		 7162	 -1.0855	 -1.1817	 -1.0269	 -1.1761	
APCDD1	 147495	 -1.1348	 -1.2389	 -1.1245	 1.1224	
TRABD2A		 129293	 1.3821	 -1.1138	 -1.0627	 3.5819	
agonists/	positive	modulators	
NDP	 4693	 -1.0369	 1.0240	 -1.0718	 2.0848	
RSPO1	 284654	 1.0478	 -1.1746	 -1.0174	 -1.0283	
RSPO2	 340419	 1.0370	 -1.0039	 -1.0317	 -1.0654	
RSPO3	 84870	 -1.2302	 -1.0685	 -1.1931	 -1.0999	
RSPO4	 343637	 1.0945	 -1.0467	 1.0296	 1.0660	
ß-Catenin	dependent	signalling	
Dvl1	 1855	 -1.1003	 -1.1709	 -1.0041	 1.0043	
Dvl2	 1856	 1.0455	 -1.1767	 -1.0992	 -1.0679	
Dvl3	 1857	 -1.2685	 -1.3125	 1.1232	 1.0129	
GSK3ß	 2932	 1.2338	 1.8717	 -1.0518	 -1.0684	
Axin	1	 8312	 1.2076	 1.1760	 1.0062	 1.1292	
Axin	2	 8313	 1.0350	 -1.0332	 1.0269	 1.0315	
APC	 324	 1.0375	 2.2416	 -1.0043	 1.0717	
CSNK1A1	 1452	 1.8013	 1.5521	 1.3138	 1.1535	
CSNK1E	 1454	 1.6840	 -2.0421	 1.3688	 1.2844	
CSNK1D	 1453	 1.0470	 1.1399	 1.0297	 -1.0389	
CSNK2A1	 1457	 2.6044	 1.8369	 1.4823	 2.0097	
CSNK2A2	 1459	 1.1685	 1.1476	 1.2627	 1.0946	
CSNK2B	 1460	 1.0833	 1.1026	 1.0244	 1.5215	
CTNNB1	 1499	 -1.3528	 -1.8149	 1.0964	 -1.1370	
CTNNBIP1	 56998	 1.0367	 -1.1387	 1.0184	 -1.1564	
NDRG1	 10397	 1.3675	 -1.2411	 1.1185	 -1.0052	
NDRG2	 57447	 13.6004	 -3.6222	 2.6683	 5.0442	
FRAT1	 10023	 1.4554	 2.5653	 -1.1292	 1.1066	
FRAT2	 23401	 1.7967	 1.9805	 1.1342	 1.5524	
PAK4	 10298	 1.0538	 1.0361	 -1.0052	 -1.0163	
AKT1	 207	 -1.5811	 -1.3680	 -1.1693	 1.1469	
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AKT2	 208	 1.7915	 1.8000	 1.1900	 -1.0811	
AKT3	 10000	 1.0042	 1.7683	 1.0245	 -1.9218	
ILK	 3611	 1.3884	 1.1856	 1.0791	 -1.2412	
CXXC4	 80319	 -1.0787	 -1.1329	 -1.0647	 1.0324	
SUMO1	 7341	 1.4611	 -1.2652	 1.1000	 -1.0351	
RANBP2	 5903	 -1.8099	 -2.2638	 -1.2854	 1.1359	
SENP2	 59343	 1.2568	 1.3686	 1.2128	 1.1050	
BTRC	 8945	 -1.5329	 1.0744	 1.0409	 1.3042	
SKP1	 6500	 -1.0166	 -1.0535	 -1.0877	 1.3078	
CUL1	 8454	 1.2999	 -1.2547	 1.4976	 1.3651	
NKD1	 85407	 1.0227	 -1.0490	 -1.0427	 -1.0767	
ARRB1	 408	 1.5494	 2.9757	 -1.0999	 -1.2502	
ARRB2	 409	 1.1524	 1.5570	 -1.0507	 -1.4050	
MACF1	 23499	 -1.0623	 1.5709	 -1.1375	 -1.3735	
PPP1CA	 5499	 2.1597	 2.5729	 1.4084	 -1.0946	
PPP1CB	 5500	 1.2699	 1.3017	 1.0037	 1.0019	
PPP1CC	 5501	 1.4864	 1.8177	 1.1833	 1.0558	
PPP2R5B	 5526	 -1.0427	 1.1492	 1.0507	 -1.0998	
PPP2CB	 5516	 -1.2115	 -1.1894	 -1.1775	 -1.1469	
PPP2CA	 5515	 1.3410	 1.4718	 1.1537	 -1.0081	
PPP3CB	 5532	 1.4256	 1.7219	 1.1706	 -1.1373	
DAB2	 1601	 -8.9419	 -41.7488	 -2.0490	 -1.6478	
TCF1	 6927	 -1.1087	 -1.0798	 -1.0857	 1.0309	
TCF3	 6929	 1.4746	 1.1788	 -1.0796	 1.1391	
TCF4	 6925	 -2.3677	 -5.3755	 -1.6344	 1.0000	
LEF1	 51176	 -1.0256	 1.0626	 -1.0399	 -1.9252	
TCF7L1	 83439	 -1.1257	 -1.0008	 -1.0836	 -1.0007	
TCF7L2	 6934	 -7.2930	 10.9486	 -1.5495	 -1.7468	
TLE1	 7088	 -1.1562	 -1.1055	 -1.1633	 4.4839	
TLE2	 7089	 -1.1277	 -1.1117	 -1.0439	 -1.1298	
TLE3	 7090	 -1.2666	 -1.4523	 1.3582	 -1.6283	
TLE4	 7091	 1.7511	 5.0735	 1.4129	 -1.0544	
CDX1	 1044	 -1.0217	 -1.1464	 -1.0495	 -1.1573	
BCL9	 607	 -1.1029	 -1.1549	 1.0165	 1.5439	
PIAS4	 51588	 1.1418	 1.5378	 1.1064	 -1.0070	
FHL2	 2274	 -1.0335	 -1.1472	 -1.1182	 1.0811	
TAX1BP3	 30851	 1.0130	 -1.3228	 1.0601	 1.1446	
SALL1	 6299	 -1.0840	 -1.0511	 -1.1329	 1.0422	
SALL4	 57167	 1.0180	 -1.2479	 -1.0865	 1.1593	
MAP1B	 4131	 -1.1177	 -1.0840	 1.0195	 -1.0332	
PCP	signalling	
ANKRD6	 22881	 -1.1921	 -1.0092	 -1.0709	 -1.2642	
DAAM1	 23002	 1.3875	 1.2873	 1.0657	 2.5715	
DAAM2	 23500	 1.0333	 -1.0028	 -1.0796	 -1.0499	
RHO	A	 387	 1.3881	 1.4257	 1.2972	 1.0488	
RHO	B	 388	 -2.7277	 -1.2100	 -1.2101	 -1.3863	
ROCK1	 6093	 1.3576	 1.3783	 1.1282	 1.0642	
ROCK2	 9475	 1.3726	 1.6438	 1.0249	 1.4028	
RAC1	 5879	 1.6136	 -1.2333	 1.3042	 -1.1747	
RAC2	 5880	 3.8572	 6.4737	 1.4315	 1.5024	
RAC3	 5881	 1.2227	 1.3297	 1.0410	 1.0900	
MAP2K7	 5609	 1.1772	 1.2152	 1.0743	 1.0392	
MAP2K4	 6416	 1.6228	 1.7046	 1.2000	 1.2608	
MAP3K4	 4216	 1.8839	 1.4221	 1.0294	 1.3378	
MAPK8	 5599	 1.4700	 1.5345	 1.3773	 -1.4576	
MAPK9	 5601	 1.2817	 1.3061	 1.2371	 1.3208	
MAPK10	 5602	 -1.0157	 1.1798	 1.0655	 -1.2491	
JUN	 3725	 -4.5396	 -8.5569	 -1.0195	 1.0658	
ATF2	 1386	 1.0757	 -1.1054	 1.1084	 -1.1124	
CDC42	 998	 1.2107	 -1.0321	 1.0517	 1.0262	
MARK2	 2011	 1.9981	 2.3728	 1.5145	 1.1750	
Ca-Signalling	
PLCB1	 23236	 -1.0711	 -1.0142	 1.0832	 1.4089	
PLCB2	 5330	 1.5102	 1.7951	 -1.0470	 1.2400	
PLCB3	 5331	 1.1409	 -1.1602	 -1.0389	 -1.1196	
PLCB4	 5332	 -1.1018	 -1.0804	 -1.1142	 -1.0168	
PLCG1	 5335	 -1.3671	 -1.2939	 -1.0268	 1.0632	
PLCG2	 5336	 1.1676	 1.6333	 -1.0479	 1.0387	
PLCD1	 5333	 -1.0294	 -1.0821	 1.0977	 1.1187	
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PLCD3	 113026	 -1.0137	 -1.0446	 -1.0161	 1.0868	
PLCD4	 84812	 -1.0273	 -1.0314	 -1.1525	 -1.1341	
PLCE1	 51196	 1.0021	 1.0926	 -1.0255	 -1.0663	
PRKCA	 5578	 1.3714	 -1.4873	 1.0023	 1.6590	
PRKCB	 5579	 3.9927	 7.5222	 1.7442	 -1.6910	
PRKCG	 5582	 1.0591	 -1.0952	 1.0456	 -1.0857	
CAMK1	 8536	 1.0037	 2.3223	 1.0299	 1.4221	
CAMK1D	 57118	 1.8969	 1.4238	 1.4937	 1.1630	
CAMK1G	 57172	 -1.1636	 -1.0564	 -1.0457	 -1.1238	
CAMK2A	 815	 -1.2072	 -1.0568	 1.0183	 1.0790	
CAMK2B	 816	 1.0781	 -1.0263	 -1.0593	 -1.1159	
CAMK2G		 818	 1.5570	 -1.1664	 1.0419	 -1.0961	
CAMK2D	 817	 -1.5758	 -2.5413	 1.2151	 1.7960	
CAMK4	 814	 -1.0485	 -1.1461	 -1.0883	 -1.4048	
PPP3CA	 5530	 2.0980	 1.8450	 1.5470	 1.0562	
NFkB1	 4790	 1.6854	 -1.0498	 1.6017	 -1.7144	
NFkB2	 4791	 1.0364	 -1.7759	 1.1308	 -1.3089	
RELA	 5970	 1.0204	 1.1109	 1.0592	 1.0439	
RELB	 5971	 -1.0420	 -1.3304	 -1.0693	 -1.3590	
REL	 5966	 1.0393	 -1.0561	 1.1015	 -1.1801	
NFATC1	 4772	 -1.5256	 2.5389	 -1.1689	 -1.4578	
NFATC2	 4773	 1.3582	 -6.7436	 -1.2706	 1.4631	
NFATC3	 4775	 1.4056	 1.6297	 1.0922	 1.1901	
NFATC4	 4776	 1.0049	 -1.0797	 -1.0440	 1.0244	
CREB1	 1385	 1.1763	 1.8634	 -1.0683	 -1.1082	
MAPK1	 5594	 1.9619	 3.0605	 1.1845	 1.8177	
MAP3K7	 6885	 1.2715	 2.0198	 -1.0133	 -1.0448	
NLK	 51701	 -1.1397	 1.1441	 -1.0498	 1.9392	
HIPK2	 28996	 -1.0261	 1.2703	 1.0243	 1.5712	
MYB	 4602	 -1.1398	 -1.0786	 1.0075	 -1.8152	
	
9.3 Supplementary	table	3:	Microarray	data	of	RCC	tissue	samples		
Supplementary	table	3	displays	the	microarray	data	of	RCC	tissue	samples	with	WHO	G1	and	G3.	It	displays	calculated	
Fold	changes	(FC)	of	RCC	tissue	samples	with	WHO	grading	G1	and	G3	compared	to	control	healthy	renal	tissue	for	
the	canonical	and	non-canonical	Wnt-pathways.	Genes	are	represented	by	gene-IDs	and	official	gene-symbols.	The	
green	colour	indicates	an	up	regulation	with	a	FC	of	>1.5.	The	red	colour	a	down	regulation	with	a	FC	of	<-1.5.	#N/A	
indicates	that	this	gene	was	not	present	on	the	microarray	chip.		
Gene:	 Entrez-ID:	
FC:	
G1	/Control	 FC:	G3/Control	 FC:	G3/G1	
Wnt-ligands	
Wnt	1	 7471	 -1.133980143	 -1.115985825	 -1.029608124	
Wnt	2	 7472	 -1.324275188	 -1.245568656	 1.000790296	
Wnt	2b	 7482	 -1.383356436	 1.195510709	 1.388362855	
Wnt3	 7473	 -1.303414366	 -1.18008834	 1.164342384	
Wnt	3a	 89780	 #N/A	 #N/A	 #N/A	
Wnt	4	 54361	 -1.168875127	 -1.170559825	 -1.005386424	
Wnt	5a	 7474	 2.967342144	 6.876444758	 2.299245364	
Wnt	5b	 81029	 1.066702146	 1.403380922	 1.249449144	
Wnt	6	 7475	 1.057031097	 -1.07443072	 -1.248936964	
Wnt	7a	 7476	 -1.208725642	 -1.112176136	 -1.02900337	
Wnt	7b	 7477	 -1.455952281	 -1.445384083	 -1.004953069	
Wnt	8a	 7478	 1.122277964	 1.073397815	 1.093807796	
Wnt	8b	 7479	 -1.555566312	 -1.427779097	 1.047735221	
Wnt	9a	 7483	 #N/A	 #N/A	 #N/A	
Wnt	9b	 7484	 -1.336612456	 -1.290677636	 1.012397217	
Wnt	10a	 80326	 -1.026980859	 1.013708925	 1.110479976	
Wnt	10b	 7480	 -1.761407872	 -1.581129476	 1.066790244	
Wnt	11	 7481	 -1.373157757	 -1.390156425	 -1.015667923	
Receptors	
Fzd1	 8321	 3.584257605	 1.849677915	 -2.010417659	
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Fzd2	 2535	 1.382497028	 2.303297739	 1.800645271	
Fzd3	 7976	 -1.277587363	 -1.87702466	 -1.533562287	
Fzd4	 8322	 1.423966297	 -1.308237859	 -2.083311916	
Fzd5	 7855	 -1.634196906	 -1.947267112	 -1.258913966	
fzd6	 8323	 -1.294774616	 1.060103946	 1.515763069	
Fzd7	 8324	 -1.115610105	 -1.369425415	 -1.251774174	
Fzd8	 8325	 1.270067557	 -1.071674828	 -1.336411161	
Fzd9	 8326	 -1.044390052	 -1.1607386	 -1.055789619	
Fzd10	 11211	 1.012074109	 1.025773762	 1.034965364	
Co-receptors	
LRP5	 4041	 1.452710066	 1.102076251	 -1.395097147	
LRP6	 4040	 1.466950006	 -1.138501484	 -1.877185505	
LRP1	 4035	 1.380646437	 2.375572422	 1.640301972	
Kremen	1	 83999	 -1.365676664	 -1.253400595	 1.046379683	
Kremen	2	 79412	 -1.22663849	 -1.062784499	 1.168823393	
RYK	 6259	 1.004126323	 1.073230925	 1.046274711	
ROR1	 4919	 1.107936489	 1.120996208	 1.003997867	
ROR2	 4920	 1.246196506	 1.446230373	 1.431407663	
VANGL1	 81839	 1.365706487	 1.180956609	 -1.152042507	
VANGL2	 57216	 -1.291596448	 1.016583275	 1.355722227	
CELSR1	 9620	 -1.4027793	 -1.261592842	 1.036283093	
CELSR2	 1952	 1.461351444	 1.036603234	 -1.374416876	
CELSR3	 1951	 -1.203939888	 1.021429824	 1.123296299	
PTK7	 5754	 1.314843236	 1.125148787	 1.013381741	
SDC1	 6382	 -2.653625065	 -1.312103094	 1.841708379	
SDC2	 6383	 1.675387267	 1.424077117	 -1.350628384	
SDC3	 9672	 1.205074266	 1.511596329	 1.334483728	
SDC4	 6385	 -1.318786785	 -1.259788369	 1.120200438	
GPC2	 221914	 -1.252343651	 -1.111942655	 1.029825539	
GPC3	 2719	 -10.34923525	 -7.298622465	 1.816855872	
GPC4	 2239	 -1.713973771	 1.140729316	 1.399841684	
GPC5	 2262	 -21.44636268	 -14.44903445	 -1.001580361	
GPC6	 10082	 1.32757433	 1.113963397	 -1.406348327	
GPC1	 2817	 1.125962321	 1.476452189	 1.306008657	
CD44	 960	 3.635172769	 15.32325927	 4.476799056	
Antagonists	
Dkk1	 22943	 1.398918147	 1.98636612	 12.46478436	
Dkk2	 27123	 -1.152840138	 -1.233538254	 -1.226955505	
Dkk3	 27122	 8.778332478	 9.220783697	 1.08650795	
Dkk4	 27121	 -1.347272405	 -1.206882165	 1.174759914	
WIF1	 11197	 -2.769029059	 -2.673839412	 1.101479509	
sFRP1	 6422	 -5.763880963	 -7.132151556	 1.070088766	
sFRP2	 6423	 10.89794626	 6.780467736	 -1.727027119	
sFRP3	 2487	 6.70220794	 3.640778043	 -1.719907159	
sFRP4	 6424	 3.48080581	 3.389897133	 1.117281517	
sFRP5	 6425	 -1.230444446	 -1.189231739	 1.016892915	
Shisa2	 387914	 -6.127026881	 -6.633182403	 1.13942511	
Shisa3	 152573	 -4.264092225	 -6.062618983	 -1.407634887	
CTHRC1	 115908	 34.38466931	 99.39512642	 3.202101901	
IGFBP1	 3484	 -2.458884854	 18.98350353	 40.41981721	
IGFBP2	 3485	 1.202135667	 -1.171464323	 -1.017927391	
IGFBP4	 3487	 1.417368018	 1.14861181	 -1.149470495	
IGFBP6	 3489	 1.924971692	 3.518554816	 1.534162127	
CER1	 9350	 -1.622301362	 -1.622993816	 1.016844264	
SOST	 50964	 -5.385682106	 -6.543979511	 -1.144876174	
SOSTDC1	 25928	 -6.795064991	 -12.72653298	 -1.950021998	
TPBG		 7162	 2.312788181	 3.474359865	 1.621467976	
APCDD1	 147495	 6.103822689	 5.190308729	 -1.157545143	
TRABD2A		 129293	 -1.332610907	 -1.038193912	 1.187153844	
agonists/	positive	modulators	
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NDP	 4693	 -1.096484654	 1.107123335	 1.526145594	
RSPO1	 284654	 -1.3649201	 -1.293597928	 1.060267233	
RSPO2	 340419	 -1.059399167	 -1.021525136	 1.056231263	
RSPO3	 84870	 -1.051008475	 1.769600894	 1.316544231	
RSPO4	 343637	 -1.431480644	 -1.203809198	 1.21129907	
ß-Catenin	dependent	signalling	
Dvl1	 1855	 1.289714447	 1.246211774	 1.107754455	
Dvl2	 1856	 1.028367491	 1.085761675	 1.005707339	
Dvl3	 1857	 1.491242996	 2.134870565	 1.500093647	
GSK3ß	 2932	 1.328278241	 1.323190456	 1.089648881	
Axin	1	 8312	 -1.196247428	 -1.14847243	 1.060728434	
Axin	2	 8313	 -1.258074717	 -1.200803178	 1.021873822	
APC	 324	 1.465982822	 1.23273068	 -1.277144188	
CSNK1A1	 1452	 1.311053249	 1.295546305	 1.009418706	
CSNK1E	 1454	 1.911017554	 1.748559183	 -1.079365007	
CSNK1D	 1453	 1.69226951	 2.129454545	 1.154614177	
CSNK2A1	 1457	 1.401391878	 1.753027332	 1.255121631	
CSNK2A2	 1459	 1.248237741	 1.64423934	 1.171093671	
CSNK2B	 1460	 1.269759514	 1.134931547	 -1.088843294	
CTNNB1	 1499	 -2.66095652	 -3.898603411	 -1.262693819	
CTNNBIP1	 56998	 -1.358448567	 -1.361630174	 -1.014461705	
NDRG1	 10397	 2.290167694	 2.003738116	 -1.16936675	
NDRG2	 57447	 1.16828069	 -2.038885469	 -2.832898978	
FRAT1	 10023	 1.259220336	 1.256125631	 -1.025011507	
FRAT2	 23401	 1.550701092	 1.825562063	 1.08886623	
PAK4	 10298	 -1.240240289	 -1.323829306	 -1.046531636	
AKT1	 207	 2.390895553	 2.151040028	 -1.107751563	
AKT2	 208	 -1.335050618	 -1.198904989	 1.145284987	
AKT3	 10000	 2.37748746	 1.411176519	 -1.536053311	
ILK	 3611	 2.245027334	 2.013829177	 -1.22528232	
CXXC4	 80319	 -1.257415191	 -1.536550648	 -1.325931229	
SUMO1	 7341	 -1.121368304	 -1.251783678	 -1.043864812	
RANBP2	 5903	 -1.109158462	 -1.169324841	 -1.043454544	
SENP2	 59343	 -1.066203629	 1.053395277	 1.099180338	
BTRC	 8945	 -1.018086309	 -1.043770138	 -1.021840072	
SKP1	 6500	 1.063203059	 -1.152498308	 -1.221901265	
CUL1	 8454	 1.704737398	 2.095852631	 1.179458761	
NKD1	 85407	 -1.373908261	 -1.268853517	 1.040940034	
ARRB1	 408	 1.809813068	 1.452289174	 -1.267615895	
ARRB2	 409	 2.029399769	 3.434748787	 1.580898944	
MACF1	 23499	 1.786425641	 1.506029338	 -1.22782369	
PPP1CA	 5499	 1.477688468	 1.71407989	 1.17414777	
PPP1CB	 5500	 -1.238201441	 -1.195191299	 1.108768723	
PPP1CC	 5501	 1.260405787	 1.250892278	 1.035899142	
PPP2R5B	 5526	 1.061451675	 1.025841853	 1.025026972	
PPP2CB	 5516	 -1.436446446	 -1.33886331	 -1.102953743	
PPP2CA	 5515	 -1.004758838	 1.072804763	 1.051081344	
PPP3CB	 5532	 1.080063556	 1.356917165	 1.236252359	
DAB2	 1601	 1.164301469	 -1.158955809	 -1.380338409	
TCF1	 6927	 -1.530051115	 -1.972436498	 -1.280701909	
TCF3	 6929	 1.084544628	 1.294155363	 1.180643626	
TCF4	 6925	 10.22102336	 5.189265059	 -1.922066902	
LEF1	 51176	 1.138632599	 1.657525087	 1.65601457	
TCF7L1	 83439	 2.248597044	 1.259975702	 -2.038217267	
TCF7L2	 6934	 1.462326866	 -1.162132728	 -1.601614088	
TLE1	 7088	 2.429193731	 2.155936325	 -1.193833056	
TLE2	 7089	 1.280791965	 -1.127047458	 -1.374994321	
TLE3	 7090	 1.496525347	 1.494982502	 1.074806545	
TLE4	 7091	 -1.183244107	 -1.091672674	 1.12347155	
CDX1	 1044	 -1.085536361	 -1.011578062	 1.150406159	
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BCL9	 607	 -1.362178286	 -1.741934664	 -1.091691886	
PIAS4	 51588	 -1.111491921	 -1.1980189	 1.038515881	
FHL2	 2274	 3.329528166	 8.329019353	 2.198952864	
TAX1BP3	 30851	 #N/A	 #N/A	 #N/A	
SALL1	 6299	 1.004734576	 -2.477178189	 -2.415650485	
SALL4	 57167	 -1.436634307	 -1.431046897	 -1.051475876	
MAP1B	 4131	 6.074013744	 5.238552109	 -1.069927648	
PCP	signalling	
ANKRD6	 22881	 1.742713169	 1.359020888	 -1.042948328	
DAAM1	 23002	 1.009453656	 -1.262825447	 -1.315831589	
DAAM2	 23500	 1.732905748	 1.207742125	 -1.31315434	
RHO	A	 387	 1.846909082	 2.110809094	 1.042177498	
RHO	B	 388	 1.520962404	 -1.716785354	 -2.500086048	
ROCK1	 6093	 1.584387054	 1.425687306	 -1.108313198	
ROCK2	 9475	 1.339074617	 1.247466827	 1.00111951	
RAC1	 5879	 1.328458805	 1.433274369	 1.060350703	
RAC2	 5880	 4.08874283	 10.07493166	 2.263784778	
RAC3	 5881	 -1.542901535	 -1.51462049	 1.137959544	
MAP2K7	 5609	 -1.027864834	 -1.005100529	 -1.014774998	
MAP2K4	 6416	 -1.099965766	 1.068826953	 1.052906644	
MAP3K4	 4216	 1.483073738	 1.194525514	 -1.262007554	
MAPK8	 5599	 -2.25872637	 -2.63432144	 -1.243079946	
MAPK9	 5601	 1.29004651	 1.355271919	 1.038577125	
MAPK10	 5602	 -2.524020898	 -3.432548437	 -1.454735636	
JUN	 3725	 1.988653599	 1.7417627	 -1.350791103	
ATF2	 1386	 1.234215251	 1.082645845	 -1.027613523	
CDC42	 998	 -1.139600981	 -1.018081185	 1.101781963	
MARK2	 2011	 2.126391661	 2.214945365	 1.031941706	
Ca-Signalling	
PLCB1	 23236	 2.777261538	 1.623132108	 -1.724282305	
PLCB2	 5330	 -1.321955152	 -1.141593069	 1.201913509	
PLCB3	 5331	 -1.244635264	 -1.067696636	 1.04100577	
PLCB4	 5332	 2.029270852	 8.627119408	 3.535088233	
PLCG1	 5335	 1.009942854	 1.016920234	 -1.044699153	
PLCG2	 5336	 -1.722484548	 -1.356941956	 1.116611218	
PLCD1	 5333	 -1.345298093	 -1.441158673	 -1.181675697	
PLCD3	 113026	 -1.100471874	 -1.008918092	 1.19476375	
PLCD4	 84812	 -4.312582026	 -2.698849939	 1.424287042	
PLCE1	 51196	 -1.393012619	 1.136634573	 1.355819519	
PRKCA	 5578	 -1.699574687	 -1.246047358	 1.405377313	
PRKCB	 5579	 1.197818149	 1.595511116	 1.349703551	
PRKCG	 5582	 -1.311002605	 -1.310415823	 1.062479787	
CAMK1	 8536	 1.828809625	 1.891619375	 -1.007996616	
CAMK1D	 57118	 2.026101077	 1.923216022	 -1.031548829	
CAMK1G	 57172	 -1.12031656	 -1.139301845	 1.009346511	
CAMK2A	 815	 -2.141586935	 -2.140552189	 1.031997465	
CAMK2B	 816	 -1.285865389	 -1.226629584	 1.092573587	
CAMK2G		 818	 -1.743880887	 -1.568126553	 1.132000332	
CAMK2D	 817	 -1.016006978	 -1.191151311	 -1.219818519	
CAMK4	 814	 -1.231335085	 -1.213443951	 -1.015567417	
PPP3CA	 5530	 1.073327679	 1.014770572	 -1.018062525	
NFkB1	 4790	 2.620207883	 2.512596401	 -1.150557457	
NFkB2	 4791	 1.712433148	 1.869465336	 1.392446338	
RELA	 5970	 1.355806855	 1.420662784	 1.020914462	
RELB	 5971	 1.64304941	 2.037120771	 1.279179867	
REL	 5966	 1.941812493	 2.411602709	 1.240428454	
NFATC1	 4772	 1.209499021	 1.161418352	 -1.080612511	
NFATC2	 4773	 1.579927484	 1.715789398	 1.133516808	
NFATC3	 4775	 1.241450506	 1.33321685	 1.001947506	
NFATC4	 4776	 -1.048379179	 -1.167421008	 -1.144693204	
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CREB1	 1385	 1.966645631	 1.845680333	 -1.127479107	
MAPK1	 5594	 1.941009924	 2.049992218	 1.088210692	
MAP3K7	 6885	 1.537663421	 1.7339144	 1.146743566	
NLK	 51701	 1.341225471	 1.207841684	 -1.191006666	
HIPK2	 28996	 2.757924464	 1.727160185	 -1.590288812	
MYB	 4602	 -1.13805442	 1.066585629	 1.34276616	
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